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Abstract 
 
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that establishes lifelong latent 
infection in B lymphocytes. It is known to contribute to several malignancies including 
Burkitt's lymphoma (BL), Hodgkin's lymphoma, and nasopharyngeal carcinoma. EBV 
produces two non-coding RNAs, EBERs (Epstein-Barr encoded RNAs) 1 and 2, which are 
the most abundant viral transcripts in latent infection. EBER1 and EBER2 are expressed at 
high levels in almost all cells of EBV-associated malignancies and have been reported to 
contribute to the oncogenic phenotype of EBV-positive BL. Recent microarray analysis of 
lymphoblastoid cell lines (LCLs) containing EBER deletion mutants of EBV has identified 
several genes whose expression changes in response to deletion of EBER1 or EBER2. 
EBERs have also been recently shown to induce interferon alpha during the first three days of 
EBV infection. Therefore gene expression in B cells was investigated during early EBV 
infection, using recombinant EBER knockout EBV strains, with a focus on microarray targets 
and interferon alpha genes. The study showed that expression changes in the target genes did 
not occur directly following infection, indicating that expression changes previously 
identified were the downstream result of complex processes. The other method developed to 
investigate roles of the EBERs was the introduction of EBER expression into EBER negative 
cell lines using a lentiviral vector-based approach. This will enable stable EBER-expression 
in a variety of cell lines once the variability in EBER expression has been improved.  
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1 Introduction 
 
1.1 Epstein-Barr virus 
 
1.1.1 The discovery of Epstein-Barr virus  
Epstein-Barr virus (EBV) was discovered in 1964 by Epstein, Achong and Barr [1]. 
They had successfully cultured lymphoma cells from Burkitt’s lymphoma (BL) biopsies and 
identified a herpesvirus-like particle within the biopsies by electron microscopy (EM). BL 
was first described in 1958 by surgeon Denis Burkitt, who documented it as a jaw tumour 
commonly affecting young children in Uganda [2], and later provided Epstein with biopsies. 
Burkitt suspected the tumour to have a viral aetiology as its geographical and climatic 
restriction to areas of equatorial Africa suggested the involvement of an insect-borne 
pathogen [3-5]. (This insect-borne pathogen was actually found to be Plasmodium falciparum, 
malaria [6]). EBV was found to be smaller than known herpesvirus herpes simplex virus 
(HSV) but could not be isolated and characterised by methods suitable for HSV; therefore 
EBV was classified as a novel herpesvirus [7-10]. EBV was thus the first candidate human 
tumour virus, a controversial assertion at the time. The first experimental evidence of the 
oncogenic potential of EBV was the demonstration that EBV was able to transform cord 
blood cells into continuously proliferating cells [11, 12]. Serological tests showed the virus 
was not geographically limited to areas of endemic BL but was ubiquitous in all populations 
tested and generally acquired during childhood [10, 13]. Also, rare cases of BL were 
observed in non-endemic regions (sporadic BL) [14]. Therefore tumour development was an 
epidemiologically rare outcome of a common virus infection. 
 
1.1.2 The Herpesviridae family 
EBV is a member of the herpesvirus family, Herpesviridae, a family of large double-
stranded DNA viruses belonging to the recently classified order Herpesvirales [15]. 
Herpesviruses have natural hosts in mammals, birds and reptiles, whereas the other members 
of the order, Alloherpesviridae and Malacoherpesviridae, infect fish and frogs, and bivalves, 
respectively. According to genome sequence and biology, herpesviruses can be further 
classified into three distinct subfamilies: Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae (see Figure 1.1). Alphaherpesvirinae, such as herpes simplex viruses 
18 
 
(HSV) 1 and 2, have a typically short reproductive cycle, variable host range and rapid spread 
in cell culture. Betaherpesvirinae, such as cytomegalovirus (CMV), are characterised by a 
long reproductive cycle and a slow spread in cell culture, and are restricted to mammals [16]. 
EBV is from the Gammaherpesvirinae, whose host range is restricted to a specific taxonomic 
family or order, and whose members are largely lymphotropic viruses. The 
gammaherpesvirus subfamily comprises four genera: Lymphocryptovirus (LCV), 
Rhadinovirus (RDV), Macavirus and Percavirus [16]. LCV has a natural host in primates and 
EBV is the only known human LCV. Kaposi’s sarcoma-associated herpesvirus (KSHV), 
another oncogenic herpesvirus, is the only known human RDV. There are only 8 human 
herpesviruses (HHV) out of over 130 known herpesviruses, and these vary in the severity of 
disease they cause. 
EBV is not the only herpesvirus to be associated with malignancies. Marek’s disease 
virus (MDV) is an alphaherpesvirus which causes T cell lymphomas in chickens. Also, a 
feature of gammaherpesviruses is that latent infection may lead to epidemiologically rare 
development of malignancies, caused by oncogenic effects of the latent virus [16]. KSHV is 
the aetiological agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric 
Castleman’s disease [17]. Another RDV, herpesvirus saimiri (HVS) is asymptomatic in its 
natural host, the squirrel monkey, but can cause T cell lymphomas in experimental infections 
of monkeys. 
 
1.1.3 The structure of the EBV virion 
The structure of EBV is consistent with that of other herpesviruses. The linear, double 
stranded DNA (dsDNA) genome is wrapped around a protein core encased by a 162-
capsomere icosahedral capsid. A protein tegument layer made up of viral and cellular 
proteins including actin, tubulin and cofilin separates the capsid from the envelope [16]. The 
virus is coated by a lipid envelope containing several viral glycoproteins which are important 
for cell tropism and receptor recognition, including gp350/220, gp150, gB, gH and gp42 [18]. 
The EBV genome is 172 kb in length and contains around 85 protein coding genes and 
encodes over 30 functional RNAs [19]. Its gene organisation and genome features resemble 
those found in other LCV genomes. The genome ends are terminated with several tandem 
terminal repeats (TRs) 0.5 kb in length. These mediate the circularisation of the genome upon 
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Figure 1.1 The taxonomy of the Herpesviridae family   
 
infection, enabling it to persist in cells as an episome. The EBV genome also contains several 
internal direct repeats (IR) 3.1 kb in length, containing the Wp latency promoters. Almost all 
of the genome coding capacity is contained within the unique sequence domains US (short) 
and UL (long).  
EBV was the first herpesvirus to have its complete genome sequenced [20]. This was 
achieved by sequencing an EcoRI and BamHI fragment library of the B95-8 EBV strain 
which was derived from an infectious mononucleosis patient. The restriction fragments were 
labelled alphabetically according to size and EBV genes were initially named according to 
their position and orientation on each BamHI fragment. For example, BALF4 is the fourth 
leftward open reading frame (ORF) starting in the BamHI A fragment. 
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1.1.4 Primary infection with EBV 
EBV is generally transmitted via the saliva but can be acquired from blood or 
transplants [21]. Primary infection occurs in the oropharyngeal lymphoid organs (tonsils) but 
it is unclear as to whether B cells or epithelial cells are the initial targets of EBV infection. 
Primary infection of naïve B lymphocytes occurs when EBV transits the tonsillar epithelium 
and establishes latent infection of B cells in the lymphoid organs. Primary infection of 
epithelial cells occurs when EBV establishes sites of lytic replication in the Waldeyer’s ring 
epithelium and subsequent virus production may facilitate B cell infection [22]. A dual 
tropism model has been proposed for EBV primary infection considering that in the 
Waldeyer’s ring B cells and squamous epithelial cells are in close proximity. Latently 
infected B cells could transfer EBV to epithelial cells in which the virus would be amplified. 
Alternatively EBV could first be amplified in epithelial cells and subsequently establish 
persistent infection in nearby B cells [23]. This model is supported by the observation that 
EBV particles released from B cells infect epithelial cells more efficiently and EBV released 
from epithelial cells is better at infecting B cells [22]. Also, the glycoprotein content of the 
viral envelope changes according to the host cell and this supports a dual tropism model in 
which there is an interplay between B lymphocytes and epithelial cells [22]. 
It appears that different strains of EBV have different cell tropisms: B95-8 EBV 
infects B cells much more efficiently than epithelial cells, but the reverse is the case for M81 
EBV [24]. However, Akata EBV-resistant epithelial cells can be infected in vitro in the 
presence of virus producing B cells [25], potentially because B cells can be used as a vehicle 
for EBV transfer [26]. B cells lacking the EBV internalisation receptor gp42 can transfer 
EBV to epithelial cells to facilitate infection [26] as can B cells infected with BZLF1 
knockout EBV which is defective in lytic replication [27]. These studies suggest that the 
primary target for EBV might vary according to the virus strain used. Both cell types appear 
to be important for EBV infection: EBV is unable to establish successful infection in patients 
with X-linked agammaglobulinaemia who lack mature B cells, and EBV is strongly 
associated with oropharyngeal malignancies such as NPC and AIDS-associated oral hairy 
leukoplakia [28-30], indicating roles for both B cells and epithelial cells during EBV 
infection. 
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1.1.5 Primary infection of B lymphocytes in vivo 
The main B cell receptor for EBV is CD21/CR2 (complement receptor 2), which is 
bound by the viral glycoprotein gp350/220 [31, 32]. Virus binding activates the receptor, 
which oligomerises and initiates a tyrosine kinase signal transduction pathway and activates 
NF-κB signalling, leading to B cell activation and cell cycle entry [33, 34]. EBV infection 
mimics the natural activation of naïve B cells in response to antigen, and allows the virus to 
persist by following the life cycle of its host cell. Once bound, the virus penetrates the B cell 
using a complex of glycoproteins including gH, gL and gp42 [35, 36] to mediate fusion of the 
viral envelope with cell membranes. Viral entry is initiated by gp42 binding to the human 
leukocyte antigen (HLA) class II receptor, which is a co-receptor for EBV [37]. The virus 
enters the cell by endocytosis into smooth vesicles [32]. Once inside the cell, viral capsids are 
released into the cytoplasm and translocated to nuclear pores via microtubules [38]. The viral 
genome is released into the nucleus where is circularises and is maintained as an 
extrachromosomal episome [19]. 
 
1.1.6 EBV lytic infection in B lymphocytes 
EBV has a biphasic life cycle, like all herpesviruses, comprising a lytic phase and a 
latent phase. Lytic infection involves viral replication and the construction of progeny virions, 
which go on to infect naïve cells either in the same host or following transmission to a new 
host. Reactivation from latency occurs when memory B cells, the site of EBV persistence, 
differentiate into plasma cells [39, 40]. Differentiation occurs when the memory B cells 
recognise a specific antigen during an immune response and is thought to involve the cellular 
transcription factor XBP-1 [41], which activates the Zp promoter and consequently 
transcription of master lytic regulator BZLF1[42]. Expression of immediate early genes 
BZLF1 and BRLF1 is triggered by signalling through the B cell receptor (BCR) [43], whose 
protein products induce early EBV lytic genes. BZLF1 transactivates expression of a number 
of viral and cellular genes as well as autoactivating its own expression [44]. It also mediates 
viral DNA replication from the lytic origin of replication OriLyt , in combination with other 
immediate early and early gene products [19]. Late genes mostly encode EBV structural 
proteins. Mature virions are constructed in the nucleus and are released by exocytosis 
following budding through both the nuclear and plasma membranes [19]. 
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1.1.7 EBV latent infection 
Like other herpesviruses EBV can establish and maintain latent infection [16] during 
which viral replication is suppressed and the virus remains dormant, enabling the virus to 
persist in the host without immune detection. EBV latent infection is thought to follow the 
widely accepted Thorley-Lawson model [45] in which EBV uses and mimics the B cell 
differentiation pathway in order to persist in the memory B cell compartment (Figure 1.2). 
Upon infection of naïve B lymphocytes, EBV uses the Latency III program of gene 
expression, in which all viral latent genes are expressed (detailed in Table 1A): Epstein-Barr 
nuclear antigen proteins (EBNAs) 1, 2, 3A, 3B and 3C; EBNA-LP  (EBNA leader protein); 
latent membrane proteins (LMPs) 1, 2A and 2B; Epstein-Barr encoded RNAs (EBERs) 1 and 
2, and BART and BHRF1 microRNAs. The Latency III program enables infected B cells to 
become activated and proliferate as if responding to antigen since EBV mimics cellular 
proteins involved in the antigen response [46-48]. EBV-activated B cells resemble antigen-
activated B cells in their cell surface phenotype and morphology [45]. When a B cell 
encounters antigen, the antigen binds and activates the B cell receptor (BCR), initiating a 
cellular signalling pathway. The B cell displays the receptor CD40 which binds the CD40 
ligand (CD40L) on antigen-specific T helper (Th) cells. LMP2A mimics a constitutively 
active BCR and LMP1 acts as a functional homologue of CD40 [49, 50].  
 
 Figure 1.2 Thorley-Lawson model of EBV latent infection EBV infects naïve B cells and infected cells 
follow the normal pathway of B cell differentiation. EBV infected cells exhibit different patterns of viral gene 
expression according to the differentiation state of the cell. Infected B cells persist as memory B cells in the 
periphery until the viral lytic replication is reactivated.  
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Table 1A: The EBV transcriptional programs associated with different stages of latent infection 
 
 
The activated B blast now migrates to the follicle where the transcriptional program 
switches to Latency II, in which EBNA1 and the LMPs are the only proteins expressed [47]
 
[51-53]. EBNA1 is required for viral DNA replication. Latency II enables the B blast to 
undergo the germinal centre reaction to differentiate into a memory B cell [45, 54]. This 
involves clonal expansion and rearrangement of the immunoglobulin (Ig) genes through 
somatic hypermutation (SHM) and isotype switching. The LMPs are thought to provide the 
survival signals required to rescue latently infected B cells from apoptosis during the 
germinal centre reaction [50]. LMP1 upregulates the anti-apoptotic protein BCL-2 (B cell 
lymphoma 2) [55, 56], which has been shown to protect germinal centre B cells from 
apoptosis [57]. Latently infected memory B cells enter the peripheral circulation and are the 
site of EBV persistence [58]. They constitute around 1/10
5
-1/10
6
 of the memory B cell 
BHRF1 miRNAs 
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population [19]. The transcriptional program switches to Latency 0 in which no viral proteins 
are expressed. This is thought to enable the virus to evade immune detection [45, 58], 
allowing it to persist for the lifetime of the host. Sometimes, peripheral memory B cells 
replicate [45]. In this situation latently infected cells are believed to switch to Latency I, 
where EBNA1 is the only viral protein expressed, to enable viral genome replication [58]. 
Memory B cells eventually return to the Waldeyer’s ring in the tonsils. Here memory B cells 
can encounter antigen and be stimulated to differentiate into plasma cells, which is coupled to 
lytic reactivation of EBV. 
 
1.1.8 Transformation of B cells in vitro by EBV latent infection  
In vitro, EBV efficiently infects naïve human B lymphocytes [11, 12, 19]. Fully 
differentiated plasma cells cannot be infected. In vitro infection of primary human B 
lymphocytes resembles some of the initial stages of in vivo infection. Upon infection, some of 
the latently infected cells (3-10%) are transformed to become continuously proliferating 
lymphoblastoid cell lines (LCLs) [11, 12, 19]. LCLs display Latency III gene expression and 
proliferate rapidly so are comparable to EBV-activated B blasts. LCLs have a similar cell 
surface phenotype to activated B blasts, displaying high levels of B cell activation markers 
CD23, CD30, CD39 and CD70 in addition to cell adhesion molecules [19, 59]. The 
expression of several cell adhesion molecules on LCLs, including lymphocyte function 
associated antigens 1 and 3 (LFA1 and LFA3), explains the clustering phenotype of LCLs in 
cell culture. LCLs have lost the round morphology and small size typical of resting B cells 
and are large and irregular in shape, consistent with the phenotype of naïve B cells stimulated 
by antigen or by activators IL-4 and anti-CD40 [19]. Every cell in an LCL culture contains 
multiple copies of the EBV episome [60]. The Latency III program is responsible for 
maintaining the latent infection and the continual proliferation of the LCLs [60]. Virus 
replication in LCLs is negligible [11, 12] but latent EBV can replicate upon reactivation [19]. 
 
1.1.9 Infection of B lymphocytes in vitro  
EBV attachment, entry and uncoating occurs as previously described in section 1.1.5. 
The viral genome enters the host cell nucleus and circularises around 12-16 hours post 
infection (PI) [19]. The viral genome is depicted in Figure 1.3. At this point viral  
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Figure 1.3 Schematic of the EBV genome Adapted from [61] 
 
 
 
transcription begins from the W promoter, Wp, located inside the internal repeats, carried out 
by the host cell RNA polymerase II [62-64]. The first latent gene products to be expressed are 
EBNA2 and EBNA-LP. These transcripts are differentially spliced from pre-mRNA 
transcribed from the Wp promoter. The proteins reach detectable levels between 12 and 24 
hours PI [63]. These two proteins act as transcriptional co-activators, driving expression from 
a number of viral and cellular promoters [65]. EBNA2 and EBNA-LP reach steady state 
levels around 24-36 hours PI [63]. EBNA2 activates transcription from the upstream C 
promoter, Cp, and the transcript is alternatively spliced to give rise to mRNAs for all of the 
other EBNAs [19, 65-69]. Transcription from Cp shuts down Wp and viral transcription is 
subsequently controlled by Cp [70, 71]. EBNA2 also activates the expression from the 
LMP2A promoter and the LMP1/2B bidirectional promoter [72-79]. Cooperation of EBNA2 
with EBNA-LP enhances activation of some of the above promoters [80-86]. The other 
EBNAs and LMPs reach steady state (LCL) levels around 46-72 hours PI [63]. EBNA1 
assists in the EBNA2 and EBNA-LP mediated activation of the Cp and LMP1 promoters by 
regulating enhancer elements within the OriP region of the genome [70, 87, 88]. The LMP2A 
promoter is solely controlled by EBNA2 [76, 89] but the LMP1/2B promoter can be activated 
by EBNA2, EBNA-LP and EBNA3A [73, 74, 81, 82, 90].  
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EBNA2 is essential for B cell transformation and induces several cellular genes 
required for cell proliferation, such as transcription factors c-MYC and RUNX3 and cellular 
activation markers CD21 and CD23 [77, 91-94], by mimicking the cellular Notch signalling 
pathway [95, 96]. LMP1 and EBNA3C are also essential for the transformation and 
outgrowth of EBV-infected B cells in vitro [49, 97-100]. EBNA3C represses several genes 
including those encoding pro-apoptotic protein BIM (BCL-2-interacting mediator of cell 
death), which enables latently infected cells to evade apoptosis [101, 102], and cell cycle 
regulator p16 [103], permitting cell proliferation. The repression of p16 is thought to be the 
critical function of EBNA3C in LCLs [104]. LMP1 signals to NF-κB causing induction of 
BCL-2, which is an anti-apoptotic protein [55, 56]. In fact, c-Myc and Rel/NF-κB are thought 
to be the main transcriptional programs driving EBV-mediated proliferation and 
transformation of B cells into LCLs [105]. EBNA3A has been shown to improve the 
efficiency of B cell transformation and increase the proliferation rate of LCLs [106, 107]. 
EBNA-LP and LMP2 are also thought to aid transformation [97, 100]. Expression of EBERs 
is delayed and only reaches detectable levels around 36 hours PI [63]. EBERs reach steady 
state levels around 70 hours PI and are not essential for transformation [108-110]. Other EBV 
functional RNAs, the BHRF1 miRNAs, have been shown to increase the efficiency of 
transformation [111].  
EBNA2 and EBNA-LP act together to induce cell cycle entry, upon which cyclin D2 
is upregulated [80]. DNA synthesis begins around 48-72 hours PI. EBNA1 binds to the EBV 
plasmid origin of replication, OriP, and the cellular chromosomes to maintain the viral 
episomal genome in progeny cells. Around 72 hours PI latently infected cells begin rapid 
proliferation, with a doubling time between 20 and 30 hours [19]. During this phase, the 
telomeres shorten at each round of cell division, until, after about 100-150 cell doublings the 
telomeres reach a critical length and a crisis occurs. Many cells die except for those which 
have stabilised telomeres and high telomerase activity [112, 113]; these cells are 
immortalised and will grow continuously in cell culture. 
 
1.1.10 EBV and disease 
EBV is a ubiquitous virus present in 90-95% of the adult population. Primary 
infection generally occurs in childhood and leads to lifelong latent infection of memory B 
cells. Initial infection after childhood can manifest as infectious mononucleosis (IM), 
characterised by lymphadenopathy, splenomegaly, pharyngitis, tonsillitis, fever and lethargy. 
IM is a self-limiting disease resulting from a strong T cell response to EBV infection [19, 
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114]. The vast majority of EBV infections are benign and tumour development is 
epidemiologically rare. Despite this, EBV is linked to around 1.5% of human cancers 
worldwide. EBV is associated with a variety of lymphoid malignancies, including Burkitt’s 
lymphoma (BL) [115], Hodgkin’s lymphoma (HL), post-transplant lymphoproliferative 
disease (PTLD), AIDS-associated lymphoma, X-linked lymphoproliferative disease, T/NK 
cell lymphoma and peripheral T cell lymphoma [116]. EBV is also linked to epithelial 
malignancies such as nasopharyngeal carcinoma (NPC) [117], and some cases of gastric 
carcinoma (GC) [118, 119]. The role of EBV in causing some of these malignancies will be 
discussed in the next section. 
 
1.1.11 The oncogenic role of EBV 
The transforming ability of EBV is evident from its ability to turn resting B cells into 
continuously proliferating B cells in vitro [11, 12] and is consistent with the ability of EBV to 
cause malignancies under certain circumstances. EBV+ B cell tumours exhibit different latent 
gene expression programs which is thought to indicate that these malignancies arise at 
different points in the differentiation pathway of latently infected B cells. The role of EBV in 
causing each malignancy, however, is not always clear. 
EBV is linked to around 95% of endemic Burkitt’s lymphoma (BL) cases. Endemic 
BL is found in malaria endemic regions of equatorial Africa, and is one of the most frequent 
childhood cancers in the region, accounting for up to 75% of childhood malignancies [116].  
Endemic BL is associated with a mutational genetic background in the host: a chromosomal 
translocation resulting in the fusion of an Ig enhancer with the c-MYC proto-oncogene. 80% 
of cases involve t(8;14) [116], where translocation occurs with the IGH gene due to aberrant 
VDJ recombination [120]. This genetic background induces constitutive activation and 
overexpression of c-MYC, as found in BL cells [121, 122], which is likely responsible for the 
rapid proliferation of BL cells [121, 123]. The translocation is believed to occur during class 
switching and Ig gene rearrangement in the germinal centre. BL cells have a mixed 
phenotype: the Ig gene hypermutation resembles that of germinal centre and memory B cells, 
but the cellular phenotype is similar to that of germinal centre cells [124-126].  The Latency I 
gene expression corresponds with a centrocyte/memory B cell phenotype. This suggests that 
the c-MYC translocation required for BL induces the EBV+ germinal centre B cell to 
proliferate rather than to complete differentiation [45].  
A recent study has aimed to identify essential regulatory pathways that cooperate with 
the oncogene MYC in BL pathogenesis [115]. The study demonstrated that BL is 
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pathogenetically distinct from other lymphomas that have a germinal centre origin. Mutations 
in the transcription factor TCF3 gene, or that of its negative regulator, ID3, were identified in 
40% of endemic BL samples. TCF3 acts in B cell development by binding to E-box motifs to 
regulate the expression of immunoglobulin genes and B-cell specific genes [127], and has 
shown to be essential in BL cell lines by RNAi [115], indicating that TCF3 and ID3 
mutations promote TCF3 action and that ID3 acts as a tumour suppressor. Many TCF3 
targets show the same expression patterns in BL and in germinal centre B cells, indicating a 
role for increased TCF3 activity in BL [115]. The same study found BCR signalling to be 
essential for the survival of two-thirds of BL cell lines studied, and this was dependent on 
PI3K signalling rather than NF-κB signalling. TCF3 was thought to be responsible for 
augmenting PI3K signalling in BL cells [115].  Interestingly, almost all BL lines were found 
to rely on increased PI3K signalling [115], a pathway also found to be mutated in EBV+ GC 
and NPC [117, 118]. In fact, deregulation of both the MYC and PI3K pathways in mice 
results in the development of BL-like tumours [128]. BL cells also often contain mutations in 
the p53 pathway [129] or the RB pathway [130], which may contribute to the pathogenesis. 
EBV+ BL cells exhibit the Latency I program of gene expression, in which EBNA1 is 
the only viral protein expressed, i.e. none of the growth and transformation promoting latent 
proteins are expressed. EBNA2 expression is actually incompatible with the high levels of c-
MYC observed in EBV+ BL, yet EBNA2 is required for transformation and proliferation in 
LCLs (see section 1.1.9). Endemic EBV+ BL is thought to arise in the germinal centre when 
a c-MYC translocation arises in an EBV latently infected cell, as the result of deregulated 
AID (Activation-induced cytidine deaminase) expression [131]. EBV might protect cells 
overexpressing c-MYC from apoptosis due to survival signals promoted by the LMPs, 
providing them with a selective advantage. Studies in BL cells have shown that Latency I, in 
particular the EBERs, confers some protection from apoptosis [132-135]. BHRF1, a BCL-2 
homologue, and the EBNA3s have been shown to be responsible for apoptotic resistance [101, 
133, 136]. In particular, EBNA3A and EBNA3C cooperate to downregulate BIM (BCL-2-
interacting mediator of cell death) which encodes a pro-apoptotic protein, thereby enabling 
EBV+ BL cells to evade apoptosis [101]. This is achieved by methylation of the BIM 
promoter [102, 137]. 
The involvement of malaria in endemic BL has been known for over 50 years [6], but 
has only recently been explained [131]. Thorley-Lawson et al. propose that P. falciparum, the 
causative agent of endemic malaria, targets germinal centre B cells to increase the risk of BL 
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development [131]. P. falciparum has been shown to cause deregulated expression of AID, 
which increases the risk of c-MYC translocations occurring, as well as increasing the number 
of B cells passing through the germinal centre and increasing the frequency of EBV-infected 
cells which are resistant to c-MYC-induced apoptosis. In particular, P. falciparum was found 
to increase expression of AID, but only in the presence of IL-4 and CD40 ligand, i.e. this 
only occurs in the germinal centre where T cell help is available. The fraction of germinal 
centre B cells in the tonsils was found to be nearly doubled in individuals with malaria. More 
importantly, the number of EBV-infected B cells was found to be around 70-fold higher in 
tonsils from individuals infected with P. falciparum. Therefore infection with malaria appears 
to increase the likelihood of a c-MYC translocation occurring in EBV-infected B cells. 
Around 30% of Hodgkin’s lymphoma (HL) cases are associated with EBV. HL is 
characterised by large, sporadically bi-nucleated tumour cells of B cell origin, that constitute 
around 1% of the tumour mass and are known as Reed-Sternberg (R-S) cells [138]. The vast 
majority of the tumour consists of reactive infiltrating cells, particularly T cells. EBV is most 
frequently observed in the mixed cellularity subtype in children and elderly patients [138]. 
EBV-positive Reed-Sternberg (R-S) cells exhibit the Latency II program, corresponding to a 
centrocyte-like phenotype, indicating that tumours arise from latently infected germinal 
centre B cells [139, 140]. This is supported by the fact that the R-S cells have hypermutated 
Ig genes [139]. HL does not show expression of the growth-promoting EBNAs, but LMP1 
and LMP2A, which provide survival signals for latently infected germinal centre B cells, are 
detected at high levels in R-S cells [139]. Oncogenesis might result from a combination of 
EBV-mediated survival signals and mutations blocking B cell differentiation [45]. Various 
studies have been conducted into the genetic background of HL. A translocation of the major 
histocompatibility complex (MHC) class II transactivator CIITA/MHC2TA is frequently 
found in HL [141]. Also, HLA class I alleles have been associated with EBV+ HL in 
Caucasians: HLA-A*01 has been shown to be a risk allele and HLA-A*02 has been shown to 
be a protective allele [138]. HLA-A*02:07 is thought to be a predisposing allele for EBV+ 
HL and has also been associated with EBV+ NPC. The association of HLA-A variants with 
EBV+ HL is likely due to the effectiveness of different alleles to present EBV peptides to 
CD8+ cytotoxic T cells. The HLA-A*01 allele has minimal affinity for EBV latency II-
derived peptides, but HLA-A*02 can induce effective cytotoxic T cell responses to the same 
peptides in a greater proportion of individuals. Therefore different HLA-A alleles might 
affect the number of EBV+ B cells that are available for malignant transformation and that 
can reach a fully malignant state. Another gene locus associated with EBV+ HL is the 
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FCGR2A/CD32 (Fc fragment of the IgG low affinity IIa receptor) [142], which again is 
associated with poor control of EBV latent infection and might contribute to oncogenesis in 
the same manner as HLA-A variants.  
Around 90% of nasopharyngeal carcinoma (NPC) cases are associated with EBV 
[116]. NPC arises in the epithelium of the nasopharynx and has a distinct geographical 
distribution with high incidence in Southern China and Taiwan, southeast Asia and northern 
Africa [19, 117]. Key factors involved in the pathogenesis of NPC include EBV infection 
[143], genetic background [144, 145] and chemical carcinogens found in the regional diets 
[146-148]. Recently, analysis of 128 cases with NPC by whole-exome and targeted deep 
sequencing, along with SNP array analysis, has identified a distinct mutational signature for 
NPC [117]. Genetic lesions were found to be enriched in the processes of chromatin 
modification, autophagy and ERBB-PI3K signalling. Specific frequently mutated genes 
identified included the tumour suppressor TP53, proto-oncogenes KRAS and NRAS, cell-cycle 
regulator CDKN2A, deubiquitinating enzyme BAP1 and nucleosome remodelling component 
ARID1A. ARID1A was deleted or mutated in 10% of cases and was found to negatively 
regulate c-MYC expression, cell proliferation and cell migration [117]. 
EBV protein LMP1 is detected in nearly 80% of NPC cases, indicating an important 
role for EBV in the pathogenesis of NPC [149]. In NPC, EBV shows the Latency II gene 
expression program. LMP1 has been found to contribute to tumour progression rather than to 
initiate malignant growth, however epithelial expression of LMP2 transgenic mice increases 
the frequency of papillomas and carcinomas [150]. LMP expression levels vary between 
tumours [151], although LMP1-upregulated anti-apoptotic protein BCL-2, is frequently 
overexpressed in NPC [149]. Upregulation of BCL-2 in NPC cells has also been linked to 
EBERs expression [152, 153]. EBV encoded microRNAs are highly expressed in NPC 
tumours and could be linked to NPC pathogenesis [154, 155].  
EBV is strongly associated with a subset of gastric carcinomas (GC), which account 
for up to 10% of total GC cases. In a recent Cancer Genome Atlas analysis of primary gastric 
adenocarcinomas, 81% of GC cases were found to be male, and 62% of EBV+ GCs were 
found to originate in the body or fundus of the stomach [118]. Interestingly, EBV-positive 
GCs were observed to have extensive DNA promoter hypermethylation and all EBV+ GCs 
were found to have promoter hypermethylation at the CDKN2A (p16
INK4A
) cell cycle 
regulator locus [118]. Also, 80% of EBV+ GCs had mutations in PIK3CA, a component of 
the PI3K signalling pathway. Importantly, mutation of each of these two genes was also 
found to be associated with NPC [117].  ARID1A has been found to be mutated in 55% of 
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EBV+ GC tumours [118, 119], as well as in 10% of NPC cases, and ERBB2 mutations have 
also been observed in both EBV+ GC and NPC [117-119]. This indicates a specific role for 
EBV in the development and progression of epithelial malignancies. Mutations in the gene 
encoding anti-apoptotic protein BCOR have found in 23% of EBV+ GC cases, and 
amplifications at the 9p24.1 locus have been identified in 15% of cases [118], and also 
chromosome 18q loss is frequent in EBV-associated GC tumours [119]. The 9p24.1 locus 
contains JAK2, encoding a receptor tyrosine kinase, and CD274 and PDCD1LC2, genes 
encoding immunosuppressant proteins PD-L1 and PD-L2, respectively. PD-L1 expression 
has been found to be upregulated in EBV+ lymphoid cancers [156, 157]. Interestingly, unlike 
NPC, EBV+ GC tumours are characterised by a lack of TP53 mutation [117-119]. EBV+ GC 
tumours are also relatively chromosome stable [119]. Prominent levels of A to C base 
transversions at AAG trinucleotides have been observed in EBV+ GC cases and IL-12 
signalling signatures were also strongly associated with EBV+ GC tumours [118]. 
Upregulation of insulin-like growth factor 1 (IGF1), an autocrine growth factor, is repeatedly 
detected in biopsies from EBV+ GC [158] but not in EBV- biopsies, and may contribute to 
disease pathogenesis. The EBERs in particular have been shown to induce expression of 
IGF1 [158]. 
 It is clear that EBV-associated malignancies are the result of the interaction between 
the host’s genetic background with EBV and other cofactors, such as other pathogens or 
carcinogens. Whilst EBV gene products enable the virus to infect and persist in B 
lymphocytes, these also promote transformation and malignant growth under certain 
physiological circumstances. 
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1.2 The Epstein-Barr encoded RNAs 
 
1.2.1 Non-coding or functional RNAs 
In 2001, the first draft of the human genome sequence was published [159] and 
initially predicted the human genome to have around 31,000 genes. This was much smaller 
than previous estimates [160] and meant that only around 2% of the human genome was 
occupied by protein-coding regions [161], posing the question why do humans have so few 
genes? This was named the G-value paradox [162]: that protein-coding capacity did not 
increase with the complexity of the organism and that only a small fraction of the genome 
was translated. This could only be partly accounted for by the existence of alternative 
splicing.  
It has been understood since the 1970s that many DNA sequences are transcribed but 
not translated, and recent estimates suggest that almost 80% of the human genome is 
transcribed [163], making the vast majority of human transcripts non-protein coding. These 
transcripts were termed noncoding RNAs (ncRNAs). Substantial evidence indicates that the 
proportion of non-protein-coding DNA sequences increases with organism complexity [163], 
resolving the G-value paradox and strongly suggesting the involvement of ncRNAs in 
organism complexity. 
ncRNAs are transcribed from introns and regions of the genome previously thought to 
be “gene deserts” [163] as well as from protein-coding exons, either from reading frames 
overlapping the exons or by transcription from the antisense DNA strand [164]. They fulfil a 
variety of functions, including regulation of splicing, structural roles, regulation of protein 
synthesis, epigenetic regulation, RNA editing, and regulation of development, hence the term 
“functional RNAs”.  
 
1.2.2 Types of non-coding RNA 
ncRNAs are increasingly being shown to be important in development and disease. 
This will be illustrated by the discussion of a few of the best understood ncRNA types. Non-
coding RNAs also include tRNAs and rRNAs but these are well-established in their roles and 
will not be discussed here. Non-coding RNAs can be broadly divided into two groups: small 
ncRNAs and long ncRNAs, which are considered to be those greater than 200 nt in length. 
Small non-coding RNAs include microRNA (miRNA), short interfering RNA (siRNA), 
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PIWI-interacting RNA (piRNA), spliceosomal RNAs (snRNAs), small nucleolar RNA 
(snoRNA) and Cajal-body specific RNAs (scaRNA) [165]. 
Long noncoding RNAs are transcribed from intergenic and intronic regions and are 
also transcribed antisense to protein-coding genes. Their general definition of being greater 
than 200 nt in length is arbitrary and corresponds to a convenient cut-off point in RNA 
fractionation [165]. These can be classified into antisense, intronic or intergenic (large 
intergenic noncoding RNA, lincRNA) out of convenience rather than functional significance. 
Some long ncRNAs span tens to hundreds of kilobases [166] and many are expressed at low 
levels or poorly conserved. However, several long ncRNAs are highly conserved [167] or cell 
type- or primate-specific [168, 169], and it is emerging that long ncRNAs might be conserved 
at the structural level [170]. Many long ncRNAs are alternatively spliced [171] and 
expression is generally regulated by conventional transcription factors [172]. Few long 
ncRNAs have been functionally characterised. Those studied have been found to regulate 
gene expression [171, 173] and to be involved in development [174, 175] and disease [176] 
(most notably HOTAIR which promotes cancer metastasis [177]). 
The small ncRNAs miRNA, siRNA and piRNA are all part of the phenomenon of 
RNA interference (RNAi), in which gene expression is silenced following the introduction of 
sense-antisense RNA pairs [178]. This was first discovered in plants [179] and C. elegans 
[180]. These RNAs are all less than 30 nt in length and all use as their minimal effector an 
RNP complex containing an Argonaute family protein and mediate their effects by base 
pairing with target RNAs. Both siRNA and miRNA are single stranded RNAs (ssRNAs) 
between 21 and 23 nt in length which bind to complementary sequences generally in the 3’ 
UTR of target mRNAs [178]. siRNAs are exogenously encoded and typically act by perfect 
base pairing to target mRNAs resulting in degradation of these mRNAs. miRNAs are 
endogenously encoded and generally act by imperfect base pairing to target mRNAs resulting 
in specific translational repression. Both siRNA and miRNA are transcribed as larger dsRNA 
precursors [178]. The precursor miRNA, called primary miRNA, is cleaved in the nucleus by 
the endonuclease Drosha into dsRNA around 70 nt in length (pre-miRNA), which is then 
exported to the cytoplasm [181]. In the cytoplasm, pre-miRNA and precursor siRNAs are 
cleaved into smaller dsRNA, typically by a Dicer RNaseIII enzyme [178]. The strand of the 
RNA duplex with the least stable 5’ end is incorporated into the RNA-induced silencing 
complex (RISC), which is an RNP effector complex containing an Argonaute family protein 
[182, 183]. Perfect base pairing between the siRNA and target mRNA results in degradation 
of target mRNAs by catalytically active Argonaute proteins, whereas imperfect base pairing 
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induces recruitment of translation repressing factors such as MOV10 and ribosome inhibitory 
protein eIF6 [184]. The level of complementarity of the ssRNA with its target sequence 
appears to determine whether the outcome is Argonaute-mediated mRNA degradation or 
translational repression [181, 185]. miRNA can also mediate degradation of nascent mRNA 
via the interaction of RISC with the CCR4-NOT1 deadenylase complex [186]. RNA-driven 
silencing typically occurs in cytoplasmic foci called P-bodies [178]. 
The miRNA pathway has been shown to be essential for development in mice [187, 
188]. Several miRNAs have also been identified as oncogenes or tumour suppressor genes. 
let-7 miRNAs are implicated as tumour suppressors and target oncogenes including RAS and 
HMGA2 [189]. miR-21 is overexpressed in a variety of human cancers including breast, 
colon and liver, and has been shown to downregulate four tumour suppressor genes: PTEN, 
mapsin, PDCD4 and TPM1 [189]. miRNAs have also been shown to contribute to 
haematopoietic differentiation [190] and skeletal development [191] in mice. 
piRNAs are ssRNAs 26-30 nt in length which mediate RNAi by utilising a distinct 
subclade of AGO proteins termed PIWI [165]. PIWI proteins are required for germ cell 
development [192-195] and act by epigenetically and post-transcriptionally silencing 
transposons in germ cells [196-199]. PIWI proteins also colocalise with Polycomb group 
proteins in an RNA-dependent manner [200] and further roles for piRNAs in the brain [201, 
202] and other somatic tissues [203] have been identified. 
 snRNAs were identified by biochemical fractionation and were found to be part of 
ribonucleoprotein complexes central to the process of mRNA splicing [204]. snRNAs U1, U2, 
U4, U5 and U6 are involved in the RNA-RNA and RNA-protein interactions crucial for the 
proper assembly and function of canonical spliceosomes. The 5’ splice site is recognised by 
U1 and the branch point is recognised by U2. U4, U5 and U6  displace U1 and interact with 
U2 via U6, and the 5’ and 3’ splice sites via U5 [205]. There are also sets of less abundant 
snRNAs found in ‘minor’ spliceosomes, for example the variant U12-dependent spliceosome 
contains U11, U12, U4atac and U6atac along with U5 snRNA [206]. 
 snoRNAs were found to be localised in the nucleolus after original identification by 
biochemical fractionation [165]. The box C/D subclass of snoRNAs guides methylation of 
rRNAs, tRNAs and snRNAs, whilst the box H/ACA subclass guides pseudouridylation of 
those same RNAs. It was found that these modifications were essential for proper function of 
rRNAs, tRNAs and snRNAs, in particular the disruption of snoRNAs was found to prevent 
processing of specific rRNAs in plants [207]. Cajal body RNA (scaRNA) is a related small 
RNA class similar to snoRNA in size, structure and function. scaRNAs are localised to 
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subnuclear structures called Cajal bodies, which are thought to process the telomerase RNP 
and to contribute to the maturation of RNPs involved in splicing [208]. 
 
1.2.3 Functional RNAs in EBV infection 
The importance of noncoding RNAs in virus infection is becoming increasingly clear: 
many viruses encode their own ncRNAs and viruses can also target cellular miRNAs to 
subvert cellular processes. EBV is no exception and produces various functional RNAs 
during its life cycle. It was the first virus found to encode miRNAs [209] and the first and 
only virus so far found to encode a small nucleolar RNA, EBV v-snoRNA1 [210]. EBV 
produces the two Epstein-Barr encoded RNAs, which are the most abundant transcripts in 
latent infection [211] (and will be discussed further in section 1.2.4). New EBV ncRNA 
families have recently been proposed [212, 213]: a recent bioinformatics- and RNA-Seq-
based study identified 249 novel regions which might generate conserved structured RNAs 
[213]. Two potential novel EBV RNAs, EBV stable intronic sequence RNAs 1 and 2 (ebv-
sisRNA-1 and ebv-sisRNA-2) were identified [213]. 
The EBV v-snoRNA1 is a 64 nt ncRNA transcribed from an intronic sequence in the 
BART region, around 100 nt downstream of the BART2 miRNA [210]. It is similar to 
eukaryotic C/D box snoRNAs in sequence and structure but does not have the terminal stem. 
v-snoRNA1 has been shown to bind three canonical snoRNA proteins, fibrillarin, Nop56 and 
Nop58 [210]. v-snoRNA1 was expressed in all EBV-positive cell lines that were tested, 
including LCLs, and expression levels increased by up to 30-fold upon lytic induction. It is 
possible that v-snoRNA is processed into a 24 nt RNA, v-snoRNA1
24pp
, during lytic 
replication [210]. This small RNA might target a sequence in the 3’ UTR of BALF5 (EBV 
DNA polymerase) mRNA. A v-snoRNA homologue has also been found in the rhesus LCV 
genome by computational analysis.  
EBV can produce up to 50 different mature miRNAs [214, 215], which are also 
largely conserved in rhesus LCV [216, 217]. The miRNAs occur in two clusters on opposite 
sides of the EBV genome, in the BHRF1 and the BART regions [209, 217-220], and are 
differentially expressed during latency. BART miRNAs are expressed at high levels in 
latently infected epithelial cells and at lower levels in B cells at all latent stages, whereas 
BHRF1 miRNAs are mostly detected in Latency III [209, 217, 221, 222]. This suggests that 
the BART miRNAs might play a particular role in EBV infection of epithelial cells. LCLs 
made using the B95-8 strain of EBV express a limited selection of miRNAs due to a deletion 
of BART genes 5-14 and 16-20, suggesting that these miRNAs are dispensable for EBV 
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infection and transformation [223]. EBV miRNAs target viral and host genes [215, 224] and 
both viral and host miRNAs can regulate EBV genes [215].  
The EBV miRNA targetome has recently been analysed by RIP-chip (RNA binding 
protein immunoprecipitation-microarray profiling) [225] and PAR-CLIP (photoactivatable 
ribonucleoside-enhanced crosslinking and immunoprecipitation) [224]. EBV miRNAs were 
found to target cellular transcripts mainly during latent infection, in particular targeting the 
processes of innate immunity, cell proliferation and cell survival [224]. Also the induction of 
lytic replication has been found to enhance the expression of many EBV-encoded miRNAs 
[217]. Targets of specific EBV-encoded miRNAs have been identified. The EBV miRNA 
miR-BART2 is transcribed antisense to BALF5 and can target the BALF5-encoded viral 
DNA polymerase for degradation [209, 226]. This miRNA has also been shown to 
downregulate the expression of the NK cell ligand MICB, thereby contributing to immune 
evasion [227]. Other EBV miRNAs that could contribute to immune evasion are miR-
BHRF1-3, which downregulate interferon inducible chemokine CXCL11, a T cell attractant 
[228]. BART miRNAs can also reduce the expression of EBV immunogenic proteins LMP1 
[229] and LMP2A [230] to evade immune surveillance. Another EBV immunogenic protein, 
EBNA2, is downregulated by miR-BART6 [231]. EBV-encoded miRNAs do not just target 
latent proteins; miR-BART6 also inhibits lytic master regulator BZLF1 [231] and as 
mentioned before miR-BART2 targets the viral DNA polymerase [226]. EBV miRNAs can 
also promote host cell survival: miR-BART5 downregulates the protein p53 upregulated 
modulator of apoptosis (PUMA) in NPC cells, thereby conferring resistance to apoptosis 
[232]. BIM, another cellular pro-apoptotic protein, is downregulated by miR-BART cluster 1, 
which targets the 3’ UTR of its transcript [233]. EBV miRNAs have also been found to 
contribute to LCL formation in vitro: BHRF1 miRNA mutational inactivation inhibits LCL 
outgrowth, impairs G1 to S cell cycle transitions and alters EBV latent gene expression [111, 
234, 235]. 
EBV also controls the expression of various cellular miRNAs during infection. In 
vitro EBV primary infection of B cells was found to cause a dramatic downregulation of 
cellular miRNA expression, in particular downregulating miR-1, miR-196b and let-7 tumour 
suppressor RNAs. [236]. The same study also showed that immuno-modulatory miR-146a is 
downregulated on initial infection and upregulated more than 100-fold during the lytic cycle 
[236]. miR-150 levels have been found to be low in EBV-positive BL cell lines [237] and 
hsa-miR-127, which is involved in the regulation of B cell differentiation, has been shown to 
be found to be upregulated in EBV-positive BL samples [238]. Also, EBV latent gene 
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expression has been found to be regulated by MYC-regulated host genes from the miR-17/92 
cluster [224]. 
miR-34a, a p53-targeted tumour suppressor, is strongly induced by EBV infection, 
and expressed in many EBV and KSHV-infected lymphoma cell lines [239]. LMP1 was 
found to induce miR-34a in a p53-independent manner and miR-34a was found to have a 
growth-promoting role in EBV infection [239]. In the same study, EBV infection of naïve B 
cells was found to induce the expression of 42 cellular miRNAs and repress the expression of 
60 cellular miRNAs. A set of 17 miRNAs were specifically regulated during LCL outgrowth, 
indicating roles for different cellular miRNAs at different stages of EBV infection. miRNAs 
involved in B cell activation and oncogenesis were induced by EBV infection, including 
miR-155 and miR-21. miRNAs repressed at early stages of EBV infection included miR-223, 
miR-150, and let-7b. miRNAs regulated by oncoprotein c-MYC, which drives BL cell 
proliferation, were found to be induced during the period of outgrowth to LCLs [239], 
consistent with the c-MYC driven transcriptional program induced in B cells early after EBV 
infection [240]. LMP2A was found to maintain LMP1 induction of miR-34a, and miR-34a is 
thought to mediate its effects through targeting components of the Notch signalling pathway 
[239]. These data indicate that EBV and cellular proteins dynamically regulate cellular 
miRNA expression during different stages of latent infection. 
LMP1 has specifically been found to induce expression of miR-146a in B cells [241] 
and to transactivate expression of miR-155 [239, 242, 243]. miR-146a is a candidate tumour 
suppressor gene [244] whereas miR-155 is a likely proto-oncogene [245, 246] that has been 
shown to be required for growth and survival of EBV-immortalised LCLs in vitro [247]. 
Expression of miR-155 in BL has been linked with EBV latency III infections, but is not 
found in Daudi cell lines, possibly due to the absence of LMP, EBNA2 and EBNA-LP 
expression in this cell line [223, 248]. Interestingly, herpesviruses KSHV and Marek’s 
disease virus both encode functional analogues of miR-155, suggesting a role in oncogenic 
herpesvirus biology [249, 250]. 
As well as being induced by EBV infection in B cells [239], miR-155 and miR-21 
have been found to be upregulated in Reed-Sternberg cells in EBV+ HL [251]. miR-200a was 
found to be downregulated in these R-S cells [251], as well as in EBV+ gastric carcinoma-
derived cell lines [252]. miR-200 family downregulation in EBV+ GC cells appears to be due 
to latent genes BARF0, EBNA1 and LMP2A, and results in upregulation of proteins ZEB1 
and ZEB2 which repress E-cadherin expression. E-cadherin dysregulation disrupts cell 
adhesion and promotes migration, and is a crucial step in the carcinogenesis of EBV+ GC. 
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Overexpression of ZEB1 and ZEB2 may also contribute to the maintenance of latent 
infection as these repress transcription of lytic regulator BZLF1 [253]. 
To date, more than 200 viral miRNAs have been identified, and most known viral 
miRNAs are encoded by herpesviruses [254]. This indicates that miRNAs play a specific role 
in the herpesvirus life cycle. A close relative of EBV, rhesus LCV (rLCV), encodes 36 
known miRNAs, 18 of which have conserved sequences to EBV miRNAs, suggesting that 
these miRNAs have particular conserved targets crucial for the viral life cycle. 
Other noncoding RNAs expressed by EBV include ebv-sisRNA-1 and ebv-sisRNA-2, 
two ncRNAs transcribed from introns in the W repeat region of the EBV genome [212]. 
These were identified by computational modelling and RNA-Seq analysis [213]. Ebv-
sisRNA-1 is an 81 nt long linear RNA molecule whose sequence is 100% conserved between 
EBV strains. This transcript is highly expressed, and is the third most abundant EBV-
produced ncRNA in Latency III after EBER1 and EBER2. Ebv-sisRNA-2 is a conserved, 
stable RNA structure that consists of around 40% of the long W repeat intron [213]. Ebv-
sisRNA-2 resembles the HSV1 latency-associated transcript (LAT), which is an abundantly 
expressed intronic transcript ~2000 nt long. The thermodynamically stable hairpin loop of 
ebv-sisRNA-2 is 100% conserved between EBV strains [212]. The roles of these novel EBV 
ncRNAs are not yet known, however the hairpin loop of ebv-sisRNA-2 is predicted to 
contain strong sites for RNA editing by ADAR, the adenosine deaminase acting on RNA 
[213]. 
It is likely that more EBV-encoded functional RNAs will be described in the future. 
The high expression of many of these RNAs suggests that these play a role in EBV latent 
infection. The roles of the EBV miRNAs in immune evasion best characterised of the EBV 
noncoding RNAs. The EBERs have been the focus of various studies since their 
identification, and are of particular interest due to their abundant expression levels and high 
degree of conservation between different EBV strains.  
 
1.2.4 Expression of the Epstein-Barr encoded RNAs (EBERs) 
The EBER1 and EBER2 are two nontranslated, nonpolyadenylated EBV-encoded 
RNAs which are 167 and 172 nucleotides in length, respectively [211, 255]. The EBERs 
form similar stable stem-loop structures by intramolecular base pairing (Figure 1.4) [256]. 
The EBERs are estimated to be present in latently infected cells at 10
4
-10
5
 copies per cell, 
making them the most abundant EBV transcripts [257-259].  
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Figure 1.4 Secondary structures of EBER1 and EBER2 EBER1 and EBER2 form similar stem-loop 
structures by intramolecular base pairing, enabling interaction with various cellular proteins [255, 256]. A) First 
proposed secondary structures of EBER and EBER2. Adapted from [255]. B) More recently proposed structures 
of EBER1 (taken from [213]) and EBER2 (taken from [260]). Secondary structure models were proposed for 
based on a combination of free energy minimisation and comparative sequence analysis. 
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The EBERs have been shown by in situ hybridisation to have nucleoplasmic 
localisation [259, 261], but have been observed in the cytoplasm of Raji cells during 
interphase, where they were localised in the rough endoplasmic reticulum and the Golgi 
apparatus [262]. These localisation patterns may be due to the interaction of EBERs with 
cellular proteins such as RPL22 [110] (see section 1.3.1).  
EBER1 and EBER2 are located in tandem on the EBV genome near to the episomal 
origin of replication, OriP, and are separated by a 161 nt long intragenic region [20, 257, 263]. 
The EBERs are transcribed by RNA polymerase III [255] and as such rely on downstream 
intragenic promoter elements, Box A (+10) and Box B (+50) [258]. These are required for 
high levels of EBER expression: mutation of Box A reduces expression by 20% compared to 
wild type and mutation of Box B reduces expression by 97% [258]. The EBER genes also 
contain three upstream RNA polymerase II regulatory elements required for high EBER 
expression levels: a Sp1 motif, an ATF motif, and a TGTA motif or TATA box for EBER1 or 
EBER2, respectively. Deletion of these upstream elements reduces expression of each EBER 
by over 95% [258]. It is not known whether the EBERs are also transcribed by RNA 
polymerase II in vivo [264]. The structure of the EBER genes is depicted in Figure 1.5 and it 
is worth noting the similarity in structure of the two EBER genes. The combination of RNA 
polymerase II and RNA polymerase III promoter elements is unusual and shared only by a 
few cellular RNA polymerase III-transcribed genes including 7SL [265] and the vault 
ncRNAs [266]. Normally, RNA polymerase III-directed genes have either upstream promoter 
 
 
Figure 1.5 Structure each of the EBER genes The genes for EBER1 and EBER2 contain RNA polymerase II 
upstream regulatory elements Sp1, ATF and TATA/TGTA, along with RNA polymerase III intragenic promoter 
elements Box A and Box B. The transcription termination signal for both EBER1 and EBER2 is a short run of T 
residues. In addition, EBER1 contains two upstream enhancer elements (EE) which can bind cellular 
transcription factor and proto-oncogene c-MYC. 
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elements only, such as the genes U6 [267] and 7SK [268], or intragenic promoter elements 
only, such as tRNA genes [269]. Genes transcribed by RNA polymerase III are commonly 
terminated with a poly-thymidine tract, a feature shared by the EBERs [270, 271]. The gene 
for EBER1 also includes two upstream enhancer elements which are not present in EBER2. 
These two boxes have the sequences CAGATG and CACGTG [272]. 
 Regulation of EBER expression is dependent on the host cell factors as well as viral 
factors. Viral factors act to upregulate the host factors that promote EBER expression. 
EBNA1 upregulates expression of two transcription factors which contribute to the high 
levels of EBER expression: activating transcription factor 2, ATF2, and the TFIIIC complex 
(transcription factor for polymerase III C) [273, 274]. ATF2 interaction with the EBER 
promoters is enabled by its phosphorylation in EBV-infected cells [274]. These transcription 
factors also increase the expression of other RNA polymerase III transcripts, such as tRNA 
and rRNA, enabling an increase in protein synthesis in latently infected cells. EBNA1 and 
EBNA2 also increase the expression of proto-oncogene c-MYC [93, 273] which binds to the 
two E boxes upstream of EBER1 to enhance EBER1 expression [272]. c-MYC does not 
affect EBER2 expression. c-MYC also interacts with transcription factor TFIIIB to enhance 
expression of other RNA polymerase III targets [275], and expression of TFIIIB subunit 
BDP1 is increased following EBV infection [274]. EBER expression is also potentially 
regulated epigenetically by CpG methylation of the EBER promoters [276] and the local 
nucleosome structure might be unusual because this region of the EBV genome is especially 
sensitive to micrococcal nuclease [277]. 
EBER1 and EBER2 differ in both their transcription rates and half-lives. In Daudi 
cells, EBER2 transcription is 1.5 times that of EBER1 transcription, but the steady-state level 
of EBER1 is over 10-fold greater than for EBER2 due to a much faster rate of turnover of 
EBER2 [278]. In the presence of actinomycin D, the half-lives of EBER1 and EBER2 were 
found to be 8-9 hours and 45 minutes, respectively [278]. The functional significance of these 
differences in turnover are not yet known but suggest distinct roles for EBER1 and EBER2.  
The EBERs are expressed at high levels in all forms of latent infection and all EBV-
associated malignancies [19]. The EBERs are downregulated in lytic infection, with EBER1 
expression being decreased to a larger extent than EBER2 expression [279]. Consistent with 
this, EBERs are not detected in AIDS-associated EBV+ oral hairy leukoplakia [280]. The 
EBERs reach steady state levels (the same as in LCLs) around 72 hours post infection [63]. 
However, recently EBERs have been detected at much earlier timepoints [281]: EBERs 
contained within the virion, termed transduced viral RNAs (tvRNAs), were detected in EBV-
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infected cells two hours post infection. In the same study, different kinetics for EBER1 and 
EBER2 were identified during early infection by qRT-PCR. EBER2 levels were found to 
increase in a logarithmic fashion between two and six hours post infection, at which point 
EBER2 levels reached a plateau. However, EBER1 remained at constant low levels between 
two and six hours post infection and increased to a slightly higher constant expression level at 
around eight hours post infection. These different dynamics for EBER1 and EBER2 during 
the early stages of EBV infection suggest that the EBERs might have specific roles in 
primary infection. 
EBER1 and EBER2 only have sequence similarity at their 3’ and 5’ ends, and their 
overall sequence similarity is 54% [135]. EBERs are highly conserved between EBV strains 
but do vary slightly between EBV Type I and EBV Type II (classified by EBNA2 and 
EBNA3 sequences [282]) [283, 284]. Using B95-8 Type I EBV, and AG876 and P3HR-1 
Type II EBVs, it was shown that EBER1 is entirely conserved, there are two polymorphism 
sites in the EBER2 coding region, and there are eight sites of polymorphism located in the 
161 nt spacer between the EBER genes. EBER polymorphisms have also been compared in 
NPC and GC using PCR analysis [285]. This again showed EBER1 to be conserved and also 
found six further differences in EBER2 and three variants in the intergenic region. All of 
these studies indicate a role for EBER1 due to its high degree of sequence conservation, 
although there are no known functional consequences of the polymorphisms identified. The 
variations in EBER2 might alter its secondary structure, its binding affinity/preferences or 
any post-transcriptional modifications. EBER polymorphisms were also found to be more 
frequent in NPC compared to GC or healthy donors [285], so it would be interesting to see 
whether these polymorphisms are linked to the process of oncogenesis. 
EBER homologues are found in other LCVs, specifically those of Old World primates. 
The EBERs are also similar to two adenovirus noncoding RNAs, VAI and VAII. These 
ncRNAs have a similar size and secondary structure to the EBERs and are also transcribed by 
RNA polymerase III [286]. The EBERs can partially complement VA deletion and substitute 
VA function [287, 288], suggesting the VA RNAs and EBERs might have similar roles. VAI 
is essential for efficient translation of viral mRNAs at late timepoints in infection and VAI 
deletion confers a significant replication defect [289]. This effect is mediated by VAI binding 
to antiviral defence protein PKR and blocking its activation and downstream inhibition of 
protein synthesis [290, 291]. VA RNAs have been shown to inhibit RNAi at late during 
adenovirus infection by interfering with the activity of Dicer, and upon binding Dicer are 
processed into functional siRNAs that can be incorporated into an active RISC [292-294]. 
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These siRNAs have been shown to target specific cellular mRNAs [295, 296]. These studies 
collectively suggest that adenovirus VA RNAs block cellular defence pathways targeted 
against long and short dsRNA.  
Herpesvirus papio (HVP) produces two RNA-polymerase III transcribed noncoding 
RNAs similar to the EBERs [297]. HVP, like EBV, is a transforming virus and can transform 
marmoset lymphocytes into LCLs. HVP RNA1 and EBER1 have 83% sequence similarity, 
with HVP RNA1 containing a 22 nt insert, and HVP RNA 2 and EBER2 have 65% sequence 
similarity. The upstream promoter regions are 60% and 50% conserved, respectively, and 
EBERs and HVP RNAs have similar predicted secondary structures. Herpesvirus saimiri 
(HVS) produces seven small U-rich noncoding RNAs, Herpesvirus saimiri U RNAs 1-7 
(HSUR1-HSUR7) [298-300]. HVS, like EBV, is an oncogenic herpesvirus, and can cause 
aggressive T cell leukaemias and lymphomas in New World primates [301]. The HSURs 
upregulate several proteins linked to T cell activation [302]. The HSURs are 114-143 nt in 
length and thought to regulate gene expression at the translational level. In particular, HSUR1 
has been shown to interact with host miR-27 in a sequence-specific manner in order to direct 
miR-27 degradation [303]. This illustrates the use of viral noncoding RNA to manipulate the 
expression of specific host cell genes. Also, HSUR1, like EBER1 (section 1.3.1) has been 
shown to bind AUF1/hnRNP D in vitro [304]. Another feature that the EBERs have in 
common with the HSURs is their dispensability for transformation in vitro [305]. 
 The EBERs also contain a sequence which is present in the splicing site of the protein 
XBP1 (X-box binding protein 1) [306], a plasma cell protein that is thought to couple EBV 
lytic reactivation with B cell differentiation [41, 42]. XBP1 is a regulator of the unfolded 
protein response and exists as an unspliced pre-mRNA which is spliced in the cytoplasm 
upon induction of the unfolded protein response [307]. Hepatitis C virus has been shown to 
prevent splicing of XBP1 [308]. Therefore the EBERs may prevent lytic induction by 
competing with XBP1 for splice enzyme binding. 
The high expression levels of EBER1 and EBER2 during latent infection, but not in 
lytic infection, and their high degree of evolutionary conservation indicates a potentially 
important role for the EBERs during latent infection and EBV persistence. There is emerging 
information of the roles of the EBERs, by the study of their cellular interactions and 
investigation of similar noncoding RNAs. 
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1.3 Roles of the Epstein-Barr virus-encoded RNAs 
 
1.3.1 Interaction partners of the EBERs 
 To date, five EBER-interacting proteins have been confirmed. The antiviral response 
proteins RIG-I (retinoic acid inducible gene I) [309] and PKR (interferon inducible 
serine/threonine protein kinase R) [310] have been shown to interact with both EBER1 and 
EBER2, and La [211], AUF-1 (AU-rich element binding factor 1) [311] and ribosomal 
protein L22 [312] have been shown to interact with EBER1. 
 
RIG-I: 
Both EBERs have been shown to interact with the retinoic acid-inducible gene I 
(RIG-I) protein [309]. In response to RNA with a 5’ triphosphate moiety [313, 314], RIG-I 
activates NF-κB and interferon regulatory factor 3 (IRF3) to induce production of type I IFN 
and inflammatory cytokines. The EBER-RIG-I interaction can promote growth in BL cells by 
enhancing expression of autocrine growth factor interleukin 10 (IL-10) [315, 316]. This effect 
is dependent on IRF3 signalling but is NF-κB-independent [316]. This IL-10 induction might 
contribute to the pathogenesis of EBV+ BL. However, the significance of the interaction is 
challenged, because RIG-I is a cytosolic protein (associated with the actin cytoskeleton) [313] 
whereas the EBERs have nuclear localisation [259, 261]. The interaction could come about 
through cell-cell transmission of the EBERs (discussed in section 1.3.3), where EBERs are 
secreted from EBV-infected cells and are uptaken by other cells. EBERs would pass through 
the cytosol during uptake, enabling the interaction with cytosolic proteins such as RIG-I.  
 
PKR: 
The EBERs can also interact with the interferon-inducible serine/threonine kinase 
PKR [310, 317]. Upon viral infection, PKR binds viral dsRNA, resulting in a conformational 
change allowing PKR to homodimerise and trans-autophosphorylate [318-320]. One major 
downstream antiviral effect of PKR activation is the phosphorylation of eIF2α, an essential 
factor for the initiation of eukaryotic translation [320]. Phosphorylation of eIF2α results in 
sequestration of eIF2B, which prevents productive initiation of translation and thus inhibits 
viral and cellular protein synthesis [321-323]. PKR-mediated inhibition of translation 
ultimately leads to apoptosis of infected cells, an effective antiviral mechanism [324-328]. 
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The binding of EBERs to PKR in vitro has been shown to prevent homodimerisation of PKR 
molecules [329], and to inhibit PKR trans-autophosphorylation [134, 330]. The EBERs have 
been shown to inhibit PKR-mediated translation inhibition in vitro [331] due to prevention of 
PKR phosphorylation, a property shared by the adenovirus VAI RNA [317]. However, VAI 
was found to be more effective than EBER1 at rescuing dsRNA-induced inhibition of protein 
synthesis [317]. This might indicate how the EBERs are able to partially complement VAI 
deletion and substitute for VA function [287, 288]. Various studies have found the EBERs to 
confer resistance to apoptosis [134, 330, 332], however to date there is no direct evidence that 
this effect is mediated by EBER interaction with PKR. The nuclear localisation of the EBERs 
[259, 261], compared to the cytosolic localisation of PKR [333], makes it unlikely that the 
EBER-PKR interaction has functional significance. Concordant with this, the EBERs were 
found not to have an effect on the phosphorylation status of either PKR or eIF2α in EBV+ 
BL cells [334]. The EBERs can however compete for PKR binding with PKR activators, 
thereby preventing apoptotic induction by PKR activators [153]. Given that RNA transcripts 
from the W region of EBV are able to activate PKR and inhibit protein synthesis [335], and 
that the EBERs are highly expressed in latently infected cells [19], it is more likely that the 
EBERs are structured to prevent PKR activation rather than to be specific PKR inhibitors. It 
is also worth noting the inherent problems in studies of innate immune responses to dsRNA: 
any small amounts of dsRNA contamination, or aberrant products in in vitro transcription 
[336], can obscure results. 
 
La: 
EBER1 has been shown to be secreted from EBV-infected cells in complex with the 
protein La [211, 256, 261]. EBER1 interacts with La, a protein thought to be involved in the 
biogenesis and maturation of RNA polymerase III transcripts, via the 3’ terminus of the RNA 
[256]. Transcription termination from RNA polymerase III gives a common 3’ oligo(U) motif 
to which La binds with high affinity [337]. EBER1-La complexes are released from LCLs 
and are able to induce an interferon (IFN) response via stimulation of Toll-like receptor 3 
(TLR-3) signalling in adjacent cells [338]. However, localisation is an issue as La shuttles 
from the nucleus to cytoplasm whereas the EBERs are nucleoplasmic [261]. Therefore the 
EBER-La interaction is likely to represent a stage in the biogenesis of EBER1 rather than an 
effector complex of EBER functions.  
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rpL22: 
EBER1 has been demonstrated to interact with the protein rpL22, a component of the 
large ribosomal subunit [312]. EBER1 can bind up to three rpL22 proteins simultaneously via 
binding sites on stem-loops 1, 3 and 4 [339-343]. High affinity EBER1 binding of rpL22 is 
mediated by basic amino acids 80-93 in rpL22, a region also critical for rpL22 nucleolar 
accumulation and incorporation into ribosomes [344]. In tumour cell lines, in the presence of 
EBV or EBER1, rpL22 becomes delocalised from the nucleoli or cytoplasm into the 
nucleoplasm, potentially depleting rpL22 from ribosomes [342, 345]. However in LCLs, 
rpL22 is localised predominantly in the cytoplasm [110] and rpL22 has been observed in the 
ribosomes of EBV+ Raji cells [345]. rpL22 itself does not appear to be essential for the 
survival or overall development of rpL22 knockout mice, or for in vitro protein synthesis 
[346, 347]. However, mice lacking rpL22 show selective p53-dependent apoptosis of αβ-T 
lymphocyte precursors (γδ-T cell precursors are spared) [346]. This was shown to be 
mediated by p53 effectors miR-34a, PUMA, p21(waf), Bax, and Noxa [348]. However, 
rpL22-knockout mouse embryonic fibroblasts have been observed to behave identically to 
wild type cells in response to p53-dependent apoptosis [349]. 
Another recent study using rpL22-deficient mice identified a compensatory increase 
in expression and ribosome incorporation of rpL22 paralog rpL22-like 1 (rpL22l1) [350]. 
Knockdown of rpL22l1 in cells lacking rpL22 impairs cell growth, suggesting a specific role 
for these related proteins in translation. The same study showed that rpL22 can regulate 
expression of its paralog through binding to an internal hairpin structure in rpL22l1 thereby 
repressing rpL22l1 expression. It would be interesting to see whether EBER1 also binds 
rpL22l1. The study suggests that ribosomal subunit composition might be tailored to specific 
functions. Concurrent with this, rpL22 and rpL22l1 have been found to have specific, 
antagonistic roles in hematopoietic development [351]. In zebrafish embryos, knockdown of 
rpL22 selectively blocked the development of T lineage progenitors after seeding in the 
thymus due to p53-dependent apoptosis, consistent with the previous mouse study [346]. 
Knockdown of rpL22l1 resulted in a p53-indepdendent block to T cell development, 
indicating distinct functions for these paralogs in T cell development. Specifically, rpL22 and 
rpL22l1 were found to have opposing effects on Smad1: rpL22l1 was shown to cause Smad1 
expression and consequent induction of transcription factor Runx1, whereas rpL22 was 
shown to negatively regulate hematopoietic stem cell emergence through blockade of Smad1 
expression [351]. It would be interesting to see whether EBER1 competes with rpL22 for 
Smad1 binding in human cells, and whether this has functional consequences. 
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Interestingly, germline deletion of one allele of rpL22 predisposes T-lineage 
progenitors to transformation in mouse models, in particular accelerating development of 
thymic lymphoma [352]. rpL22 inactivation was shown to promote transformation by 
induction of Lin28B (stemness factor), a stem cell RNA-binding protein frequently 
upregulated in advanced-stage cancers [353]. The same study showed rpL22 to be inactivated 
in around 10% of T-acute lymphoblastic leukaemias. Indeed, rpL22 is frequently mutated or 
downregulated in cancers [354-356], in particular gastric cancer [357], and it is thought that 
rpL22 might be an anticancer agent [358]. Therefore EBER1-mediated alteration of rpL22 
behaviour might be contribute to carcinogenesis in EBV-associated malignancies. 
rpL22 can also interact with human telomerase RNA (TERC) [359] and histone H1 
[360], although the functional consequences of these interactions are not known. rpL22 has 
been shown to bind HSV1 infected cell proteins ICP4 [361] and ICP22 [362], equine 
herpesvirus immediate-early gene protein [363], and the 3’ X-untranslated region of hepatitis 
C virus [364]. rpL22 can also interact with the HVP RNA 1 due to the structural similarities 
between HVP RNA 1 and EBER1 [343]. The wide range of rpL22 roles and interactions 
suggest specific functions for this protein and therefore it is likely that rpL22 is a key 
mediator of EBER1 functions, for example evasion of apoptosis. 
 
AUF1: 
The most recently identified interaction partner of EBER1 is AUF1 (AU-rich element 
binding factor 1)/hnRNP D (heterogeneous nuclear ribonucleoprotein D) [311]. By inserting 
an RNA aptamer which binds the MS2 protein into EBER1, EBER1 RNA-protein complexes 
were isolated, and a combination of this approach with SILAC (stable isotope labelling of 
amino acids in culture) facilitated identification of potential EBER1-binding proteins by mass 
spectrometry. This method yielded AUF1 as a novel EBER1 interaction partner, confirmed 
by RNA-protein crosslinking and coimmunoprecipitation. AUF1 exists in four isoforms 
generated by alternative splicing: p37, p40, p42, p45 [365]. AUF1 is primarily known for its 
ability to bind AU-rich elements (AREs) which are typically present in 3’ UTRs of mRNA 
[366, 367]. These AREs generally enhance the decay of short-lived mRNAs, including those 
for proto-oncogenes and cytokines [368, 369]. However, AUF1 has also been observed to 
stabilise mRNA [370]. AUF1 has also been reported to be involved in suppression of 
senescence and telomere maintenance [371], and AUF1 isoforms are non-redundant [372-
376]. EBER1 was shown to predominantly interact with the p40 isoform of AUF1 in vivo, 
and EBER1 was able to compete with ARE-containing mRNA for AUF1 binding in vitro  
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[311]. Therefore EBER1 is likely to cause an increase in levels of specific ARE-containing 
mRNAs. AUF1 overexpression leads to tumorigenesis [377], therefore it is possible that the 
interaction between EBER1 and AUF1 could contribute to the EBV-mediated oncogenesis. 
AUF1 has also been reported to bind to c-MYC mRNA [378, 379] and therefore EBER1 
binding of AUF1 may dysregulate c-MYC levels leading to carcinogenesis. AUF1 p42 and 
p45 isoforms have also been shown bind to the telomerase promoter to activate its 
transcription [371], and AUF1 interaction with EBER1 has been shown to reduced TERT 
mRNA levels by at least twofold in EBV+ BJAB cells, although this is mediated by the p40 
isoform [311]. Therefore it is possible that the interaction between EBER1 and AUF1 
impacts telomere maintenance. AUF1 has also been shown to inhibit viral translation in 
enterovirus and human rhinovirus infections, suggesting a role as an antiviral factor [380], 
and targeting of AUF1 by EBER1 may limit any potential antiviral activity during EBV 
infection. AUF1 has also been reported to negatively regulate Dicer expression [381], and 
EBER1 sequestration of AUF1 might enable unrestricted expression of EBV-encoded 
miRNAs. Interestingly, HVS noncoding RNA HSUR1 has been shown to bind AUF1/hnRNP 
D in vitro [304], suggesting a conserved role for this interaction.   
 
1.3.2 EBER-mediated induction of interferon alpha 
As part of the host’s innate immune response, interferons (IFNs) are produced 
immediately following infection [382]. IFNs were first discovered from their ability to 
interfere with primary viral infection in culture [383] and are also thought to prevent viral 
spread in vivo [384]. Interferons are classified into Type I, Type II and Type III according to 
the cellular receptors they bind. Type I interferons are generally antiviral and comprise 
interferon alpha (IFNα), interferon beta (IFNβ), interferon epsilon (IFNε), interferon kappa 
(IFNκ) and interferon omega (IFNω) [384].  
IFNα is a family of 13 closely related proteins encoded by the following genes: 
IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, 
IFNA17 and IFNA21 [382]. The IFNA genes lack introns, encode similar length proteins 
(161-167 amino acids) and share 75-99% amino acid sequence identity [385, 386]. IFNα is 
synthesised by many cells types but is expressed at higher levels in plasmacytoid dendritic 
cells. Binding of viral DNA and RNAs to pattern recognition receptors (PRRs) such as toll-
like receptors (TLRs) and binding of viral RNAs to RIG-I and MDA-5 [382] activates NFκB 
or MAPK signalling, resulting in expression of “primary” Type I IFN genes IFNB and IFNA4 
from the interferon beta promoter [387, 388]. IFNβ and IFNα-4 bind IFNAR creating an 
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autocrine loop and also act to initiate transcription of IRF7. IRF7 is required to induce 
expression of the other IFNA genes [388, 389].  
Once secreted, Type I IFNs bind the interferon alpha/beta receptor, IFNAR [384]. 
This leads to the activation of a JAK/STAT signalling cascade resulting in the induction of 
various interferon stimulated genes (ISGs), which act to promote an immune response and 
inhibit viral replication [384]. Some of these ISGs act to reduce viral load by inhibiting viral 
transcription and translation [318, 390]. ISGs involved in mounting an immune response can 
activate NK cells [391, 392], increase B cell and CD8+ T cell responses [393-396], and 
mediate dendritic cell maturation [393, 394]. Dendritic cells in particular mediate B cell 
responses. Type I IFNs activate dendritic cells, resulting in the induction of IL-6 secretion 
[397]. IL-6 has been shown to be required for the activation of B cells and their subsequent 
differentiation into antibody-secreting plasma cells [397]. In particular, IFNα acts directly on 
B cells to amplify BCR-mediated activation [398, 399], which promotes early IgM responses. 
IFNα was also shown to be able to induce a state of partial activation in B cells, characterised 
by increased expression of CD69, CD86 and CD25, but without proliferation or complete 
differentiation [399]. The same study also demonstrated an increased resistance to Fas-
mediated apoptosis in B cells treated with IFNα. 
 Interestingly, the IFNα proteins differ in their biological activities, which is thought 
to be because their binding affinities for IFNAR differ [400-403] as well as due to the cell 
type [402]. It is also likely that different viruses induce different subsets of the IFNA genes 
[384]. IFNα-2 is thought to induce chemokinesis and migration of T cells [404]. IFNα-5, 
which is the main subtype in the liver, has been shown to induce stronger STAT1/TYK2 
signalling than IFNα-2 [405]. Activation of STAT1/TYK2 signalling has been observed to 
promote cell survival by upregulation of anti-apoptotic protein BCL-2 [406]. 
Recently, EBERs contained within the EBV virion, known as transduced viral RNAs 
(tvRNAs) have been shown to induce IFNα production during the first three days of B cell 
primary infection [281]. EBER induction of IFNα has been previously described in EBV-
transformed B cells and peripheral mononuclear cells: free or protein-complexed EBERs 
were shown to activate TLR3, possibly during endocytic uptake, and thereby induce IFNα 
[338]. As quiescent B cells do not appear to express TLR3 [407], it is more likely that tvRNA 
EBERs induce IFNα through RIG-I signalling [309]. Also, in a recent microarray study 
(section 1.3.4), three IFNα genes were observed to be have increased expression in the 
presence of EBER1: IFNA4, IFNA5 and IFNA6 [110]. It is therefore a possibility that the 
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IFNA genes are a specific target for the EBERs. Interestingly, the adenovirus-encoded VA 
RNAs have also been shown to induce the production of IFNα [408, 409]. 
 Type I interferons have been observed to have roles in the maintenance of persistent 
viral infection [410] indicating that the induction of IFNα could be beneficial to the virus 
[411]. Type I IFNs induce IL-6 secretion by dendritic cells, which causes B cell activation 
and differentiation [397]. IL-6 has been shown to enhance LCL growth  and confer resistance 
to apoptosis [109], as well as to mediate tumorigenicity in EBV-transformed B cells [412, 
413]. IL-6 has been observed to be induced by the EBERs (discussed in section 1.3.3) [109, 
412, 414], and it is possible that this occurs in an IFNα-dependent manner under 
physiological conditions. Also, IFNα has been observed to amplify BCR-mediated activation 
[398, 399] and to increase resistance to Fas-mediated apoptosis in B cells [399]. Therefore it 
is possible that EBER-mediated induction of IFNα acts on B cells, both directly and 
indirectly, to promote B cell activation and growth and to confer resistance to apoptosis. This 
could contribute to the survival of latently infected cells in the germinal centre, and also 
could provide a potential role for the EBERs in the pathogenesis of EBV-associated 
malignancies. 
 
1.3.3 Potential physiological roles of the EBERs 
 The EBERs have been observed not to be essential for primary infection, viral 
replication or B cell immortalisation in vitro, using EBER1/EBER2 double deletion mutants 
with the P3HR-1 virus background [108]. P3HR-1 EBV lacks EBNA2 and cannot transform 
B cells. Recombination of P3HR-1 EBV with the EBER/EBNA2 region of B95-8 EBV 
enables transformation, and the role of the EBERs in transformation was tested by 
recombination with either EBERs+EBNA2 or EBNA2 only. The EBERs were found not to 
affect  B cell transformation, LCL transformation, latent expression or levels of spontaneous 
lytic replication in LCLs [108]. Recent work from the Farrell lab supports these findings: 
EBER1- and EBER2-single deletion EBV in the B95-8 background was used to infect B 
cells, and the EBERs were found to have no effect on the transformation or growth of LCLs 
at a variety of cell densities [110].  However, other studies in Akata cells showed that whilst 
EBER1 and EBER2 are dispensable for B cell transformation, EBER2 did contribute to the 
efficiency of B cell transformation and LCL outgrowth, especially at low cell density [109, 
415]. These differences may be due to the experimental procedures or EBV strains used. 
However, it is worth noting that whilst several of the BART miRNAs are absent in B95-8 
EBV, these RNAs are present in P3HR-1 EBV [416] and therefore are unlikely to account for 
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the differences observed in EBER contributions to B cell transformation and growth. As all 
the above studies were performed in vitro, there is still a possibility that the EBERs could be 
involved in B cell transformation and the establishment of persistent infection in vivo. 
EBER1 and EBER2 have been reported to contribute to the oncogenic phenotype of 
EBV-positive Burkitt’s lymphoma and are expressed at high levels in almost all cells of EBV-
associated malignancies. The EBERs have been linked to the development of tumours and 
malignant phenotypes in SCID (severe combined immunodeficiency) mice [132, 330, 332]. 
Transgenic mice expressing EBER1 in the lymphoid compartment were found to develop 
lymphoid hyperplasia and B cell-derived tumours more frequently than normal mice, [417]. 
In Akata cells, reintroduction of EBER expression into EBV-lost clones by transfection 
restored the malignant phenotype and resistance to apoptosis seen in EBV-reinfected cell 
clones. Taken together, these studies indicate that the EBERs are sufficient to mediate 
oncogenic effects in target cells. 
The EBERs have been observed to provide resistance to apoptotic inducers, such as 
cycloheximide, glucocorticoid and hypoxic stress [332], and BJAB cell proliferation in 
normal conditions and under serum starvation was observed to be increased by EBER 
expression [330]. In BJAB cells, and epithelial cells, the EBERs have been shown to confer 
resistance to FAS-mediated apoptosis [330, 418]. The EBERs have also been shown to 
protect BL-derived Akata cells from c-MYC induced apoptosis via the upregulation of BCL-
2 [332, 334, 419, 420] and transfection of EBERs into BL and NPC cells has been observed 
to cause an upregulation of BCL-2  [152, 153]. c-MYC is frequently deregulated in BL [123] 
and therefore the EBERs could permit c-MYC-controlled proliferation whilst preventing the 
apoptotic effects of high c-MYC levels.  
EBER1 and EBER2 have been reported to induce the expression of various cytokines. 
The EBER-RIG-I interaction can promote growth in BL cells by enhancing expression of 
autocrine growth factor interleukin 10 (IL-10) [315, 316]. This effect is dependent on IRF3 
signalling but is NF-κB-independent [316]. IL-10 is commonly expressed in EBV+ BL 
biopsies [315], and EBV encodes its own IL-10 [19], suggesting a role for IL-10 in EBV 
infection. Interestingly, the growth of Akata cells can be inhibited by antibodies to IL-10 and 
under low serum conditions Akata cell growth can be increased by adding recombinant IL-10 
[315]. Consistent with this observation, IL-10 can promote B cell activation and survival 
[421]. IL-10 is a major regulator of innate immunity, and can function to suppress the activity 
of CD4+ T cells and dendritic cells [421], and therefore EBV/EBER-mediated induction of 
IL-10 may contribute to EBV immune evasion.  
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EBER1 and EBER2 have been observed to induce autocrine growth factor insulin-like 
growth factor 1 (IGF-1) in GC and NPC: IGF-1 was found to be upregulated in GC-derived 
cells (EBV-negative) that had been infected with EBV or transfected with the EBERs [158]. 
Secreted IGF-1 was shown to act as an autocrine growth factor for these cells as addition of 
recombinant IGF-1 stimulated growth, but addition of an IGF-1 antibody to the EBV-infected 
GC cells blocked growth. In vivo, EBV+ GC biopsies typically express IGF-1 whereas EBV- 
GC biopsies do not [158], indicating that EBER-mediated induction of IGF-1could contribute 
to the pathogenesis of EBV+ GC. EBER induction of IGF-1 has also been demonstrated in 
NPC cells: IGF-1 was found to be secreted by EBV-positive, but not EBV-negative, NPC-
derived cell lines [422]. Transient transfection assays showed the EBERs to be responsible 
for transcriptional induction of IGF-1. IGF-1 was again shown to act as an autocrine growth 
factor as treatment of the EBV+ NPC cell lines with anti-IGF-1 restricted growth in low 
serum conditions. As with EBV+ GC, EBV+ NPC biopsies consistently express IGF-1, again 
implicating a role for EBER-mediated growth factor induction in disease pathogenesis.   
 Also, the EBERs have been observed to cause upregulation of IL-9 in T-cells [423]. 
IL-9 was found to be expressed at higher levels by EBV-positive T cell lines compared to 
EBV-negative T cell lines, and luciferase assays demonstrated that the EBERs were 
responsible for the increase in IL-9 transcription. IL-9 was again shown to act as an autocrine 
growth factor in these cells. Biopsies of EBV+ T/NK nasal lymphomas showed IL-9 
expression in 3 out of 4 cases, indicating a role for EBER-induced IL-9 in disease progression. 
 RT-PCR analysis of EBER1- and EBER2-knockout LCLs has indicated that IL-6 is 
expressed at higher levels in EBER2-expressing LCLs, and addition of anti-IL6 was shown to 
impair the growth of EBER2-expressing LCLs whilst addition of recombinant IL-6 enhanced 
the growth of EBER2-knockout LCLs [109]. IL-6 was also reported to have an anti-apoptotic 
effect on these LCLs. It is possible that induction of IL-6 by EBER2 is RIG-I-mediated. 
Constitutive induction of IL-6 in EBV-transformed B cells has been observed to lead to 
malignant phenotypes, shown by tumorigenicity in nude mice and clonogenicity in soft agar 
[412], and IL-6 has been shown to be an important factor in the pathogenesis of EBV-
associated PTLD [413]. Recently, ectopic expression of the EBERs in GC cells has been 
shown to upregulate the expression of IL-6 and thereby activate its downstream effector 
STAT3 [414]. Use of an antibody to IL-6 and dominant-negative STAT3 reduced 
chemoresistance and invasion of EBER-expressing GC cells, implicating the EBERs in the 
survival and metastasis of EBV-positive GC tumours. 
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 A recent study investigated RNAs contained within the EBV virion, known as 
transduced viral RNAs (tvRNAs) [281]. qRT-PCR analysis showed that EBV virions 
contained EBNA2, LMP1, LMP2 and viral IL-10 mRNAs, as well as the EBERs. The authors 
suggested that productively EBV-infected cells might release a mix of complete virions, 
virus-like particles, exosomes and other microvesicles, all potentially containing viral RNAs. 
EBV latently-infected cells in vitro have been shown to spontaneously release gp350-positive 
exosomes containing viral proteins or miRNAs [424-428]. EBV uses the exosome biogenesis 
pathway during viral replication so some proteins from this pathway are in viral exosomes 
[429]. Therefore it is possible that EBV releases EBER-containing exosomes. Exosomal 
EBERs could be used for intercellular communication and to target other cell types. 
Exosomes and microvesicles have been shown to transport miRNA and mRNA between cells 
[430, 431], and recently Raji cells have been observed to be able to transfer EBV miRNAs to 
T cells [432]. It is also possible that the EBERs could be transmitted to other cells via 
membrane receptors or cell-cell contact; RNAs have been proposed to be spread between 
cells via membrane receptors or cell-cell contact [433] and act as signalling molecules in a 
similar manner to protein hormones [434]. The EBERs have been shown to be released into 
the supernatant by EBV latently infected cells in culture [338, 349] and therefore it is 
possible that the EBERs could act as extracellular signalling molecules and exert their effects 
on specific target cells through binding membrane receptors. 
 
1.3.4 Potential target genes of EBER1 and EBER2  
The major limitation with many of these studies on the EBERs is the fact that the 
EBERs were not studied separately and therefore it has been difficult to determine the 
individual roles and particular targets of EBER1 and EBER2. Recently, lists of potential 
EBER1- and EBER2- target genes have been identified by comparative microarray study of 
EBER1- and EBER2-knockout LCLs [110]. These LCLs were created from novel EBER1 or 
EBER2 deletion recombinant EBV strains in the B95.8 background. Deletion of EBER2 was 
found to give clearer changes in gene expression than deletion of EBER1. EBER 1 appeared 
to be linked to genes involved in biosynthetic processes and interferon/antiviral responses, 
whereas EBER2 appeared to be linked to genes regulating apoptosis and genes encoding 
membrane signalling molecules [110]. The complete lists of these genes can be found in the 
Appendix section of this thesis. 
Genes linked to EBER1 expression which had the largest expression changes included:  
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IL12RB2 (interleukin 12 receptor beta subunit 2), FAM189A1 (transmembrane protein 
FAM189A1), CDC42BPA (CDC42 binding protein kinase alpha), SEPP1 (selenoprotein P 
plasma 1), CD96 (T cell surface protein tactile), CHL1 (cell adhesion molecule with 
homology to L1CAM), GAS2 (growth arrest specific 2) and IFNA5 (interferon alpha 5). 
Genes linked to EBER2 expression which had the largest expression changes included:  
TBX15 (T-box 15), MMP7 (matrix metallopeptidase 7), GPR125 (G protein coupled receptor 
125), SASH1 (SAM and SH3 domain containing 1), IL12RB2 (interleukin 12 receptor beta 
subunit 2), CXCR3 (chemokine C-X-C motif receptor 3), IGSF4 (immunoglobulin 
superfamily member 4), CNKSR3 (CNKSR family member 3), IGF1 (insulin-like growth 
factor 1) and DACT1 (dapper antagonist of beta catenin homologue 1). RT-PCR validation 
was carried out on some of these gene targets [110] and is shown in Figure 1.6. 
  
 
 
   
 
Figure 1.6 RT-PCR validation of microarray targets Taken from [110]. A) RT-PCR validation of EBER1 
target genes identified by microarray. B) RT-PCR validation of EBER2 target genes identified by microarray. 
CXCR3 was also validated at the protein level. GAPDH and β-actin were used as loading controls.  
 
A subset of genes was identified that had expression changes in response to the 
presence of both EBER1 and EBER2. These were ASS (arginosuccinate synthetase), RNF43 
A 
B 
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(Hap95 binding ubiquitin ligase), NTRK2/TrkB (neurotrophic tyrosine kinase receptor type 2), 
SLC7A11 (solute carrier family 7), CHST6 (carbohydrate sulfotransferase 6), HHEX 
(haemopoietically expressed homeobox), CCDC74B (coiled-coil domain containing 74B), 
TGM2 (transglutaminase 2), SASH1 (SAM and SH3 domain containing 1), ADARB1 
(adenosine deaminase RNA-specific B1) and IL12RB2 (interleukin 12 receptor beta subunit 
2). All of these genes appear to have similar expression changes in response to both EBER1 
and EBER2 except for SASH1 and IL12RB2. SASH1 was found to be upregulated 20x more 
due to EBER2 than EBER1, and IL12RB2 was found to be downregulated twice as much by 
EBER2 compared to EBER1. 
 
SASH1 protein is thought to be associated with the cytoskeleton and cell-matrix 
adhesion [435], as well as with mediating TLR4 signalling to promote migration and the 
production of proinflammatory cytokines in endothelial cells [436]. SASH1 is also a 
candidate tumour suppressor gene that is found to be downregulated in various cancers 
including breast [437] and colon [438]. It is possible that upregulation of SASH1 by the 
EBERs contributes to the phenotype of activated B cells. IL12RB2 encodes a subunit of the 
IL-12 receptor, which, on binding to proinflammatory cytokine IL-12, initiates a 
JAK2/STAT4 signalling pathway resulting in the production of IFNγ and the differentiation 
of T helper 1 cells [439]. It might be that EBER-mediated downregulation of IL12RB2 
contributes to immune evasion. 
Interestingly, IGF-1 was found to be upregulated over 3-fold in the presence of 
EBER2.  IGF-1 mediates processes involved in growth, development and differentiation. 
IGF-1 has been shown to be upregulated and secreted by GC- and NPC-derived cells, and to 
act as an autocrine growth factor in these malignancies [158, 422]. In both cases, the EBERs 
were shown to be responsible for the induction of IGF-1 expression. Therefore it is possible 
that EBER2-mediated IGF-1 production acts to promote growth of latently infected B cells. 
Also, three IFNα genes were observed to be have increased expression in the presence of 
EBER1: IFNA4, IFNA5 and IFNA6 [110]. This supports previous studies showing the EBERs 
to induce IFNα expression [281, 338] (see section 1.3.2). 
The gene ADARB1 (adenosine deaminase, RNA-specific, B1) was found to have over 
five-fold decreased expression in the presence of either EBER1 or EBER2. Interestingly, the 
adenovirus VAI RNA has been shown to interfere with the RNA-editing function of the 
ADAR1 enzyme [440]. This suggests that the EBERs might act to modulate cellular and viral 
gene expression through modulation of RNA editing.  
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TBX15 and MMP7 were the genes identified with the greatest expression changes, 
having expression increases in response to EBER2 of 65.4 and 52.4, respectively. TBX15 is a 
transcription factor involved in the regulation of developmental processes, and in particular is 
involved in skeletal development [441, 442] and adipocyte differentiation [443, 444]. MMP7 
encodes metalloprotease enzyme matrilysin which degrades various protein components of 
the extracellular matrix including elastin, fibronectin and type IV collagen. Matrilysin is often 
overexpressed in human malignancies and is associated with tumour progression, and is 
thought to promote tumour invasion and migration [445]. The roles these EBER2-associated 
genes in EBV latent infection seem unclear but it is possible that MMP7-encoded matrilysin 
might contribute to the growth and phenotype of latently infected B cells. CXCR3 was the 
only gene validated at both the RNA and protein levels. CXCR3 is the receptor for CXCL9, 
CXCL10 and CXCL11, and is highly expressed at sites of infection and inflammation. 
Signalling through CXCR3 results in T cell recruitment and chemotaxis, tissue repair and 
wound healing [446]. Therefore EBER2-mediated downregulation of CXCR3 expression 
might contribute to immune evasion. 
 
Overall, these studies of EBER roles and targets strongly suggest the involvement of 
the EBERs in promoting growth and a tumorigenic phenotype in EBV latently infected cells. 
Cell culture and murine studies have identified particular cytokines that are induced by the 
EBERs and immunoprecipitation studies have enabled identification of five EBER-
interacting proteins. Only recently have specific target genes for each of EBER1 and EBER2 
been identified. Identification of EBER target genes enables future study into the exact 
molecular mechanisms of EBER1 and EBER2.  
The study of EBER1 and EBER2 target genes only validated a small fraction of the 
potential EBER target genes identified, and only using RT-PCR. Therefore an obvious 
starting point for any further study of the EBERs would be the continued validation of 
potential EBER gene targets, and to extend the validation beyond RT-PCR. A clear way to 
validate particular gene targets would be by complementation of EBER expression in EBER-
knockout LCLs. As the efficiency of gene transfer by transfection in LCLs is low, 
complementation of EBER expression would need to be achieved by using the alternative 
method of viral vectors-mediated gene transfer. 
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1.4 Lentiviral vectors  
 
1.4.1 Viral vectors 
Viral vectors are a means of introducing transgene expression into various cell lines. 
Viral vectors were first developed as an alternative to transfection in order to increase cell 
viability and increase levels of transgene uptake [447-449]. They also are currently being 
developed for clinical use in gene therapy and vaccines, to deliver “healthy” gene copies to 
cells and to introduce expression of pathogen proteins, respectively [450]. The vectors take 
advantage of the biology of DNA viruses and retroviruses: that virions release a DNA copy 
of the viral genome into target cells during infection. There are various types of viral vectors, 
including adenoviral vectors, adeno-associated viral vectors, retroviral vectors and lentiviral 
vectors [450, 451]. Adenoviral vectors (from adenovirus) have limited use in basic research 
as they do not integrate into the host cell genome and are not replicated in cell division, and 
their high immunogenicity limits their clinical use [450]. Adeno-associated viral vectors 
(from adeno-associated virus) can transduce both dividing and quiescent cells, and can 
integrate into the host cell genome at a defined location [452]. The ability to target specific 
genes or DNA sequences, along with the minimal immunogenicity of adeno-associated virus 
in humans, makes these vectors attractive candidates for use in gene therapy [450]. Retroviral 
vectors were developed from viruses such as murine leukaemia virus and are used in both 
clinical and basic research due to their ability to stably insert into the host genome [450]. 
They can be replication competent or engineered to be replication defective, however the 
major caveat is that retroviral vectors are unable to transduce non-dividing cells [453]. 
Lentiviral vectors (from lentiviruses, a type of retrovirus) are created from modified HIV-1 
[454, 455] and as retroviruses can stably insert into the host genome so are used in both 
clinical and basic research [455, 456]. Due to their origin they are always rendered replication 
incompetent. Lentiviruses are unique among the retroviral vectors in their ability to transduce 
non-dividing cells [457, 458], which makes them very useful for basic research. 
 
1.4.2 Lentivirus 
Lentivirus is a genus of the family Retroviridae (retrovirus), named after the Latin for 
“slow”, lente, due to a long incubation period following initial viral infection. Lentiviruses 
include human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), feline 
immunodeficiency virus (FIV) and ovine lentivirus (Visna virus) [459]. The lentiviral life 
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cycle is as follows: upon receptor binding, the membrane of the virion fuses with the cell 
membrane, allowing the virus to enter the target cell. Upon entry, the virus uncoats and the 
viral RNA genome is reverse transcribed to produce a complementary double-stranded DNA 
copy of the genome [459]. This cDNA is imported into the host cell nucleus and integrated at 
nearly random locations in the host cell genome [459]. Once the genome is integrated, the 
virus can enter latent infection, in which the virus persists in the host for its lifetime and 
evades immune detection. Alternatively, upon activation, the virus can enter lytic replication 
and cause the host to transcribe the viral genome then synthesise viral proteins and ultimately 
construct new viral particles which are released from the host cell by budding [459]. 
 
1.4.3 Lentivirus genome and proteome 
Lentiviruses have a positive sense, single-stranded RNA (ssRNA) genome. An HIV-1 
virion contains two copies of this viral genome [459]. The genome contains non-coding 
regulatory elements, including the LTRs (long terminal repeats) and RRE (rev response 
element), which comprise the cis-acting elements required for encapsidation, reverse 
transcription and integration of the viral genome. The viral LTRs, are identical RNA 
sequences situated at the ends of the genome, each approximately 640 bp in length [460]. The 
LTRs can be subdivided into the U3, R and U5 regions. The U3 region contains the HIV-1 
transcriptional promoter and adjacent regulatory elements, the R region is involved in the 
reverse transcription process, the U5 regions are involved in packaging of the viral genome 
during virion assembly, and these regions also mediate other viral processes [460]. The 
lentivirus genome contains three genes encoding viral structural proteins, gag, pol and env; 
two genes encoding regulatory proteins, tat and rev; and additional virus-specific regulatory 
genes [459]. In HIV-1 the genes encoding regulatory proteins are vif, vpr, vpu and nef [460]. 
The gag (group-specific antigen) gene encodes three core structural proteins p24 capsid 
protein (CA), p17 matrix protein (MA) and p7 capsid protein (NC), as well as late protein p6 
[460]. pol encodes the reverse transcriptase required to create a cDNA copy of the genome 
and the integrase necessary to insert this into the host cell genome and also a protease critical 
for virion production. env encodes two viral coat glycoproteins, gp120 surface glycoprotein 
(SU) and gp41 transmembrane (TM) glycoprotein [460]. tat encodes transcriptional 
transactivators for the LTRs flanking the viral genome. rev (regulator of virion expression) 
encodes a nuclear export protein which enables differential splicing of the lentiviral genome 
[460]. The vif, vpr, vpu and nef genes encode “accessory proteins”, so called as they can be 
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deleted without affecting viral replication in vitro. However, these four proteins represent 
virulence factors in vivo [461-465]. 
 
1.4.4 Lentiviral vectors created from modified HIV-1 
Introduction of transgenes into target cells using lentiviral vectors is achieved by the 
insertion of the gene of interest into a modified HIV-1 genome. The recombinant genome is 
packaged into virions. The process of viral infection transfers the modified RNA into target 
cells where it is reverse transcribed into dsDNA and stably integrated into the host genome 
[455]. This process of using a viral vector to introduce exogenous genes into target cells is 
referred to as transduction. Wild-type HIV-1 infects a variety of immune cells such as CD4
+
 
T cells and macrophages (mediated by the interaction between the viral gp120 and the 
cellular CD4 antigen) [459, 460]. To broaden the tropism of the lentiviral vector, the HIV-1 
env gene is replaced by the coat protein gene of another virus, commonly VSV-G, the 
vesicular stomatitis virus (VSV) coat glycoprotein gene [466], which enables infection of a 
wide range of cell types (due to its receptor being the LDL receptor, which is expressed on 
most cell types [467]). The use of alternative viral coat proteins is referred to as pseudotyping, 
and the above example would be described as a VSV-G pseudotyped lentivirus. Importantly, 
all lentiviral vectors are engineered to be replication incompetent due to the dangers posed by 
the HIV-1 virus. This is achieved by a deletion of promoters and enhancers in the U3 region 
of the 3’ LTR, abolishing its transcriptional activity [454]. The replication incompetent vector 
is termed self-inactivating (SIN).  
 
1.4.5 Components of an HIV-1 based lentiviral vector system 
A viral vector system is made up of a series of plasmids encoding transgenes as well 
as the genes necessary for virion production and transduction of target cells. This facilitates 
genetic manipulation/amplification in bacteria and introduction into human cells for virion 
production. The viral genetic material is separated across plasmids according to function: the 
vector construct is a modified HIV-1 genome and contains the transgene cassette along with 
cis-acting elements (for encapsidation, reverse transcription and integration of the lentiviral 
genome) flanked by the LTRs; the packaging constructs contain the HIV-1 genes gag, pol, tat 
and rev without lentiviral packaging signals; and the envelope construct contains the coat 
protein gene, commonly VSV-G [454, 455]. This is represented in Figure 1.7. The separation 
of lentiviral genes onto different vectors enables the vector construct to be free of all genes 
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required for viral replication, increasing biosafety, and also creates space for the transgenes to 
be inserted.  
 
     
 
Figure 1.7 Schematic of the lentiviral vector system (adapted from www.addgene.com) The vector 
construct contains the transgene cassette and lentiviral cis-acting elements flanked by LTRs. The packaging 
cassette encodes the viral genes required for encapsidation, reverse transcription and integration of the vector 
construct. The envelope construct contains genes encoding coat proteins and determines the tropism of the virus. 
Diagram not to scale. 
 
Lentiviral particles are produced by simultaneously transfecting the plasmids 
comprising the lentiviral vector system into a packaging cell line, such as HEK 293T, as 
represented in Figure 1.8. The human cells are able to transcribe the encoded genes and 
synthesise the viral proteins, as well as replicate the expression vector (lentiviral genome). 
Virus particles self-assemble inside the cell then bud from the cell membrane to be released 
into the supernatant. 
 
 
Figure 1.8 Production of lentiviral particles The system comprises three plasmids containing a) the transgene 
cassette b) HIV-1 structural genes and c) viral coat protein genes. The plasmids are simultaneously transfected 
into a packaging cell line, such as HEK 293T, to enable production of viral components and the assembly of 
virions, which are released into the supernatant. 
 
1.4.6 Different generations of lentiviral vector systems 
Three generations of lentiviral vector system have been developed to date. First 
generation lentiviral vector systems have one packaging plasmid containing all HIV-1 genes 
61 
 
except for env and therefore have low safety [468]. These systems also use vector constructs 
with a wild-type 5’ LTR, which has a requirement for the tat gene. Second generation 
lentiviral vector systems differ in that the packaging construct contains only four out of the 
nine HIV-1 genes. Auxiliary genes vpr, vif, vpu, and nef, have been removed to increase the 
biosafety of the system [455]. Third generation lentiviral vector systems use a vector 
construct with a chimeric 5’ LTR, replacing the HIV-1 promoter sequence with a promoter 
commonly used in basic research such as the CMV or RSV promoters. This bypasses the 
need for tat on the packaging construct [469]. Therefore third generation systems only 
contain three HIV-1 genes on packaging plasmids: gag, pol and rev. In the third generation 
system, these three genes are separated onto two packaging constructs: one containing gag 
and pol, and the other containing rev [469]. These modifications further increase the 
biosafety the system by further reducing the potential for any replication competent virions to 
be generated. 
 
1.4.7 Factors determining lentiviral transduction and transgene expression 
It is clear that the more transducing units of lentivirus added, the greater the 
proportion of cells that will uptake the foreign DNA. Increasing the number of transducing 
units also increases the likelihood of multiple transduction events so that the target cell will 
contain more than one integrated lentiviral genome, giving higher transgene expression. 
Lentiviral titres are affected by the amounts of expression, packaging and envelope plasmids 
used to transfect the packaging cell line [470] and also by the transfection efficiency. Particle 
infectivity can be increased by harvesting vector supernatants at early timepoints after 
initiation of vector production, collection in serum-free medium and concentration by 
ultracentrifugation [470]. Infectivity on HEK 293T cells and some haematopoietic progenitor 
cells can be increased by the inclusion of a polypurine tract in the expression vector [470]. 
Infectivity on particular cell lines can be increased by changing the coat protein used to 
pseudotype the virus particles [470, 471]. The packaging limits of VSV-G pseudotyped 
lentiviral vectors, i.e. the maximum lentiviral genome sizes that can be packaged to produce 
functional lentivirus particles, have been systematically determined [472]. There appears to 
be no absolute packaging limit and measurable titres are still obtained with a proviral length 
of over 18 kb. Viral titres decrease semi-logarithmically with increasing vector length, and 
this appears to occur at the level of viral encapsidation, although increasing proviral size may 
also pose a block to nuclear export of proviral RNA. The packaging limit for HIV-1 based 
lentiviral vectors is greater than that of oncoretroviral vectors [472].  
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The main benefits of using a VSV-G pseudotyped lentiviral vector-based approach 
are that transgene expression can be stably introduced into a wide variety of cell lines at high 
levels without an impact on cell viability. The stable insertion of the lentiviral genome into 
the host genome enables the development of stable cell lines that do not rely on a drug 
selectable marker to maintain the transgene, unlike transgenes contained on an 
extrachromosal plasmid. Therefore this is an ideal method to use for the complementation of 
EBER expression in EBER-knockout LCLs. 
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Aims of the thesis 
 
EBERs are the most abundant EBV transcripts in latent infection but their exact roles during 
EBV infection have not yet been elucidated. Recent studies have suggested particular gene 
targets for the EBERs [110] as well as implicating the EBERs in induction of interferon 
during the early stages of B cell infection [281]. Therefore the first aim of this study was to 
investigate the roles of the EBERs during early infection of B cells. The alternative approach 
of introducing EBER expression into EBER negative cell lines was the second aim of this 
study. 
 
The specific research objectives were as follows: 
 
1) Are there specific gene targets of EBER1 and EBER2 during initial infection of 
primary B cells? 
 
 Do the previously identified EBER target genes respond to EBER expression 
during primary infection? 
 Do the EBERs affect the expression of interferon-related genes during early 
infection? 
 
 
2) Can a lentiviral vector-based approach enable introduction of EBER expression in 
EBER-negative cell lines? 
 
 Can EBER-expressing lentiviral vectors be developed? 
 Can EBER expression be introduced into different EBER-negative cell lines? 
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2 Materials and Methods 
 
2.1 Solutions and chemicals 
 
All chemicals were supplied by Sigma Aldrich unless otherwise stated. 
 
2.1.1 Solutions for cell culture protocols 
 PBS: 137 mM NaCl, 19 mM Na2HPO4, 2.7 mM KCl, 1.7 mM KH2PO4, pH 7.0 
 
Solutions for virus protocols 
 500 mM sodium butyrate, filter sterilised (0.2 μm filter, Nalgene) 
 
2.1.2 Solutions for flow cytometry protocols 
 Buffer for live cell staining (PBS/BSA/azide): 1x PBS, 1% (w/v) bovine serum 
albumin (BSA), 0.1% (w/v) sodium azide. Solution was filter sterilised through 0.2 
μm filter (Nalgene). 
 
2.1.3 Solutions for DNA protocols 
 Agarose gel loading buffer: 60% (v/v) glycerol, 10% (w/v) sucrose, 60 mM EDTA, 
10 mM Tris-HCl pH 7.6, 0.03% (w/v) xylene cyanol FF, 0.03% (w/v) bromophenol 
blue in ddH2O  
 Annealing buffer: 10 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM EDTA pH 8.0 
 Buffer BB: QIAGEN PlasmidPlus Maxiprep Kit #12963 
 Buffer EB: 10 mM Tris-HCl pH 8.5 
 0.25 M EDTA pH 8.0: 93.05 g EDTA dissolved in ddH2O to final volume 1 l after pH 
adjustment with NaOH. Solution autoclaved and stored at room temperature. 
 Buffer ER: QIAGEN EndoFree Maxiprep Kit #12362 
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 Buffer ETR: QIAGEN PlasmidPlus Maxiprep Kit #12963 
 Luria Bertani (LB) agar plates: 15 g agar dissolved in 1 l LB medium and autoclaved 
before pouring plates. 
 Luria Bertani (LB) medium: 10 g bacto tryptone, 10 g NaCl, 5 g bacto yeast extract 
dissolved in ddH2O to final volume 1 l after pH adjustment with NaOH. Solution was 
autoclaved.  
 For antibiotic selection, ampicillin was used at 50 μg/ml and kanamycin at 25 μg/ml. 
The 1000x stock solutions were filter sterilised through 0.2 μm filters. 
 Buffer N3: 4.2 M guanidine hydrochloride, 0.9 M potassium acetate, pH 4.8 
 Buffer P1: 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 mg/ml RNase A 
 Buffer P2: 200 mM NaOH, 1% (w/v) SDS 
 Buffer P3: 3 M potassium acetate pH 5.5 
 Buffer PB: 5 M guanidine hydrochloride, 30% isopropanol 
 PCR master mix: 1x GoTaq Flexi reaction buffer, 2 mM MgCl2, 0.2 mM dNTPs, 0.2 
μM forward primer, 0.2 μM reverse primer, 1.25 units GoTaq DNA polymerase 
 Buffer PE: 10 mM Tris-HCl pH 7.5, 80% ethanol  
 Buffer QBT: 750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol, 0.15% 
(v/v) Triton X-100 
 Buffer QC: 1 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol 
 Buffer QG: 5.5 M guanidine thiocyanate, 20 mM Tris-HCl pH 6.6 
 Buffer QN: 1.6 M NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol 
 Buffer S3:  QIAGEN PlasmidPlus Maxiprep Kit #12963 
 20x TBE: 242.3 g Tris base, 61 g boric acid, 14.9 g Na2EDTA.2H2O dissolved in 
ddH2O to final volume 1 l. Solution autoclaved and diluted to 1x with ddH2O before 
use. 
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 Buffer TE: 10 mM Tris-HCl pH 7.6, 1 mM EDTA pH 8.0  
 1 M Tris-HCl pH 8.0: 121.1g Tris base dissolved in ddH2O to final volume 1 l after 
pH adjustment with HCl. Solution autoclaved and stored at room temperature. 
 
2.1.4 Solutions for RNA protocols 
 50x Denhardt’s solution: 1% (w/v) polyvinylpyrrolidone, 1% (w/v) Ficoll, 1% (w/v) 
bovine serum albumin (BSA) dissolved in ddH2O and filter sterilised through 0.2 μm 
filter. 
 Glyoxalation mix: 75.5% (v/v) DMSO, 21.5% (v/v) glyoxal (40%), 15 mM sodium 
phosphate pH 7.0, DMSO. (Glyoxal de-ionised before use on Duolite MB6113 mixed 
resin and aliquots stored at -20°C.) 
 HGT agarose gel: 1.4g RNase-free HGT agarose melted in 100 ml 10mM sodium 
phosphate pH 7.0 
 Hybridisation mix: 10x Denhardt’s solution, 6x SSC, 0.5% (v/v) SDS, 10 mM EDTA 
pH 8.0, 5 mg salmon sperm DNA (Agilent Technologies) 
 RNA electrophoresis running buffer: 10 mM sodium phosphate pH 7.0 
 10% (w/v) SDS solution: 100g SDS dissolved in water to total volume of 1 l. Solution 
was stirred at 50°C to aid dissolving. 
 1 M sodium phosphate pH 7.0: 57.7% (v/v) 1M Na2HPO4 and 42.3% (v/v) 1 M 
NaH2PO4 
 1 M Na2HPO4: 141.96 g Na2HPO4 dissolved in ddH2O up to total volume 1 l. 
 1 M NaH2PO4: 119.98 g NaH2PO4 dissolved in ddH2O up to total volume 1 l. 
 Buffer RLT: QIAGEN RNeasy Mini Kit #74104 
 Buffer RPE: QIAGEN RNeasy Mini Kit #74104 
 Buffer RW1: QIAGEN RNeasy Mini Kit #74104 
 20x SSC: 350.6 g NaCl, 176.4 g sodium citrate dissolved in ddH2O to total volume 1 l. 
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2.1.5 Solutions for protein protocols 
 SDS-PAGE gels: 15% resolving gel: 375 mM Tris-HCl pH 8.8, 15% (v/v) 
acrylamide/bis-acrylamide 29:1, 0.1% (w/v) SDS. Stacking gel: 125 mM Tris-HCl pH 
6.8, 5% (v/v) acrylamide/bis-acrylamide 29:1, 0.1% (w/v) SDS. Polymerisation was 
achieved by addition of 10 μl TEMED and 50 μl 10% (w/v) APS per 10 ml gel 
volume. 
 10x SDS-PAGE running buffer: 400 mM glycine, 50 mM Tris-HCl, 0.1% (w/v) SDS. 
Stored at room temperature and diluted with ddH2O to 1x prior to use. 
 2x SDS sample buffer: 120 mM Tris-HCl pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 
2% (v/v) β-mercaptoethanol, 0.01% (w/v) bromophenol blue 
 1x TBS: 140 mM NaCl, 10 mM Tris-HCl pH 7.6 
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2.2 Cell culture protocols 
 
2.2.1 Cell lines and cell maintenance 
All cell lines, with the exception of NP460 hTERT, were cultured in DMEM or RPMI 
cell culture medium (Gibco) + 2 mM L-Glutamate supplemented with 10% (v/v) heat 
inactivated (20 min at 56°C) foetal bovine serum (FBS, Biosera) and a mix of penicillin and 
streptomycin (each at final concentration 200 U/ml, Gibco). Antibiotic selection was included 
where necessary. NP460 hTERT cells (kindly provided by Professor G. Tsao, Hong Kong 
University [473]) were cultured in a 1:1 ratio of Defined Keratinocyte Serum-Free Medium 
(DKSFM) supplemented with growth factors (Gibco) and Epilife medium supplemented with 
Epilife Defined Growth Supplement (EDGS, Cascade Biologics). All cells were grown at 
37°C with 10% CO2.  
Suspension cells were maintained by dilution of the culture 1:3 in fresh pre-warmed 
medium every two days. Adherent cells were maintained by sub-culturing 2-3 times per week. 
All adherent cells were washed with pre-warmed PBS and trypsinised (0.05% trypsin-EDTA 
1x, Gibco) for 5 min at 37°C. NP460 hTERT cells were resuspended in DMEM + 5% (v/v) 
FBS, pelleted by centrifugation at 100 x g for 4 min at room temperature, resuspended in the 
appropriate pre-warmed medium and diluted 1:10 for further culture. All other adherent cells 
were washed with complete culture medium and a fraction resuspended in fresh pre-warmed 
medium for further culture. Cell lines and the corresponding culture media are listed in Table 
2A. 
 
2.2.2 Viable cell counts 
 Cells were diluted 1:5 in Trypan Blue live/dead cell staining solution and counted in a 
Neubauer counting chamber under a light microscope (Olympus CK2). The number of viable 
cells was determined by counting unstained cells. 
 
2.2.3 Freezing cells 
Adherent cells were washed once in PBS, trypsinised then resuspended in complete 
medium. Resulting cell suspensions were centrifuged at 300 x g for 5 min at room 
temperature. Non-adherent cells were centrifuged directly using the same conditions. Cell 
pellets were resuspended in 1 ml Recovery Cell Freezing Medium (Gibco) and transferred to  
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Table 2A: Cell lines used in this work   P/S = 200 U/ml penicillin and 200 U/ml streptomycin (Gibco), L-Glu 
= 2 mM L-Glutamate, Hyg = hygromycin 100 μg/ml (Roche) 
 
 
cryovials. Cryovials were frozen slowly in a Nalgene Cryo 1°C/min freezing container at  
-80°C overnight. Cryovials were transferred to liquid nitrogen for long-term storage. 
 
2.2.4 Thawing cells for culture 
Cells were thawed quickly at 37°C then centrifuged at 300 x g for 5 min at room 
temperature to remove all traces of DMSO. Cell pellets were resuspended in complete 
medium (including antibiotics where appropriate) for cultivation. 
 
2.2.5 Transient transfection using Lipofectamine 2000  
The day before transfection, HEK 293T/HeLa cells were seeded in a 24-well plate in 
DMEM + 5% (v/v) FBS (without P/S) at a density of 1 x 10
5
 cells/ml. The following day, 
cells were transfected with 0.8 µg of sterile DNA by lipofection using Lipofectamine 2000 
Cell line   Origin Features Culture medium Reference 
       
HEK 293T  Human embryonic 
kidney 
EBV - DMEM, 10% FBS, 
P/S, L-Glu 
[474] 
HeLa  Human cervical cancer  EBV - DMEM, 10% FBS, 
P/S, L-Glu 
[475] 
NP460 hTERT  Human nasopharyngeal 
epithelium 
EBV - DKSFM/GF + 
Epilife/EDGS (1:1) 
[473] 
HEK 293T + EBV BAC  Human embryonic 
kidney 
EBV + (BAC-
derived), +/- EBER 
DMEM, 10% FBS, 
P/S, L-Glu, Hyg 
[110] 
LCL + B95-8 EBV  Human B cell + B95-8 
EBV strain 
EBV + RPMI, 10% FBS, 
P/S, L-Glu  
[476] 
LCL  Human B cell + BAC-
derived EBV 
EBV + (BAC-
derived), +/- EBER 
RPMI, 10% FBS, 
P/S, L-Glu  
[110] 
Raji  Burkitt's lymphoma EBV + RPMI, 10% FBS, 
P/S, L-Glu  
[477] 
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(Invitrogen). For each transfection, 2 µl Lipofectamine 2000 was diluted in 50 µl DMEM 
(without FBS or P/S) and 0.8 µg DNA was diluted separately in DMEM (without FBS or P/S) 
to a volume of 50 µl. The two mixtures were combined to give a total volume of 100 µl per 
transfection and incubated at room temperature for 5 min. Each 100 µl transfection mixture 
was added to one well. Cells were returned to incubation and harvested after two to four days. 
 
2.2.6 Isolating B cells from buffy coats by negative selection 
Buffy coats (mixed donors) were obtained for non-clinical use from the NHS Blood 
and Transplant Service (NHSBT) and were used immediately following delivery. 50 µl 
RosetteSep Human B Cell Enrichment Cocktail (StemCell Technologies) was added per ml 
of buffy coat and incubated at room temperature for 30 min. The buffy coat was diluted 1:1 in 
sterile DPBS (without Ca
2+
/Mg
2+
,
 
Gibco) supplemented with 2% (v/v) filtered (0.2 µm filter, 
Nalgene) FBS. The mixture was then loaded onto a Ficoll-Paque Plus density gradient 
(StemCell Technologies) and blood components were separated by centrifugation at 1200 x g 
for 20 min at room temperature without the brake. B cells, enriched at the plasma interface, 
were recovered, diluted 1:1 with DPBS + 2% FBS, and pelleted by centrifugation at 300 x g 
for 15 min at room temperature. Cells were resuspended in 0.8% (w/v) sterile ammonium 
chloride solution (StemCell Technologies) and incubated at room temperature for 5 min to 
lyse erythrocytes. The suspension was diluted 1:5 with DPBS + 2% FBS to end lysis and 
centrifuged at 300 x g for 10 min at room temperature. Erythrocyte lysis was carried out up to 
three times as necessary. Purified B cells were washed once with DPBS + 2% FBS and 
resuspended in RPMI + 20% FBS + P/S. After B cell yield was determined by viable cell 
count (section 2.2.2), B cells were plated at 2 x 10
6
 cells/ml  in RPMI + 20% FBS + P/S in 
24-well plates and incubated overnight. 
 
2.2.7 Visualisation of cells using fluorescence microscopy 
Cells were visualised using an Olympus 1x 70 fluorescence microscope. Images were 
acquired using an Axiovert 200M microscope (Zeiss) with an Axiocam HRC camera (Zeiss) 
in conjunction with AxioVision Rel 4.7 software. 
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2.3 Virus protocols 
 
2.3.1 Production of lentivirus 
HEK 293T cells were seeded in 10 cm dishes in DMEM + 5% (v/v) FBS (without P/S) 
to be 60% confluent the following day. The next day, cells were transfected with 24.6 µg 
sterile DNA (12 µg lentiviral vector [pWPT-derived] + 8.4 µg psPAX.2 packaging vector + 
4.2 µg pMD.2 VSV-G envelope vector, see Table 2C) by lipofection with Lipofectamine 
2000. For each transfection, 30 µl Lipofectamine 2000 was diluted in 500 µl DMEM (without 
FBS or P/S) and the total DNA was diluted separately in DMEM (without FBS or P/S) to a 
volume of 500 µl. The two mixtures were combined to give a total volume of 1 ml per 
transfection then incubated at room temperature for 5 min. Each 1 ml transfection mixture 
was added to one 10 cm dish and cells were returned to incubation for four days. The 
supernatant of each plate was then collected and cell debris was pelleted by centrifugation at 
300 x g for 5 min at 25 °C. Each supernatant was subsequently filtered through a 0.45 µm 
filter. Filtrates were concentrated using Ultracel Ultra-15 30K Spin Columns (Amicon) and 
either used immediately, stored at 4°C for use within a week or kept at -80°C for long-term 
storage. 
 
2.3.2 Generation of lentivirus-transduced adherent cell lines 
Adherent cells (HeLa, HEK 293T or NP460 hTERT) were seeded the day before 
transduction in 24-well plates at a density of 5 x 10
4
 cells/ml. On the day of transduction, 
medium was removed from each well and replaced by a mixture of lentiviral supernatant and 
complete DMEM to give a total volume of 1 ml per well. Transduction was achieved by 
centrifugal inoculation. Plates were first incubated for 1 hr at 37 °C then centrifuged at  
1000 x g for 2 hr at 25 °C. After centrifugation, the medium in each well was replaced with  
1 ml fresh pre-warmed complete DMEM and plates were returned to incubation. Culture 
volume was scaled up as appropriate as the cell lines grew out.  
 
2.3.3 Generation of lentivirus-transduced non-adherent cell lines 
For each transduction, 5 x 10
4
 non-adherent cells were pelleted by centrifugation at 
300 x g for 5 min at 25 °C and resuspended in a mixture of lentiviral supernatant and 
complete RPMI supplemented with 8 µg/ml polybrene to give a total volume of 3 ml. Cells 
were incubated for 1 hr at 37 °C then centrifuged at 1000 x g for 2 hr at 25 °C. After 
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centrifugation, medium was replaced with 1 ml fresh pre-warmed complete RPMI and cells 
were transferred to 24-well plates for incubation. Culture volumes were continually scaled up 
as appropriate. 
 
2.3.4 Production of EBV 
HEK 293T + EBV BAC cells (created by Dr R. Bosshard, Dr G. Gregorovic and Prof 
P. Farrell [110]) were seeded in 10 cm dishes in DMEM + 5% (v/v) FBS (without P/S) to be 
60% confluent the following day. The next day, cells were transfected with 6 µg sterile DNA 
(3 µg pBALF4 + 3 µg pBZLF1 [pCMV-EB1], see Table 2C) by lipofection. For each 
transfection, 30 µl Lipofectamine 2000 was diluted in 500 µl DMEM (without FBS or P/S) 
and the total DNA (6 µg) was diluted separately in DMEM (without FBS or P/S) to a volume 
of 500 µl. The two mixtures were combined to give a total volume of 1 ml per transfection 
then incubated at room temperature for 5 min. Each 1 ml transfection mixture was added to 
one 10 cm dish and cells were returned to incubation for four days. The supernatant of each 
plate was then collected and cell debris was pelleted by centrifugation at 300 x g for 5 min at 
25 °C. Each supernatant was subsequently filtered through a 0.45 µm filter (Nalgene) and 
kept at 4°C for long-term storage. If necessary, virus preparations were concentrated using 
Ultracel Ultra-15 30K Spin Columns (Amicon) then returned to storage at 4°C. 
 
2.3.5 Titration of EBV on Raji cells 
For each virus, a tenfold dilution series was prepared from 100 µl to 0.1 µl in 
complete RPMI in a 24-well plate. 1 x 10
5
 actively growing Raji cells were added per well. 
After incubation for two days, each well was supplemented with 5 mM sodium butyrate +  
20 nM phorbol myristate acetate (PMA) in 0.5 ml medium. PMA is a protein kinase C 
activator so helps to induce EBV lytic reactivation. n-butyrate induces histone deacetylation 
which enables higher expression levels of GFP and of viral genes. The following day GFP-
positive cells were resuspended as single cells, allowed to settle, then counted under a 
fluorescent microscope (Olympus 1x 70) to determine virus titres in Green Raji Units per µl 
(GRU/µl).  
 
2.3.6 Infection of primary B cells with EBV 
B cells were plated in 24-well plates at 2 x 10
6
 cells/ml in RPMI + 20% (v/v) FBS + 
P/S directly following purification (section 2.2.6) and incubated overnight. To achieve a 
multiplicity of infection (MoI) of 0.1, 2 x 10
5
 GRU of recombinant virus in a volume of  
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0.5 ml was added per well. Total cell RNA was isolated at various timepoints following 
infection. As infected cells grew out as LCLs culture volume was scaled up as appropriate. 
 
 
 
2.4 Flow cytometry protocols 
 
2.4.1 CD20 staining for FACS 
To determine the purity of B cells isolated from buffy coats, B cells were stained for 
FACS the day after purification using fluorescein isothiocyanate (FITC)-conjugated 
antibodies. 3 x 10
6
 cells were washed with PBS/BSA/azide live cell staining buffer at 4°C. 
Cells were pelleted by centrifugation at 300 x g for 5 min at 4°C, resuspended in 
PBS/BSA/azide and separated into aliquots of 1 x 10
6
 cells. Cells were incubated with a 1:10 
dilution of antibody at 4°C in the dark for one hour. Three antibody conditions were used: 
unstained, monoclonal mouse anti-human CD20-FITC (Dako) and monoclonal mouse IgG1-
FITC (Dako) as an isotype specific negative control. Cells were then washed with 
PBS/BSA/azide at 4°C, resuspended in PBS/BSA/azide and stored at 4°C in the dark until 
FACS analysis. Cells were analysed using a BD FACS Canto II Flow Cytometer and data 
was processed using FlowJo software. 50,000 events were recorded per sample. A 
representative analysis is shown in Figure 2.1. 
 
2.4.2 Sorting of transduced cells 
HeLa cells transduced with GFP-expressing lentiviral vectors were sorted using 
machine BD FACS Aria IIIU, performed by Dr M. Paulsen. Before sorting, cells were 
washed twice with pre-warmed PBS and trypsinised (0.05% trypsin-EDTA 1x, Gibco), then 
cells were resuspended in complete medium to stop trypsinisation. Cells were washed twice 
with pre-warmed PBS, then each sample was resuspended in 1 ml PBS and transported to the 
sorter on ice.  
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2.5 DNA protocols, vectors and cloning 
 
2.5.1 DNA quantification 
DNA was quantified using a NanoDrop Lite spectrophotometer. 
 
2.5.2 Primers  
All primers used are listed in Table 2B. 
 
2.5.3 Polymerase Chain Reaction (PCR) 
PCR amplification of DNA was carried out using GoTaq Hot-Start DNA polymerase 
kit (Promega). PCR reactions were carried out in a total volume of 20 μl per reaction, 
consisting of: 1x GoTaq Flexi reaction buffer, 2 mM MgCl2, 0.2 mM dNTPs, 0.2 μM forward 
primer, 0.2 μM reverse primer, 1.25 units GoTaq DNA polymerase and approximately 1 ng 
template DNA. Reactions were carried out in an Applied Biosystems GeneAmp System 9700 
thermocycler. Reaction conditions were: Denaturing at 95°C for 5 min. Followed by 95°C 
denaturing for 30s, 55°C annealing for 30s and 72°C extension for 1min/kb, repeated for the 
appropriate number of cycles. Final extension of 72°C for 5 min. 
RT-PCR: All targets were amplified for 35 cycles except for GAPDH (27 cycles) and 
EBNA2 (30 cycles). 
Colony PCR: Colonies were replica plated then added to 20 µl PCR reaction. All 
targets were amplified for 20 cycles. 
 
2.5.4 Quantitative Polymerase Chain Reaction (qPCR) 
DNA/cDNA was diluted in nuclease-free water (Promega) and 2x Power SYBR 
Green PCR Master Mix (Applied Biosystems) to give a total volume of 20 µl per reaction. 
Real-time PCR was carried out on a ViiA 7 Real-Time PCR System machine (Life 
Technologies). The cycling conditions were: 15 min at 95°C, then 40 cycles of 15 s at 95°C, 
30 s at 60°C and 40 s at 72°C on a fast block. Dissociation curve analysis was carried out to 
ensure absence of non-specific products. Relative quantification of mRNA levels was 
determined using the Delta-Delta Ct method using the ViiA 7 System Software. Target gene 
mRNA levels were normalised to levels of the housekeeping gene GAPDH, used as a loading 
control.  
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Table 2B Primers used in this work 
 
Primer Sequence Source Use Reference 
ADARB1f CAGATAGACACCCAAATCGT Invitrogen RT-PCR [110] 
ADARB1r TTGTTGAGGGTGTAGAGAGG Invitrogen RT-PCR [110] 
BamHItoXhoI GATCGGGCTCGAGCCC  Eurofins Cloning  
CDC42BPAf AATGGATTACAACCTTGCAC Invitrogen RT-PCR [110] 
CDC42BPAr TTGAAGGATTTCAGGAGAGA Invitrogen RT-PCR [110] 
CHL1f GATGACATCTCCACTCAAGG Invitrogen RT-PCR [110] 
CHL1r TTCTCCTTAGATCCAGCGTA Invitrogen RT-PCR [110] 
CXCL12f GGTCCTGGTGGTATTTGTAA Eurofins RT-PCR [110] 
CXCL12r CCCACATACAGTAGGACGTT Eurofins RT-PCR [110] 
CXCR3f GGTCATGGCCTACTGCTAT Invitrogen RT-PCR [110] 
CXCR3r CTCTGGAGCCCTCTCTGGT  Invitrogen RT-PCR [110] 
EBER1f AGGACCTACGCTGCCCTAGA Invitrogen RT-PCR [478] 
EBER1r AAAACATGCGGACCACCAGC Invitrogen RT-PCR [478] 
EBER2f TGCCCTAGTGGTTTCGGACA Invitrogen RT-PCR [478] 
EBER2r CAGAGGGATTAGAGAATCCT Invitrogen RT-PCR [478] 
EBNA2f CTTGAGTCTTAGAGGGTTGC Eurofins RT-PCR  
EBNA2r CTCATCAAAGCACCCCAAAT Eurofins RT-PCR  
EcoRItoBamHI AATTGCGGATCCGC Eurofins RT-PCR  
FYBf AGCAGGAAAAAGAAGAAAAAG Invitrogen RT-PCR  
FYBr AAATCCAGACTTCACATTGG Invitrogen RT-PCR  
HCKf TATTAGCACCATCCATAGGAGGCTT  Eurofins RT-PCR  
HCKr GTTAGGGAAAGTGGAGCGGAAG   Eurofins RT-PCR  
GAPDHf TGAAGGTCGGAGTCAACGGATTG Invitrogen RT-PCR [110] 
GAPDHr GCCATGGAATTTGCCATGCCATGGGTGG Invitrogen RT-PCR [110] 
qGAPDHf TGCCTCCTGCACCACCAACT Invitrogen qRT-PCR  
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Primer Sequence Source Use Reference 
qGAPDHr CGCCTGCTTTACCACCTTC Invitrogen qRT-PCR  
GPR125f GCGAACATTAAGAATTACGG Invitrogen RT-PCR [110] 
GPR125r AACATCCACAGTGCAACATA Invitrogen RT-PCR [110] 
IFNAf GTACTGCAGAATCTCTCCTTTCTCCTG Eurofins RT-PCR [479] 
IFNAr GTGTCTAGATCTGACAACCTCCCAGGGC
ACA Eurofins 
RT-PCR [479] 
IFNA1/13f TGGCTGTGAAGAAATACTTCCG Eurofins RT-PCR [480] 
IFNA1/13r TGTTTTCATGTTGGACCAGATG Eurofins RT-PCR [480] 
IFNA2f CCTGATGAAGGAGGACTCCATT Eurofins RT-PCR [480] 
IFNA2r AAAAAGGTGAGCTGGCATACG Eurofins RT-PCR [480] 
IFNA4f TCTCTTCAGCACAGAGGACT    Eurofins RT-PCR  
IFNA4r GATCATTTCCATGTTGAACC   Eurofins RT-PCR  
IFNA5f GGACAGACATGACTTTGGAT Eurofins RT-PCR [110] 
IFNA5r CATGATTTCTGCTCTGACAA Eurofins RT-PCR [110] 
IFNA6f CTGTCCTCCATGAGGTGATT Eurofins RT-PCR [480] 
IFNA6r GGTCTTATTCCTTCCTCCTTAAC Eurofins RT-PCR [480] 
IFNA7f CAGACATGAATTCAGATTCCCA Eurofins RT-PCR [480] 
IFNA7r TTTCCTCACAGCCAGGATGA Eurofins RT-PCR [480] 
IFNA8f GTGATAGAGTCTCCCCTGATGTAC Eurofins RT-PCR [480] 
IFNA8r CTTCAATCTTTTTTGCAAGTTGA Eurofins RT-PCR [480] 
IFNA10f TGGCCCTGTCCTTTTCTTTACTT Eurofins RT-PCR [480] 
IFNA10r TCAAACTCCTCCTGGGGGAT Eurofins RT-PCR [480] 
IFNA14f TGAATTTCCCCAGGAGGAA Eurofins RT-PCR [480] 
IFNA14r TCCCAAGCAGCAGATGAGTT Eurofins RT-PCR [480] 
IFNA16f CAAAGAATCACTCTTTATCTGATGG Eurofins RT-PCR [480] 
IFNA16r CAATGAGGATCATTTCCATGTTGAAT Eurofins RT-PCR [480] 
IFNA17f TGTGATACAGGAGGTTGGGA Eurofins RT-PCR [480] 
78 
 
Primer Sequence Source Use Reference 
IFNA17r GTTTTCAATCCTTCCTCCTTAATA Eurofins RT-PCR [480] 
IFNA21f ATCTCAAGTAGCCTAGCAATATTG Eurofins RT-PCR [480] 
IFNA21r AGGTCATTCAGCTGCTGGTT Eurofins RT-PCR [480] 
IGF1f CCTCGCATCTCTTCTACCT Invitrogen RT-PCR [110] 
IGF1r TACATCTCCAGCCTCCTTAG Invitrogen RT-PCR [110] 
IGSF4f CAGGAAAGTTACACCACCAT Invitrogen RT-PCR  
IGSF4r AATGTGCACTTGAGGCTTAT Invitrogen RT-PCR  
IL10 TGCTCTGTTGCCTGGTCCTCCTGA Eurofins RT-PCR [315] 
IL10 GCTCCACGGCCTTGCTCTTGTTTT Eurofins RT-PCR [315] 
IL12RB2f TGGAAATGTTCTACCTCTGC Invitrogen RT-PCR [110] 
IL12RB2r GATTACAGGCATGAGCTACC Invitrogen RT-PCR [110] 
qIL12RB2f ACATTCTTGGACATAGTGAGGCC Eurofins qRT-PCR  
qIL12RB2r GTACATCTGCTCACGGAAGCC Eurofins qRT-PCR  
LMP2Af GTACTTGGGATTGCAACACG Invitrogen RT-PCR  
LMP2Ar CTGCCAAGAGTAGAAGTGAG Invitrogen RT-PCR  
MMP7f CATTCCTCTGATCCTAATGC Invitrogen RT-PCR  
MMP7r GACATCTACCCACTGCAAGTA Invitrogen RT-PCR  
SacItoBglII GACGAGATCTCGTCAGCT Eurofins Cloning  
SEPP1f CATCAAGGAATCTCTTCTCG Invitrogen RT-PCR  
SEPP1r TGATGCTCATGATGGTAATG Invitrogen RT-PCR  
T3 ATTAACCCTCACTAAAGGGA Invitrogen Sequencing  
T7 TAATACGACTCACTATAGGG Invitrogen Sequencing  
TBX15f GACTTCAGCAGTGACCTTTC Invitrogen RT-PCR [110] 
TBX15r GTGAAGTCTTCGAAGGTGAG Invitrogen RT-PCR [110] 
TMPRSS3f AGCAAGTACAAGCCAAAGAG Invitrogen RT-PCR  
TMPRSS3r CTCCTCTCTTGACACACCAG Invitrogen RT-PCR  
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Primer Sequence Source Use Reference 
XhoItoBamHI TCGACGGGATCCCG Eurofins Cloning  
XhoItoBglII TCGACCTTAGATCTAAGG Eurofins Cloning  
pWPTf GGGTAAACTGGGAAAGTGAT Eurofins Sequencing  
pWPT-GFP-EBERf AAAGACCCCAACGAGAAG Eurofins Cloning  
pWPT-GFP-EBERr GAGAAAATGAAAGCCATACG     Eurofins Cloning  
 
2.5.5 Annealing oligonucleotides 
Complementary oligonucleotides were diluted to the same molar concentration  
(10 µM) in annealing buffer, incubated at 95°C for 5 min and then left to cool to room 
temperature. 
 
2.5.6 Small-scale isolation of plasmid DNA from bacteria 
Plasmid DNA was isolated from small-scale bacterial cultures using the Spin Mini-
Prep Kit (Qiagen). Single bacterial colonies were picked from selective LB agar plates and 
inoculated into 2 ml LB medium supplemented with the appropriate antibiotic selection. 
Cultures were incubated overnight at 37°C in a 225 rpm shaker. Bacteria from 1.5 ml of each 
culture were pelleted (centrifugation at 10,000 x g for 3 min) then resuspended in 250 μl 
buffer P1. 250 μl buffer P2 was added, mixed gently, and incubated at room temperature for 
5 min. 350 μl buffer N3 was added and mixed then samples were centrifuged at 18,000 x g 
for 10 min to pellet cell debris. The supernatant was applied to a QIAprep Mini Spin Column 
and centrifuged at 18,000 x g for 1 min. 500 μl buffer PB was applied followed by 
centrifugation with the above conditions, then 750 μl buffer PE to wash. Empty columns 
were then centrifuged again. DNA was eluted using 30 μl buffer EB.  
 
2.5.7 Large-scale isolation of plasmid DNA from bacteria 
Plasmid DNA was isolated from large-scale bacterial cultures using either the 
PlasmidPlus Maxi-Prep Kit (Qiagen) or, to obtain sterile DNA for transfections, the 
EndoFree Maxi-Prep Kit (Qiagen). 2 ml bacterial cultures were grown in selective medium 
for 8-10 hr then used to inoculate 250 ml overnight cultures. Bacteria were pelleted 
(centrifugation at 3000 rpm for 30 min at 4°C) then resuspended in 10 ml buffer P1. 10 ml 
buffer P2 was added followed by incubation at room temperature for 5 min.  
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PlasmidPlus Maxi-Prep Kit: 10 ml buffer S3 was added and the lysate was poured 
into a QIAfilter Cartridge then incubated at room temperature for 10 min. The lysate was 
filtered to remove cell debris and 10 ml buffer BB was added. The mixture was loaded 
equally onto two Qiagen PlasmidPlus Maxi spin columns attached via tube extenders to the 
QIAvac 24 Plus. The columns were cleared by the application of vacuum at approximately 
300 mbar. The columns were washed with 0.7 ml buffer ETR and cleared by vacuum as 
described. The columns were then washed with 0.7 ml buffer PE and cleared by vacuum. The 
columns were cleared by centrifugation at 10,000 x g for 1 min. DNA was eluted by the 
application of 200 μl buffer EB to each column and centrifugation as described. 
Endo-free Maxi-Prep Kit: 10 ml buffer P3 at 4°C was added and the lysate was 
poured into a QIAfilter Cartridge then incubated at room temperature for 10 min. The lysate 
was filtered to remove cell debris then incubated at 4°C for 30 min after the addition of 2.5 
ml buffer ER. The lysate was applied to a Qiagen-tip 500 column which had been 
equilibrated with 10 ml buffer QBT. The column was washed twice with 30 ml buffer QC, 
then DNA was eluted in 15 ml buffer QN. DNA was precipitated by the addition of 10.5 ml 
isopropanol (VWR) then pelleted by centrifugation at 3000 rpm for 1 hr at 4°C. DNA was 
washed with 5 ml 70% (v/v) endotoxin-free ethanol and centrifuged with the above 
conditions. DNA pellets were air dried in a laminar flow chamber then dissolved in 200 μl 
filter-sterilised (0.2 μm, Nalgene) endotoxin-free buffer TE. 
 
2.5.8 Agarose gel electrophoresis 
Depending upon the size of DNA fragments to be separated, 0.5-2% (w/v) agarose 
(Invitrogen) was melted in 1x TBE buffer and poured into a casting tray after addition of  
0.5 μg/μl ethidium bromide. Gel loading buffer (5x GoTaq Flexi buffer, Promega) was added 
to DNA samples before loading. Fragment size was determined by the inclusion of a standard 
100 bp or 1 kb ladder (New England Biolabs [NEB]). Electrophoresis was carried out in 1x 
TBE buffer at 100-150 V. DNA was visualised using a Syngene transilluminator UV light 
source in conjunction with GeneSnap software. 
 
2.5.9 Extraction of DNA fragments from agarose gels 
DNA fragments were visualised using a low energy UV light box and excised from 
the gel with a scalpel. DNA was purified from agarose using the QIAquick gel extraction kit 
(Qiagen) according to the manufacturer’s protocol. Agarose slices containing DNA fragments 
were each dissolved in three volumes of buffer QG (Qiagen) at 50°C for 10 min. DNA was 
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precipitated by the addition of one volume of isopropanol. Samples were loaded onto 
QIAquick spin columns and centrifuged at 18,000 x g for 1 min to bind DNA. Columns were 
washed once with 500 μl buffer QG and once with 750 μl buffer PE (Qiagen) then DNA was 
eluted in 30 μl buffer EB (Qiagen). 
 
2.5.10 Digestion of plasmid/BAC DNA with restriction enzymes 
Restriction digests were carried out using NEB restriction enzymes (supplied at 10-20 
U/μl) diluted in the corresponding NEB buffer. Enzymes were added to achieve around 10-
fold over-digestion. BSA was included when required. Digestions were performed for 1-4 hr 
at the recommended temperature for each enzyme. Where possible, enzymes were heat 
inactivated at 65°C for 20 min. Digested fragments were either separated by agarose gel 
electrophoresis or phosphatase treated directly. 
 
2.5.11 Phosphatase treatment of DNA vector backbone fragments 
5’ phosphate groups were removed from the ends of linearised vectors before ligation 
in order to reduce self-ligation and re-circularisation. 1-5 μg DNA was treated with antarctic 
phosphatase (NEB) according to the manufacturer’s protocol. DNA was diluted in 1x 
antarctic phosphatase buffer and 5 units of antarctic phosphatase were added. The mixture 
was incubated at 37°C for 30 min then heat inactivated at 65°C for 5 min. Treated DNA 
fragments were then used for ligation. 
 
2.5.12 Ligation of DNA fragments with T4 DNA Ligase 
Ligations were performed with a vector:insert ratio of 1:10 for DNA fragment inserts 
and a vector:insert ratio of 1:1000 for oligonucleotide inserts. 100 ng vector was used per 
ligation and the amount of insert was determined by the following formula: 
ng insert = ng vector x insert size in kb x molar ratio / vector size in kb 
Ligations with T4 DNA ligase (NEB) were performed in a final volume of 10-15 μl 
according to the manufacturer’s protocol. Vector and insert DNA were diluted in 1x T4 DNA 
ligase buffer and 400 units DNA ligase were added. A control reaction was set up with the 
insert DNA omitted. Reactions were incubated overnight at 16°C. 
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2.5.13 Transformation of plasmid DNA into chemically competent bacteria 
Two types of chemically competent E. coli were used: XL1 Blue for transformation of 
existing vectors and One Shot TOP10 (Invitrogen) for transformation of ligation reactions. 
Bacteria were thawed on ice, then 100 μl bacteria was added to 2 μl DNA/ligation reaction 
and incubated on ice for 30 min. Bacteria were heat shocked for 45 s at 42°C and returned to 
ice for 5 min. 300 μl LB (XL1 Blue) or SOC (TOP10) medium was added and bacteria were 
incubated at 37°C for 1 hr on a 225 rpm shaker. 10% of XL1 Blue and 90% of TOP10 cells 
were then plated on selective LB agar plates and incubated overnight at 37°C overnight. 
 
2.5.14 Freezing bacterial cells 
Bacterial cultures (in LB selective media) were frozen with 10% (v/v) glycerol in a 
total volume of 1.2 ml and transferred directly to storage at -80°C. 
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2.6 Vectors and cloning strategies 
 
All vectors used in this study are listed in Table 2C. 
 
Vector   Use Selection Reference 
      
pBALF4  EBV virus production (2.3.4) Amp [481] 
pCMV-EB1  EBV virus production (2.3.4) Amp [482] 
pMD2.G  Lentivirus production (2.3.1) Amp addgene.com #12259 
psPAX.2  Lentivirus production (2.3.1) Amp addgene.com #12260 
pPURO:OriP  Lentiviral vector cloning (2.6.8) Amp, puro See 2.6.3 
pRSET-mCherry  Lentiviral vector cloning (2.6.9) Amp See 2.6.4 
pSUPER  Lentiviral vector cloning (2.6.10) Amp Oligoengine  
VEC-PBS-0002 
pSUPER-EBER1  EBER1 expression  Amp [110] 
pSUPER-EBER2  EBER2 expression  Amp [110] 
pSUPER-H1  Empty vector control Amp [110] 
pSUPER-EBVJ-wt  Lentiviral vector cloning (2.6.10) Amp  
pSUPER-EBVJ-∆E1  Lentiviral vector cloning (2.6.10) Amp  
pSUPER-EBVJ-∆E2  Lentiviral vector cloning (2.6.10) Amp  
pSUPER-EBVJ-∆E1∆E2  Lentiviral vector cloning (2.6.10) Amp  
pWPT  GFP expression  Amp addgene.com #12255 
pWPT-EBER1  EBER1 expression Amp  
pWPT-EBER2  EBER2 expression Amp  
pWPT-H1  Empty vector control Amp  
pWPT-GFP-EBER1  EBER1 expression Amp  
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Vector   Use Selection Reference 
      
pWPT-GFP-EBER2  EBER2 expression Amp  
pWPT-GFP-H1  Empty vector control Amp  
pWPT-PURO-EBER1  EBER1 expression Amp, puro  
pWPT-PURO-EBER2  EBER2 expression Amp, puro  
pWPT-PURO-H1  Empty vector control Amp, puro  
pCWPT  mCherry expression Amp  
pCWPT-wt  EBER1 and EBER2 expression Amp  
pCWPT-∆E1  EBER2 expression Amp  
pCWPT-∆E2  EBER1 expression Amp  
pCWPT-∆E1∆E2  Empty vector control Amp  
wt EBV BAC  Recombinant EBV, cloning (2.6.10) Cam, hygro    [110] 
∆E1 EBV BAC  Recombinant EBV, cloning (2.6.10) Cam, hygro    [110] 
∆E2 EBV BAC  Recombinant EBV, cloning (2.6.10) Cam, hygro    [110] 
∆E1∆E2 EBV BAC  Recombinant EBV, cloning (2.6.10) Cam, hygro  
 
Table 2C: List of vectors used in this study Amp = 50 µg/ml ampicillin, cam = 50 µg/ml chloramphenicol, 
hygro = 100 µg/ml hygromycin, puro = 0.5 µg/ml to 1.0 µg/ml puromycin. 
 
2.6.1 Plasmids 
 Plasmids forming the second generation lentiviral vector system were pWPT-GFP 
(Addgene no. 12255 [www.addgene.com]), pMD2.G (Addgene no. 12259) and psPAX2 
(Addgene no. 12260) (all created by the Trono lab and kindly provided by Professor M. 
McClure). Schematic diagrams of these vectors are shown in Figure 2.2. pWPT-GFP (pWPT) 
contains the eGFP coding region under the control of the eIF1α promoter. The promoter is 
separated from the eGFP coding region by a BamHI restriction site. pSUPER-EBER1, 
pSUPER-EBER2, pSUPER-H1 and pPURO:OriP are all constructs created by and in current 
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use by the Farrell lab (created by Dr S Pattle). pRSET-mCherry was kindly provided by Dr R. 
White. The EBV BACs used (wt EBV BAC, ∆E1 EBV BAC, ∆E2 EBV BAC and ∆E1∆E2 
EBV BAC) are all constructs created by and in current use by the Farrell lab (created by Prof 
P. Farrell [110]).  
 
 
Figure 2.2 Plasmid vectors comprising the second generation lentiviral vector system Diagrams taken from 
www.addgene.com.  
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2.6.2 pSUPER-based EBER expression vectors 
pSUPER vectors (Oligoengine) are RNA expression vectors containing the H1 RNA 
polymerase III promoter which is compatible with the EBER AGGA transcription start site 
(depicted in Figure 4.1). These EBER expression vectors are in continuous use by the Farrell 
lab and were cloned by Dr S Pattle as follows: EBER1 and EBER2 were PCR amplified from 
pBluescript plasmids pBSJJJI and pBSJJJ2 [483] using primers 
CCAGATCTCCAGGACCTACGCTGCCCT and CCAAGCTTGGATGCATAAATCCTAA 
for EBER1 and primers CCAGATCTCCAGGACAGCCGTTGCCCT and 
CCAAGCTTGGGTGCAAAACTAGCCA for EBER2. The primers incorporated a BglII site 
at the 5’ end and a HindIII site at the 3’ end. These PCR products were cloned into 
pSUPERIOR (Oligoengine) between the BglII and HindIII sites. A stuffer sequence was 
cloned into the promoter-only control vector. The resulting vectors were named pSUPER-
EBER1, pSUPER-EBER2 and pSUPER-H1 and are depicted in Figure 2.3. 
 
Figure 2.3 pSUPER-based EBER expression vectors 
 
 
2.6.3 Puromycin resistance expression vector 
pPURO:OriP (pPuro-OriP-SUPER) was constructed by Prof P Farrell and is depicted 
in Figure 2.4. The 3.7 kb BamHI fragment from pOriP-LUC (which contained origin of 
replication OriP and puromycin resistance cassette Puro
R
) was cloned into the BamHI site of 
pSUPER. A standard 64 nt pSUPER oligo was inserted between the BglII and HindIII sites in 
the pSUPER-derived part of the vector [484]. The sequence of the region between the BamHI 
and XhoI sites in the pSUPER-derived part of the vector is: 
GGATCCCCCGGGCTGCAGGAATTCGAACGCTGACGTCATCAACCCGCTCCAAGG
AATCGCGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGCGCGTGCGCCCTGGC
AGGAAGATGGCTGTGAGGGACAGGGGAGTGGCGCCCTGCAATATTTGCATGTCG
88 
 
CTATGTGTTCTGGGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGAATCT
TATAAGTTCTGTATGAGACCACAGATCTAAGCTTATCGATACCGTCGACCTCGAG. 
 
Figure 2.4 pPURO:OriP puromycin resistance expression vector  Diagram by Prof P. Farrell 
 
 
2.6.4 mCherry expression vector 
 pRSET-mCherry was constructed by Dr R. White. mCherry was cloned into pRSET 
(Invitrogen) using the BamHI and BstBI sites (Figure 2.5). 
 
Figure 2.5 pRSET-mCherry vector used in cloning  
Diagram adapted from https://www.lifetechnologies.com/order/catalog/product/V35120 
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2.6.5 Recombinant B95-8 EBV bacterial artificial chromosomes 
The EBV BACs used (wt EBV BAC (provided by Prof W Hammerschmidt), ∆E1 
EBV BAC, ∆E2 EBV BAC and ∆E1∆E2 EBV BAC) were all previously created by Prof P 
Farrell [110] as follows: EBER1 or EBER 2 were individually (and together) deleted from the 
B95-8 wild type EBV BAC [485] by RecA mediated homologous recombination. Targeting 
constructs were cloned between the BamHI and SalI sites of pKov-Kan-Cm as described in 
[486]. EBER1 deletion (ΔE1) replaced EBV region 6599-6798 with an XbaI restriction site 
and the EBER1 targeting plasmid contained EBV region 6066-7322 as flanking sequence 
(with a BamHI site added at the start). EBER2 deletion (ΔE2) replaced EBV region 6950-
7130 with an XbaI restriction site and the EBER2 targeting plasmid contained EBV region 
6669-7413 as flanking sequence (with a BamHI site added at the start). RecA-mediated 
recombination was performed by co-transformation of EBER targeting plasmids and pDF2.5-
tet-RecA into bacteria containing the wild type EBV BAC. Colonies were cured of RecA by 
antibiotic and temperature selection. Correct cointegrants were resolved by a second round of 
RecA-mediated recombination. Bacteria were cured of targeting vector sequence by 
antibiotic and sucrose-mediated selection. Correctly resolved BACs were identified by 
antibiotic sensitivity. 
 
 
 
Figure 2.6  Deletion of EBER1 and EBER2 genes in the EBV BAC  Adapted from [110] 
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2.6.6 Cloning of EBER gene cassettes into pWPT to replace eGFP 
EBER gene cassettes (EBER1 or EBER2 under the control of the H1 promoter and a 
promoter only control) were excised from the pSUPER-derived EBER expression vectors 
using BamHI and XhoI. The eGFP coding region was removed from pWPT using BamHI and 
SalI. The inserts HI + EBER1, H1 + EBER2 and H1 only were cloned into pWPT between 
the BamHI and SalI sites. The new vectors were named pWPT-EBER1, pWPT-EBER2 and 
pWPT-H1. The procedure is illustrated in Figure 2.7. 
 
 
 
Figure 2.7 Cloning procedure for the generation of EBER-expressing lentiviral expression vectors 
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2.6.7 Cloning of EBER gene cassettes into pWPT to be co-expressed with eGFP 
Using adaptor oligo “BamHItoXhoI”, the BamHI site in the vectors pSUPER-EBER1, 
pSUPER-EBER2 and pSUPER-H1 was converted to an XhoI site. The EBER gene cassettes 
were excised from the new vectors using XhoI and inserted into the SalI site of pWPT. The 
new vectors were named pWPT-GFP-EBER1, pWPT-GFP-EBER2 and pWPT-GFP-H1. This 
process is depicted in Figure 2.8. 
 
 
Figure 2.8 Cloning procedure for the generation of EBER and GFP co-expressing lentiviral expression 
vectors 
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2.6.8 Cloning of puromycin resistance cassette into pWPT vectors 
The EcoRI site in pPURO:OriP was converted to a BamHI site using adaptor oligo 
“EcoRItoBamHI”. The puromycin resistance cassette was excised from pPURO:OriP using 
BamHI and inserted into the BamHI site in pWPT. The new vectors were named pWPT-puro-
E1, pWPT-puro-E2 and pWPT-puro-H1. The process is depicted in Figure 2.9. 
 
 
 
 
 
Figure 2.9 Cloning procedure for the generation of EBER and puromycin resistance co-expressing 
lentiviral expression vectors 
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2.6.9 Cloning of mCherry into pWPT to replace eGFP 
The mCherry coding region was excised from pRSET-mCherry using BamHI and 
BstBI. The eGFP coding region was removed from pWPT using BamHI and BstBI. The 
mCherry coding region was cloned into pWPT using the BamHI and BstBI sites. The new 
vector was named pWPT-RFP/pCWPT. mCherry expression was confirmed by fluorescence 
microscopy (see section 2.2.7). The cloning procedure is detailed in Figure 2.10. 
 
Figure 2.10 Cloning procedure for the generation of mCherry expressing lentiviral expression vectors 
 
 
2.6.10 Cloning of EBV-derived recombinant EBER fragments into pWPT-RFP 
The cloning strategy used here is taken from Komano et al. (1999) [332]. EBER-
containing fragments were released from the recombinant EBV BACs (section 2.6.5) by 
digestion with EcoRI (Figure 2.11). The EBER-containing fragments corresponded to the 
EBV J fragment of B95-8 EBV. These EBER-containing fragments varied in size between 
around 2600 bp to 3152 bp. The fragments were further digested with SacI and cloned into 
pSUPER between the EcoRI and SacI sites. The new vectors were confirmed by PCR for 
EBER expression and were named pSUPER-EBVJ-wt, pSUPER-EBVJ-ΔE1, pSUPER-
EBVJ-ΔE2 and pSUPER-EBVJ-ΔE1ΔE2. The subsequent steps are outlined in Figure 2.12. 
The EcoRI site in each vector was converted to a BamHI site using adaptor oligo 
“EcoRItoBamHI” and the SacI site was converted to a BglII site using adaptor oligo 
“SacItoBglII”. The EBER fragment was released from each vector using BamHI and BglII.  
Using adaptor oligo “BamHItoXhoI”, the existing BamHI site in pWPT-RFP 
(pCWPT) was converted to an XhoI site. Using adaptor oligo “XhoItoBamHI”, the SalI site in 
pCWPT was converted to a BamHI site. The EBER fragments were cloned into the BamHI 
site of pCWPT to generate four new vectors: pCWPT-wt, pCWPT-ΔE1, pCWPT-ΔE2 and 
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A B 
pCWPT-ΔE1ΔE2. Each EBER fragment was flanked by the restriction sites BamHI and BglII, 
so ligation into the BamHI site would leave a BamHI site at the BamHI-BamHI join and a 
“scar” at the BglII-BamHI join. This enabled concatemerisation of each EBER fragment into 
pCWPT using the BamHI site. The target was five copies of each fragment in pCWPT. 
 
 
 
 
                  
 
 
 
 
Figure 2.11 The EBER containing fragments isolated from EBV BACs by digestion with EcoRI 
A) EBV BACs were digested using EcoRI and fragments were separated using agarose gel electrophoresis with 
subsequent EtBr staining. The EBER-containing EBV J fragments, sized between 2600 and 3152 bp, were 
isolated from the gel for extraction. B) Schematic of the EBER-containing DNA fragments. 
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Figure 2.12 Cloning procedure for the generation of mCherry and EBER co-expressing lentiviral 
expression vectors, with concatemerisation of the endogenous EBER expression cassette  
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2.7 RNA protocols 
 
2.7.1 Harvesting total cell RNA 
The appropriate number of cells (usually one well of a 24-well plate) was pelleted by 
centrifugation at 1000 x g for 5 min at room temperature, washed once with room 
temperature PBS and resuspended in Buffer RLT (RNeasy Mini Kit, Qiagen) supplemented 
with 1% (v/v) β-mercaptoethanol (BME). For up to 5 x 106 cells, 350 µl RLT/BME was used, 
for larger samples 600 µl RLT/BME was used. Samples were homogenised by pipetting up 
and down using a p200 Gilson pipette. Total cell RNA was then extracted using the RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s protocol. All centrifugation steps were 
performed at 10,000 x g. One volume of 70% (v/v) ethanol was added to each sample then 
samples were transferred to RNeasy spin columns and centrifuged for 30 s. Columns were 
washed with 700 μl buffer RW1 (Qiagen) and centrifuged for 30 s, washed with 500 μl buffer 
RPE (Qiagen) and centrifuged for 30 s, washed again with 500 μl buffer RPE and centrifuged 
for 2 min, then centrifuged again for 1 min. RNA was eluted by the addition of 50 μl RNase-
free water (Qiagen) and centrifugation for 1 min. 
 
2.7.2 Quantification of RNA yield 
RNA yield was quantified using a NanoDrop Lite spectrophotometer. 
 
2.7.3 Agarose gel electrophoresis 
 Integrity of total cell RNA was confirmed by electrophoretic separation. 1% (w/v) 
HGT agarose (Invitrogen) was melted in 1x TBE buffer and poured into a casting tray after 
addition of 0.5 μg/μl ethidium bromide. Gel loading buffer (5x GoTaq Flexi buffer, Promega) 
was added to RNA samples before loading. RNA sizes were determined by the inclusion of a 
standard 1 kb ladder (New England Biolabs [NEB]). Electrophoresis was carried out in 1x 
TBE buffer at 100-150 V. RNA was visualised using a Syngene transilluminator UV light 
source in conjunction with GeneSnap software. 
 
2.7.4 Northern Blotting 
0.5 µg of each RNA sample was glyoxalated at 50°C for 10 min and subsequently 
separated by electrophoresis on a 1.4% HGT agarose gel in 10 mM sodium phosphate 
running buffer. RNA was blotted to a nitrocellulose filter by capillary action overnight. The 
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gel was placed on 3 x 3 mm Whatman papers saturated in 20x SSC. A 0.2 mm nylon filter 
(Pall Biodyne) cut to size was placed on top of the gel. This was covered with 3 x 3 mm 
Whatman papers saturated in ddH2O. A stack of paper towels was placed on top and pressed 
down with weights to facilitate RNA transfer. After transfer, the filter was UV treated at 1200 
J/cm
2
 (Spectrolinker XL-1500, Spectros corporation), then deglyoxalated by adding boiling 
20 mM Tris-HCl pH8 to the filter and allowing it to cool to room temperature. Using 
hybridisation buffer, the filter was prehybridised with salmon sperm DNA (Agilent 
Technologies) for 3 hr at 65°C with rotation, and hybridised overnight with α32P-dCTP 
labelled probe for either EBER1 or EBER2. Probes were synthesised directly before use with 
Agilent Prime-It DNA Labelling Kit (Agilent Technologies). After hybridisation, the filter 
was washed 2 x 15 min at 25 °C in 2x SSC + 0.2% (w/v) SDS then 2 x 20 min at 65 °C in 
0.1x SSC + 0.2% (w/v) SDS, and exposed to medical X-ray film (Fujifilm) with an 
intensifying screen at -80 °C for various time lengths.  
Synthesis of radiolabelled probes: EBER1 and EBER2 templates were created by 
PCR using the primers listed (Table 2B). Probes were synthesised directly before use with 
Agilent Prime-It DNA Labelling Kit according to the manufacturer’s protocol. 25 ng DNA 
template was diluted in RNase-free water up to 24 μl, 10 μl random 9-mer primers were 
added and the mixture boiled for 5 min. 10 μl 5x dCTP buffer, 5 μl α32P-dCTP (3000 
Ci/mmol 10 mCi/ml, Perkin Elmer) and 1 μl Exo(-) Klenow enzyme (5 U/μl) were added, the 
reaction was incubated at 37°C for 10 min then 2 μl Stop Mix was added. A micro bio-spin 
chromatography column (BioRad) was cleared by centrifugation (2 min at 1000 x g), then 
loaded with reaction mix and centrifuged for 4 min at 1000 x g to remove unincorporated 
dCTP. The purified probe was boiled for 5 min then added to the filter in fresh hybridisation 
mix. 
 
2.7.5 Synthesis of cDNA from total cell RNA 
Up to 1 µg of each RNA sample was DNase treated using RQ1 RNase-free DNase 
(Promega) according to the manufacturer’s protocol. RNA was diluted in 1x RQ1 RNase-free 
DNase Reaction Buffer (Promega) and one unit of RQ1 RNase-free DNase was added. The 
reaction was incubated at 37°C for 30 min then inactivated at 65°C for 10 min following the 
addition of 1 μl RQ1 DNase Stop Solution per 10 μl reaction volume.  
cDNA was synthesised from treated RNA using Protoscript First Strand cDNA 
Synthesis Kit (NEB) according to the manufacturer’s protocol. For one reaction, 6 μl RNA 
and 2 μl Random Primer Mix were denatured at 70°C for 5 min then directly transferred to 
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ice. 10 μl 2x M-MuLV Reaction Mix and 2 μl M-MuLV Enzyme Mix (or 2 μl RNase-free 
water for no RT control reaction) were added. Reactions were incubated in a thermocycler 
(Applied Biosystems GeneAmp System 9700) at 25°C for 5 min, 42°C for 1 hr and 80°C for 
5 min. 
 
 
2.8 Protein protocols 
 
2.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein separation by SDS-PAGE was performed using the BioRad Mini Protean II 
system. Proteins were separated on a 15% (v/v) polyacrylamide resolving gel in combination 
with a 5% (v/v) polyacrylamide stacking gel. 10 μl TEMED and 50 μl 10% (w/v) APS were 
used per 10 ml gel volume to polymerise gels. Protein samples diluted in 2x SDS sample 
buffer were denatured at 95°C for 10 min before loading. Protein sizes were determined by 
the inclusion of a standard, Full Range Rainbow Molecular Weight Marker (Amersham). 
Gels were run in SDS running buffer at 120-150 V. 
 
2.8.2 Metabolic labelling of cellular proteins using 
35
S-methionine 
10 ml actively growing LCLs were diluted to a density of 8 x 10
5
 cells/ml and 
returned to incubation for 3 hr. 0.2 mCi 
35
S-L-methionine (5 mCi 11 mCi/ml, Perkin Elmer) 
was added to each culture. Cells were incubated overnight. 8 x 10
6
 cells were pelleted by 
centrifugation at 300 x g for 10 min at room temperature, washed in TBS and resuspended in 
2x SDS sample buffer. Samples were sonicated to shear genomic DNA. Samples were 
separated by SDS-PAGE, with 4 x 10
5
 cell equivalents per well. Gels were soaked in 
Amplify buffer for one hour with agitation (GE Healthcare), dried under suction, then 
exposed to medical X-ray film (Fujifilm) for various time lengths. 
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3 EBER-regulated genes during primary 
EBV infection 
 
The aim of this chapter is to investigate cellular gene expression changes correlating with 
EBER1 or EBER2 expression during EBV infection of naïve B cells. 
 
3.1 Introduction 
The EBERs are the most abundant transcripts in latent infection [211, 255], reaching 
levels of 10
4
-10
5
 copies per cell [257-259]. They are first detected in B cells a few hours after 
primary infection [281], are abundant at 48 hours post infection (PI) and reach high levels at 
72 hours PI. Recently, EBERs have been detected as early as 2 hours PI [281], with different 
expression profiles for EBER1 and EBER2 during the first 24 hours of infection. Whilst 
potential roles for the EBERs in latent infection and EBV-associated tumours have been 
studied in some detail, there has been limited research into the roles of EBERs during B cell 
early infection. The fact that EBERs are detected a few hours after infection indicates a 
potential role for them during this process and their consistently high levels from 72 hours 
onwards suggests a role during latent infection. The same early infection study demonstrated 
that EBERs packaged into the virion induce synthesis of interferon alpha (IFN-α) during the 
first 72 hours of infection [281]. The EBERs have been linked to interferon (IFN) induction 
in other studies: EBER1-La complexes can induce an IFN response (in LCLs and gastric 
carcinoma cells)[338], and EBER binding to 5’ phosphorylated RNA response protein RIG-I 
[309] may induce the production of type I IFN. Also, for most viruses, the process of primary 
infection induces an interferon response [382]. Various potential target genes of the EBERs 
have recently been identified in a microarray study of wild type (wt) and EBER knockout 
LCLs [110]. These indicated potential roles for EBER1 in interferon/antiviral responses and 
biosynthetic processes, and potential roles for EBER2 in regulation of apoptosis and 
membrane signalling molecules [110].To follow on from the microarray study, this study 
aimed to investigate gene expression changes during primary infection that might correlate 
with EBER expression. This was done using EBER knockout strains of EBV to infect human 
primary B cells. This is the first time that primary infection studies have been performed 
using these recombinant single EBER deletion EBVs. Genes of particular interest were those 
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identified by microarray and IFN genes, specifically IFNA genes. Primary B cell infection is 
a good model system as B cells are natural EBV host cells and the system mimics the early 
stages of in vivo EBV infection. Infected cells eventually grow out as LCLs and these display 
a Latency III gene expression program which correlates with latently infected B blasts in vivo 
[19]. Study of the interferon response during primary infection, and the expression patterns of 
other cellular genes, can give us insights into immune and cellular responses to EBV 
infection and EBER expression. As the EBERs are highly expressed in all EBV-associated 
malignancies, these insights would be useful for understanding disease pathogenesis and 
diagnosis, and the ultimate long-term goal of such studies is to lead to new therapeutic targets 
and approaches. Further understanding of the roles of the EBERs may also contribute to the 
understanding of noncoding RNAs. 
 
3.2 Experimental design for analysis of EBER targets during 
primary EBV infection 
Primary infection was carried out in B cells isolated from human blood buffy coats 
(see section 2.2.6) as illustrated in Figure 3.1. The EBER knockout strains of EBV used were 
the same as those used to make LCLs in the microarray study [110]. These EBER knockout 
strains were: wild-type (wt), EBER1 deletion (ΔE1), EBER2 deletion (ΔE2), EBER1 and 
EBER2 deletion (ΔE1ΔE2). 2 million B cells were infected with EBV using a multiplicity of 
infection (MoI) of 0.1. This MoI was similar to that used in the primary infection studies by 
Jochum et al. [281]. Due to the variable nature of the HEK 293T EBV-producing cell lines, 
which gave EBV titres ranging from 10-700 GRU/μl, and the fact that EBV titres decrease 
over time in long-term storage, it was only possible to achieve an MoI of 1 for the first 
experiment where only wild type and EBER1 knockout EBV were used (section 3.3.2). 
Initially there were problems with virus production from the other HEK 293T + EBV BAC 
cell lines, which were producing titres in the range 0-4 GRU/μl, but subsequently new EBV 
BACs and the corresponding HEK 293T + EBV BAC cell lines were created by Dr G 
Gregorovic. Also it is worth noting that previous primary infection studies in the lab on 
EBNA2 had obtained clear gene expression changes using 5000 GRU of EBV to infect 2 
million B cells [94]. Following primary infection, various timepoints were chosen at which to 
harvest total cell RNA. This RNA was then used to investigate expression of specific genes 
by RT-PCR. Different timepoints were used to address different situations. For investigation 
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of cellular genes, 72 hours PI was used as a starting point as this is when EBER expression 
first reaches steady state levels [63]. Timepoints were extended from this to every 5 days 
during outgrowth and the establishment of LCLs. For investigation of IFNA genes the focus 
was on the early stages of infection. Therefore the first three days of infection were important, 
and during initial infection timepoints were set at every two hours.  
 
Figure 3.1 Experimental design for EBV primary infection studies. Primary B cells are infected with EBV 
and total cell RNA is harvested at various timepoints for gene expression analysis by RT-PCR. 
 
3.3 Results 
 
3.3.1 Generation of recombinant EBV 
EBER knockout EBV-producing cell lines were made by transfection of different 
recombinant EBV bacterial artificial chromosomes (BAC) into HEK 293T cells. The cell 
lines require hygromycin selection (see section 2.2.1) for BAC retention. The recombinant 
EBV BACs and corresponding HEK 293T cell lines (referred to here as HEK 293T + EBV 
BAC cell lines) were created by Dr R Bosshard, Dr G Gregorovic, and Prof P Farrell. 
Recombinant EBV BACs contain the wild-type EBV B95-8 genome and those used here 
differ only in the EBER region (Figure 3.2 A). The variants are wild-type (wt), EBER1 
deletion (ΔE1), EBER2 deletion (ΔE2), EBER1 and EBER2 deletion (ΔE1ΔE2), EBER1 
revertant (ΔE1r) and EBER2 revertant (ΔE2r). Revertant BACs are genetically identical to 
wild type and are made by re-insertion of the original EBER gene into the deletion BAC.  
Firstly, EBER expression from the HEK 293T + EBV BAC cell lines was confirmed 
by Northern Blot (Figure 3.2 B). Two cell lines were used for each EBER variant. Stocks of 
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A B 
recombinant EBER knockout EBV strains were generated by inducing lytic replication in the 
relevant EBV-producing HEK 293T cell lines using EBV lytic activators BZLF1 and BALF4 
(see sections 1.1.6 and 2.3.4). Once produced, virus stocks were titrated on Raji cells (see 
section 2.3.5). Raji cells are an EBV-positive cell line derived from a Burkitt’s lymphoma and 
are very permissive for EBV infection. Infected cells become green as the EBV BAC 
contains an eGFP cassette, so EBV titres can be determined in green Raji units per μl 
(GRU/μl) with one GRU representing one infectious virus particle. Titres obtained varied 
from 10-700 GRU/μl. 
 
Figure 3.2 EBER knockout HEK 293T + EBV BAC cell lines were used to generate recombinant EBV  
A) Schematic of the EBER knockout EBV BACs, adapted from Gregorovic et al. (2011) [110]. B) Northern 
Blot of total cell RNA from EBER knockout HEK 293T + EBV BAC cell lines, indicating expected EBER 
expression phenotypes for all cell lines used. Two cell lines were used for each EBER variant.  
 
3.3.2 Investigation of potential EBER-regulated host genes in primary infection of B 
cells 
2 x 10
6
 human B cells (isolated from buffy coat, section 2.2.6) were infected with 
2 x 10
6
 GRU wild type or EBER1 knockout EBV (MoI = 1) and total cell RNA was harvested 
after 72 hours. RNA was then analysed by RT-PCR, focusing on specific EBER1 target genes 
identified in the previous microarray [110]. These two virus stocks had sufficiently high titres 
to achieve an MoI of 1, however subsequent experiments involving additional recombinant 
EBVs were performed using an MoI of 0.1. The gene targets that were analysed either 
displayed the highest fold expression changes in the microarray or had been validated in the 
same study by RT-PCR [110]. The initial results are shown in Figure 3.3. The experiment was 
repeated using MoI = 0.1 and this yielded the same results (data not shown).       
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Figure 3.3 RT-PCR analysis shows no difference in expression levels of selected genes between wt EBV 
and ∆E1 EBV infected B cells 72 hours post infection 2 x 106 human B cells were infected with 2 x 106 GRU 
of either wild type (wt) or EBER1 knockout (ΔE1) EBV (multiplicity of infection, MoI = 1). Total cell RNA was 
harvested after 72 hours and analysed by RT-PCR. The housekeeping gene GAPDH was used as a loading 
control. EBV gene EBNA2 was used as a control for infection. Genes selected for analysis were potential 
EBER1 target genes identified in the microarray by Gregorovic et al. (2011) [110].  
 
 
The genes CHL1, IFNA4, IFNA5, CDC42BPA, IL12RB2 and ADARB1 were tested 
and all show no clear difference in expression levels between infection with wild type EBV 
and infection with ΔE1 EBV. IFNA6 was also tested but not detected in any of the samples. 
 
It seemed that there could potentially be a slight difference in expression of IL12RB2 
between infection with wild type and ΔE1 EBV. RT-PCR is not a sensitive enough technique 
to detect small differences in expression levels. Therefore IL12RB2 expression levels were 
investigated further by qRT-PCR (Figure 3.4A). GAPDH was again used as an endogenous 
control. Firstly, standard curves were carried out using the qPCR primers for GAPDH and 
IL12RB2 (Figure 3.4B). Then expression changes in IL12RB2 between wt and ΔE1 infection 
were monitored using the ΔΔCT method. IL12RB2 levels for each sample were first 
normalised to the corresponding GAPDH signal (ΔCT). Then IL12RB2 levels were 
normalised to the level of IL12RB2 in the uninfected (0 hr) sample (ΔΔCT). The results are 
shown in Figure 3.4. The analysis demonstrates that there is not a reproducible difference in 
IL12RB2 levels between wt and ΔE1 infected B cells at 72 hours post infection (PI). 
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Figure 3.4 qRT-PCR analysis shows no difference in IL12RB2 expression levels between wt and ΔE1 EBV 
infected B cells 72 hours post infection  A) 1.5 x 10
6
 human B cells were infected with 1.5 x 10
6
 GRU of 
either wild type (wt) or EBER1 knockout (ΔE1) EBV (multiplicity of infection, MoI = 1.0) and total cell RNA 
was harvested after 72 hours. Samples are the same used in Figure 3.3. Samples were subjected to qRT-PCR 
analysis of IL12RB2 and GAPDH levels using the ΔΔCT method. B) Standard curves for IL12RB2 and GAPDH 
qPCR primers. 
 
 
Once EBER2 knockout (ΔEBER2/ΔE2) and EBER double knockout 
(ΔEBER1ΔEBER2/ΔE1ΔE2) EBV had successfully been produced, the previous experiment 
was repeated with the inclusion of these viruses. 2 x 10
6
 human B cells were infected with  
2 x 10
5
 GRU of each of wt, ΔE1, ΔE2 and ΔE1ΔE2 EBV (MoI = 0.1). This time, total cell 
RNA was harvested at 12 hours, 24 hours, 48 hours and 72 hours, to pinpoint more precisely 
the time at which any EBER-related gene expression changes might occur. Two stocks of 
each virus were used, each from a different HEK 293T + EBV BAC clone. Genes analysed 
by RT-PCR were again chosen from the microarray study [110] and are shown in Figure 3.5A. 
Figure 3.5B shows the experiment carried out with only one timepoint, 72 hours PI.  
 
 
 
 
A 
B 
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Figure 3.5A RT-PCR analysis shows no differences in expression levels of selected genes between B cells 
infected with wild type and EBER knockout EBVs up to 72 hours post infection 2 x 10
6
 human B cells were 
infected with 2 x 10
5
 GRU of wt, ΔE1, ΔE2 or ΔE1ΔE2 EBV (multiplicity of infection, MoI = 0.1). Total cell 
RNA was harvested at the indicated timepoints and analysed by RT-PCR. The housekeeping gene GAPDH was 
used as a loading control. EBV gene EBNA2 was used as a control for infection. Genes selected for analysis 
were potential EBER target genes identified in the microarray by Gregorovic et al. (2011) [110].  
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Figure 3.5B RT-PCR analysis shows no differences in expression levels of selected genes between B cells 
infected with wild type and EBER knockout EBVs at 72 hours post infection 2 x 10
6
 human B cells were 
infected with 2 x 10
5
 GRU of wt, ΔE1, ΔE2 or ΔE1ΔE2 EBV (multiplicity of infection, MoI = 0.1). Total cell 
RNA was harvested at 72 hours post infection and analysed by RT-PCR. The housekeeping gene GAPDH was 
used as a loading control. EBV gene EBNA2 was used as a control for infection. Genes selected for analysis 
were potential EBER target genes identified in the microarray by Gregorovic et al. (2011) [110].  
 
 
There appear to be EBER-associated expression changes of the genes FYB, HCK, 
IFNA, IFNA2 and IGSF4. FYB and HCK appear to have increased expression in wild type 
infected cells compared to the other samples, and FYB also appears to have little expression 
in the ∆EBER1∆EBER2 infected sample. IGSF4 appears to have lower expression in the wt 
and ∆EBER1 infected cells compared to the other samples. Both IFNA (primers detecting all 
IFNα transcripts) and IFNA2 show increased exp ression in the ∆EBER1∆EBER2 infected 
cells, and IFNA levels seem to be low in the wild type infected sample. However, these 
patterns did not seem to be reproducible and were not observed in repeats of the same 
experiment (data not shown). The figures also indicate that there appear to be no clear 
expression changes in IL10, SEPP1, TMPRSS3 and IGF1 in response to EBER expression at 
these timepoints. The lack of reproducible expression changes might be due to the specific 
genes studied, but might also be due to the timepoints chosen. The microarray study [110] 
was carried out in LCLs which had been cultured for a few months before analysis and  
therefore EBER-associated gene expression changes might be observed at a later stage during 
B cell infection. 
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Figure 3.6 RT-PCR analysis shows no difference in expression levels of selected genes between wild type 
and EBER knockout EBV infected B cells in the timecourse up to 25 days post infection 2 x 10
6
 human B 
cells were infected with 2 x 10
5
 GRU of wt, ΔE1, ΔE2 or ΔE1ΔE2 EBV (multiplicity of infection, MoI = 0.1). 
Total cell RNA was harvested at the indicated timepoints and analysed by RT-PCR. The housekeeping gene 
GAPDH was used as a loading control. EBV gene EBNA2 was used as a control for infection. Genes selected 
for analysis were potential EBER target genes identified in the microarray by Gregorovic et al. (2011) [110].  
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3.3.3 Investigation of potential EBER-regulated host genes from primary infection of B 
cells up to the development of LCLs 
As no reproducible EBER-related gene expression changes had been identified during 
the first 72 hours of EBV primary infection, later timepoints during the primary infection of 
B cells were investigated. The microarray [110] was carried out on LCLs which had been in 
culture for at least one month, and therefore gene expression changes might occur at a later 
stage in primary infection or be the culmination of a gradual process. Therefore 2 x 10
6
 
human B cells were infected with 2 x 10
5
 GRU of each EBER knockout EBV (MoI = 0.1) 
and cells were allowed to grow out into LCLs. Total cell RNA was harvested after 5, 10, 15, 
20 and 25 days and analysed by RT-PCR (Figure 3.6), again focusing on specific EBER 
target genes [110]. 
As before, IL12RB2 was analysed by qRT-PCR (Figure 3.7). The figure indicates that 
throughout the timecourse, IL12RB2 expression levels remained consistent between different 
infections and did not vary according to the presence of EBER1 or EBER2. The figure does 
show that IL12RB2 levels are high at the 5 day timepoint and are lower at 15 days and 25 
days post infection, suggesting that IL12RB2 is expressed at higher levels in newly infected B 
cells compared to LCLs. 
 
 
Figure 3.7 qRT-PCR analysis shows no difference in IL12RB2 expression levels between B cells infected 
with different EBER knockout EBVs at timepoints up to 25 days post infection 2 x 10
6
 human B cells were 
infected with 2 x 10
5
 GRU of each EBER knockout EBV (multiplicity of infection, MoI = 1.0) and total cell 
RNA was harvested at the indicated timepoints. Samples were subjected to qRT-PCR analysis of IL12RB2 and 
GAPDH levels using the ΔΔCT method.  
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3.3.4 Investigation of the effects of EBERs on expression of interferon alpha genes 
during early infection of B cells with EBV 
 Previous studies have indicated that the EBERs may have a role in the induction of 
interferon. EBERs packaged in the virion have been shown to induce interferon alpha (IFNα) 
during the first 72 hours of infection [281]. EBER-La complexes have been shown to induce 
an interferon response [338], EBER binding to RIG-I [309] might induce the production of 
type I IFN, and EBER1 has been shown by microarray to cause expression changes in genes 
involved in interferon/antiviral responses [110]. The process of primary infection in general is 
linked to induction of interferons [382]. Therefore the focus of this part of the investigation 
was on the early stages of B cell infection. 2 x 10
6
 B cells were infected with 2 x 10
5
 GRU of 
wt, ∆E1, ∆E2 or ∆E1∆E2 EBV and total cell RNA was harvested at various timepoints after 
infection. Following on from the observation that EBERs are detected in B cells at increasing 
levels from 2 hours post infection [281], timepoints were initially set at 2 hour intervals, from 
initiation of infection (0 hr) until 8 hours after infection, and then at 12 hours and 24 hours 
post infection. RNA was analysed for expression of different IFNα genes (IFNA genes) using 
RT-PCR (Figure 3.8, primers taken from [480]). As interferon alpha had been shown to be 
induced in early infection [281], and IFNA subtype expression varies according to virus [384], 
it would be interesting to see which interferon alpha genes were responsible for this. 
EBER expression was not detected as samples were taken at timepoints before EBERs 
reach levels detectable by RT-PCR. Figure 3.8 shows that interferon alpha genes were 
differentially expressed during the first 24 hours of EBV infection. IFNA4 is not shown as it 
was not detected at all. Interferon alpha genes IFNA1, IFNA2 and IFNA5 were detected at the 
highest levels and throughout the time period. The poor detection of other IFNA transcripts 
might be the result of low expression levels. However, it is also possible that the differential 
detection of IFNA transcripts might be due to differing primer efficiencies. 
As a result of the limited detection of IFNA genes during the first day of EBV infection 
of B cells, the experiment was repeated but this time using different timepoints. The 
experiment was extended to the first three days of infection, as this is the time at which 
EBER-induced IFNα has previously been detected [281]. The experiment was also extended 
to include two stocks of each virus (each derived from a different HEK 293T + EBV BAC 
clone). Timepoints were taken at 0, 12, 24, 48 and 72 hours post infection. Total cell RNA 
was analysed for EBER expression and IFNA expression (only successful RT-PCR shown).  
IFNA4 was considered as it had previously been detected at 72 hours PI (Figure 3.3). The 
results are shown in Figure 3.9. 
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Figure 3.8  Interferon alpha genes are differentially expressed during the first 24 hours of B cell infection 
with EBV but do not correlate with EBER expression  A) 2 x 10
6
 B cells were infected with 20,000 GRU of 
wt, ∆E1, ∆E2 or ∆E1∆E2 EBV. Total cell RNA was harvested at 0, 2, 4, 6, 8, 12 and 24 hours post infection. 
Total cell RNA was analysed by RT-PCR, using primers for each of the human interferon alpha genes. IFNα 
indicates a primer set that detected all human interferon alpha transcripts. The housekeeping gene GAPDH was 
used as a loading control. B) IFNA genes from part A with high signal for ∆E1∆E2 at the 12 hour timepoint 
were tested again to see if this pattern was reproducible. 2 x 10
6
 B cells were infected with 20,000 GRU of wt, 
∆E1, ∆E2 or ∆E1∆E2 EBV. Total cell RNA was harvested at 12 hours post infection. IFNA indicates a primer 
set that detected all human interferon alpha transcripts. 
 
 
 
 
A 
B 
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Figure 3.9  Expression of interferon alpha genes does not correlate with EBER expression during the first 
72 hours of EBV infection of human B cells  2 x 10
6
 B cells were infected with 20,000 GRU of wt, ∆E1, ∆E2 
or ∆E1∆E2 EBV. Total cell RNA was harvested at 0, 12, 24, 48, and 72 hours post infection. Total cell RNA was 
analysed by RT-PCR, using primers for human interferon alpha genes. IFNA indicates a primer set that detected 
all human interferon alpha transcripts. The housekeeping gene GAPDH was used as a loading control. 
 
According to these figures, there appears to be no distinct pattern in expression of 
interferon alpha genes and no apparent correlation between EBER expression and interferon 
alpha expression during the first three days of EBV infection of human B cells. Expression 
patterns observed in Figure 3.8A, i.e. the high IFNA1, IFNA7, IFNA10 and IFNA17 signals in 
the ∆E1∆E2 sample at 12 hours post infection, were not reproduced when investigated further 
(Figure 3.8B). In Figure 3.9 the interferon transcripts that could be detected were generally 
expressed uniformly between the different samples taken at each timepoint. Any non-uniform 
expression did not appear to correlate with the presence of EBER1 or EBER2. Due to the 
longer timecourse, EBERs could be detected in this experiment. EBER1 first reached 
detectable levels at 24 hours post infection, whereas EBER2 could be detected earlier, at 12 
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hours post infection. Both EBERs reached maximal expression levels at 48-72 hours post 
infection. 
 
3.3.5 Investigation of global protein level changes corresponding to EBER expression in 
LCLs 
Taken together, the previous experiments indicated that EBER expression during 
primary infection did not result in any reproducible gene expression changes in the specific 
genes studied. This might be due to the EBERs acting primarily at the protein level, with 
widespread gene expression changes occurring as a downstream consequence of protein level 
changes. This is potentially supported by the gene expression changes in LCLs being spread 
across a variety of cellular processes and pathways. Therefore, initial experiments were 
performed investigating potential EBER-related expression changes at the protein level. 
Firstly, global protein levels were monitored in the different EBER knockout LCLs (wt, ∆E1 
and ∆E2) using metabolic labelling with 35S radiolabelled methionine (section 2.7.2). Two 
wild type LCL cell lines were used. 8 x 10
6
 actively growing LCLs (grown in duplicate) were 
radiolabelled overnight with 0.2 mCi 
35
S-L-methionine. Cells were harvested and analysed by 
SDS-PAGE and subsequent autoradiography (Figure 3.10), with 4 x 10
5
 cell equivalents 
loaded per lane. Figure 3.10 illustrates that there were no global protein level expression 
changes between the LCLs and this indicates that EBER expression does not correlate with 
large-scale changes in protein expression in latently infected LCLs.  
                                        
 
Figure 3.10  Metabolic labelling of proteins in EBER knockout LCLs indicates there are no global 
protein-level expression changes correlating with EBER expression  8 x 10
6
 of each of wt, ∆E1 and ∆E2 
LCLs were metabolically labelled overnight with 
35
S-methionine and analysed by SDS-PAGE and 
autoradiography. 4 x 10
5
 cell equivalents were loaded per lane. The experiment was carried out in duplicate for 
each cell line. Two cell lines were used for wild type LCLs. This is representative of two repeats. 
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3.4 Discussion 
Primary infection of B cells was carried out in order to identify potential primary 
targets of the EBERs. Target genes as identified in the microarray study [110] were tested for 
expression changes by RT-PCR. There were no reproducible expression changes correlating 
with EBER expression identified in the target genes studied. The system was then used to 
study the expression of interferon alpha genes in response to EBER expression in early 
infection. Again, although individual experiments showed some effects, no reproducible 
expression changes were found in the interferon alpha genes in response to EBER expression 
during the first three days of infection. To determine whether expression changes of target 
genes might occur at a later point during in vitro infection, RT-PCR analysis of the same 
target genes was carried out on samples taken from a timecourse from initial infection up 
until 25 days post infection. As no changes were identified at the gene expression level, 
protein level studies were begun, which indicated that EBERs did not cause large scale 
protein expression changes so might act more specifically. 
 
3.4.1 No EBER-induced changes in the expression of microarray identified EBER-target 
genes were identified during the infection of human primary B cells with EBV 
In order to identify potential primary target genes of the EBERs, work was carried out 
early in primary infection, so that potential direct target genes could be distinguished from 
downstream target genes. The target genes initially chosen for analysis were those that 
exhibited the highest expression changes in the microarray study or those that had been 
already validated by RT-PCR [110]. Human primary B cells were infected with different 
EBER knockout EBVs: wild type, EBER1 knockout, EBER2 knockout and EBER1 and 
EBER double knockout. EBER target genes were initially analysed 72 hours after infection as 
this is when EBER expression first reaches steady state (LCL) levels [63]. The first genes to 
be analysed were EBER1 target genes due to difficulties in obtaining usable titres of the 
EBER2 knockout virus. The EBER1 target genes studied were CHL1, IFNA4, IFNA5, 
CDC42BPA, IL12RB2 and ADARB1. These genes showed no difference in expression 
between infection with wild type or ∆EBER1 EBV. Once high titres of EBER2 knockout 
EBV had been successfully produced, EBER2 target genes were incorporated into the RT-
PCR analysis, as well as some genes linked to immune responses. The next genes to be 
analysed were CXCR3, TBX15, MMP7, GPR125, CXCL12, IL10, SEPP1, TMPRSS3, IGF1, 
FYB, HCK, IFNA, IFNA2 and IGSF4. Again these genes did not show reproducible 
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expression changes in response to EBER expression. FYB, HCK, IFNA, IFNA2 and IGSF4 
initially appeared to have EBER-associated expression changes however these patterns were 
not reproduced upon repeats of the experiment. The lack of clear gene expression changes 
might have been due to the samples being taken too early; gene expression changes might 
occur at a later stage during in vitro infection. As the microarray study was carried out in 
LCLs [110], the EBER-related gene expression changes might have taken time to develop. 
Therefore the timecourse was extended to 25 days, with samples being harvested every five 
days following initial infection. The genes studied were TBX15, MMP7, ADARB1, CXCR3, 
CDC42BPA and IL12RB2. These were chosen as they had been studied in the previous 
experiments. The gene expression patterns again were consistent between samples regardless 
of EBER expression. The data indicate that there were no expression changes in the selected 
genes at the timepoints studied, suggesting that there might not be any EBER-related 
expression changes in these genes at these times during in vitro infection. 
 
3.4.2 No EBER-induced changes in expression of interferon alpha genes were identified 
during the infection of human primary B cells with EBV 
 In light of the various studies suggesting the EBERs to induce an interferon response 
in latently infected cells [309, 338] and the ability of EBERs to induce IFNα in the first 72 
hours of infection [281], the effect of the EBERs on the expression of IFNα genes was 
studied up to the first three days of EBV infection of B cells. Initially, timepoints taken up to 
24 hours post infection (Figure 3.8) indicated that only a few interferon alpha transcripts were 
detected during the first 24 hours of infection; these were IFNA1, IFNA2, IFNA5 and IFNA21. 
EBERs could not be detected during the first 24 hours of infection as they had not yet 
reached levels above the RT-PCR detection threshold. The IFNA transcripts did not appear to 
show any reproducible expression changes correlating with EBER expression (Figure 3.8). 
The lack of EBER-related expression differences could have been simply due to the 
timepoints being too early: either before the EBERs had mediated any effect on interferon 
expression or before IFNA transcripts had accumulated to levels where clear differences in 
expression could be seen. Therefore the experiment was extended to a three day timecourse 
(Figure 3.9), focusing on those IFNA genes with the highest expression levels. This time two 
different stocks of each virus were used (made from different 293T + EBV BAC clones) to 
account for any differences caused by the HEK 293T + EBV BAC clone or the virus 
preparation used. In this experiment, EBER2 was first detected at 12 hours post infection and 
EBER1 was first detected at 24 hours post infection. In spite of the easily detectable levels of 
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EBER expression, no EBER-related changes in expression of interferon genes were detected. 
Generally, the interferon transcripts were expressed uniformly between infections at each 
timepoint, and any non-uniform expression did not correlate with expression of EBER1 or 
EBER2. Taken together, the data indicate that there were no EBER-associated expression 
changes in the interferon alpha genes studied. 
 
3.4.3 No EBER-induced changes in global protein levels in were identified in LCLs 
 The previous experiments suggested that EBER expression during primary infection 
did not result in any expression changes in the specific genes studied. This could be because 
the EBERs act more at the protein level of gene expression, and the previous microarray 
results [110] might represent widespread gene expression occurring as a downstream 
consequence of specific protein level changes, particularly as gene expression changes 
identified were spread across a variety of cellular processes and pathways. Therefore initial 
work was carried out to investigate roles of EBERs at the protein level of gene expression. 
Some viruses induce a selective translational shutdown of host mRNAs [487, 488], whilst the 
adenovirus VA noncoding RNAs, which resemble the EBERs, prevent PKR-induced 
translational shutdown in infected cells [289-291]. The EBERs are known not to cause a 
global translational activation or shutdown but they might perhaps cause large scale changes 
in protein expression or have an effect on the most abundant cellular proteins. Therefore 
metabolic labelling was carried out in wt, ∆E1 and ∆E2 LCLs using 35S-radiolabelled 
methionine (Figure 3.10), to investigate potential EBER-induced changes in global protein 
expression. However, there appeared to be no large-scale protein changes between the 
different LCLs, indicating that EBER expression does not cause large-scale protein 
expression changes in latently infected cells. This suggests that the EBERs might act more at 
the level of specific proteins. 
 
3.4.4 Perspectives and future directions 
In this work, no reproducible EBER-associated gene expression changes were 
identified during primary infection, either in the selected EBER target genes chosen from the 
previous microarray study or in the interferon alpha genes studied. This suggests that perhaps 
there might not be any EBER-associated expression changes in these genes at the timepoints 
studied. There are a variety of explanations for this observation. Firstly, it is possible that the 
genes studied here were simply not those in the vast array of cellular genes that might 
respond to EBER expression. Therefore a high throughput method would need to be 
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employed to facilitate identification of EBER target genes during primary infection. Secondly, 
the EBERs might not act directly at the level of gene expression. Therefore expression 
changes identified in LCLs [110] might be the result of complex cellular processes in 
response to EBER expression as opposed to genes directly regulated by the EBERs.  
The EBERs might act at the level of protein expression, a possibility which was 
beginning to be investigated (section 3.3.5). The data from this section indicated that the 
EBERs do not act at the global level of protein expression or upon the most abundantly 
expressed proteins. Therefore, if the EBERs target protein expression, it is likely to be at the 
level of individual proteins. Potential roles for the EBERs in protein expression could be the 
alteration of expression levels as well as the alteration of specific post-translational 
modifications. Currently, there is speculation as to whether the EBERs might act as miRNA 
sponges, sequestering specific miRNAs to prevent them binding to their mRNA targets [489]. 
Thirdly, EBERs might not act to control protein levels but might mediate their effects 
through interactions with cellular proteins. EBER1 has already been shown to bind the 
proteins La [211, 261], rpL22 [312], and AUF-1 [311], and both EBERs have been shown to 
bind proteins RIG-I [309] and PKR [310]. EBER1 interaction has been shown to relocalise 
rpL22 in certain cell lines [110, 342, 345] and the functional consequences of EBER 
interaction with PKR are debated [134, 329, 334]. EBER binding to cellular proteins might 
alter a protein’s localisation or ability to bind other cellular factors. It is possible that there 
are further EBER interaction partners to be identified. 
It is also worth considering the limitations of the system used for the study. B cells 
were isolated from different donors and the genetic and cellular background of each set of B 
cells differs. This might account for some of the variability seen between experiments, and is 
also seen to cause variability between the LCLs used in the previous microarray study from 
the lab [110]. It is also possible that clearer gene expression changes might be observed if the 
MoI was increased. An MoI of 0.1 was to replicate the experiments performed by Jochum et 
al. (2012) [281]. In the first study of this chapter, an MoI of 1.0 was used alongside an MoI of 
0.1 and both yielded identical gene expression patterns. It was not possible to increase the 
MoI in subsequent sections due to difficulties in producing high titres of virus from the HEK 
293T + EBV BAC producer cell lines. It is possible that a high number of uninfected cells 
might cause masking of any effects occurring in infected cells in the same population. 
However, EBERs are expressed to very high levels so it is reasonable to expect detection of 
any EBER-induced gene expression changes, regardless of MoI (supported by previous 
studies in this lab [94]). Also, by 72 hours post infection, most of the uninfected cells are 
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likely to have died (as quiescent B cells do not survive in culture without stimulation) so the 
population should mainly consist of infected cells at this point. 
The study of interferon alpha genes during early infection indicated that IFNA genes 
were differentially expressed in response to EBER expression. However, EBER-associated 
changes in IFNA expression were not detected, which is not in accordance with previous data 
[281]. This previous data identified an increase in the level of IFNα protein at three days post 
infection in response to EBERs expression. The use of purified virus by Jochum et al., but 
not in these experiments, might account for the different observations. The different 
observations might also be accounted for by a role for the EBERs at the translational level 
rather than at the level of gene expression. It is also possible that experimental conditions 
might be limiting the detection of EBER-induced changes. Alternative primer sets might 
enable better detection of particular IFNA genes. Also interferon induction might be 
widespread across samples due to contaminants present in the virus preparations (which can 
be rectified by using purified virus), or from B cells already being activated due to the 
harvesting procedure or pre-existing infection. An increase in MoI, as previously discussed, 
might facilitate the detection of any EBER-induced gene expression changes. 
 It might be that the in vitro B cell system used does not represent the true site of 
action of EBER1 and EBER2. EBERs have been shown to be released from EBV infected 
cells in exosomes [426, 490]. This suggests that secretion of the EBERs might be an 
important part of their function and also suggests that EBERs might elicit their effects in cells 
other than B cells. It is possible that EBERs act on targets that are not expressed in B cells. 
The EBERs might act in the initiation of epithelial infection, in accordance with the dual 
tropism model [22, 23]. It might be that the EBERs act at a more systemic or physiological 
level. This is being currently investigated in the lab with mouse studies being performed in 
collaboration with Prof C. Münz (University of Zurich). These studies might reveal a 
physiological phenotype for each of EBER1 and EBER2, for example an increase/decrease in 
the number of a particular blood cell type. The EBERs might also act at a later stage of 
infection, i.e. not during primary infection or the initial Latency III phase. It could be that 
EBERs are involved in the germinal centre reaction or the evasion of immune detection, in 
consideration that the EBERs, unlike the viral proteins, are expressed in the Latency 0 stage 
occurring in memory B cells. 
 Future work therefore needs to consider these potential roles of the EBERs as well as 
following on from the studies carried out here. Firstly, the experiments carried out here might 
be repeated using a higher MoI in order to see whether this enables potential EBER-induced 
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expression changes to become detectable. This might require alterations to the process of 
generation of EBV in order to obtain high viral titres. Secondly, the interferon studies might 
be repeated using purified virus in case widespread interferon induction is due to 
contaminants in the virus stocks. Future work with the primary infection system might also 
consider the effect of EBER infection on peripheral blood mononuclear cells (PBMCs), in 
consideration that B cells might not be the direct target cells for the EBERs. If EBERs are 
released into the supernatant it might be interesting to see the effect of the supernatant 
recovered from a primary infection experiment on various cell types, such as T cells and 
epithelial cells. The ongoing mouse study (previously mentioned) might shed some light as to 
any physiological roles of the EBERs. To continue on from the protein level studies, it would 
be worth employing a higher resolution technique to the analysis of protein expression in 
EBER knockout LCLs, such as 2D gel electrophoresis or SILAC.  
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4 Introduction of EBER expression into 
EBER-negative cell lines 
 
The aim of this chapter is to develop a system that can stably reintroduce EBER expression 
into EBER-negative cell lines, such as EBER deletion LCLs and healthy nasopharyngeal 
cells. This would enable the study of gene expression changes correlating with EBER 
expression in cell lines relevant to cancers and other EBV-associated diseases. 
 
4.1 Introduction 
EBV is aetiologically linked to a various cancers including Burkitt’s Lymphoma (BL), 
Hodgkin’s lymphoma (HL) and nasopharyngeal carcinoma (NPC). At least 95% of endemic 
BL cases are EBV-associated, around 90% of NPC cases are EBV-positive and about 40% of 
HL tumours are EBV-associated [116]. The strong association of EBV with these diseases 
reflects the oncogenic potential of EBV, however, the exact mechanisms of EBV-mediated 
transformation are only just starting to be understood. A surprising observation with certain 
EBV-associated cancers is the absence of the growth promoting EBNA proteins from their 
expression profiles. The viral noncoding RNAs, the BART microRNAs and the Epstein-Barr 
virus encoded RNAs (EBERs), however, are expressed in these latency programs [19]. The 
EBERs are, in fact, highly expressed in all forms of EBV latent infection as well as in all 
EBV-associated malignancies. Consequently the EBERs are used as a diagnostic marker for 
the presence of EBV in tumours and other diseases. 
The abundant and widespread expression of the EBERs implies a role for them in 
both latent infection and EBV-associated malignancies. However the exact roles and 
molecular mechanisms of the EBERs are not known. The EBERs have been shown to have 
potential roles in oncogenesis and immune evasion [132, 134, 135], important aspects of 
disease progression. In the recent microarray study from our lab, EBER1 was found to be 
associated with genes involved in interferon/antiviral responses and biosynthetic processes, 
whereas EBER2 was found to be associated with genes involved in regulation of apoptosis 
and membrane signalling molecules [110]. An understanding of the roles of the EBERs 
would be beneficial for our understanding of their contribution to the onset and progression 
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of EBV-associated malignancies and would improve our understanding of EBV latent 
infection. The ultimate long-term goal would be identification of new therapeutic targets and 
approaches. 
Therefore systems modelling the role of EBERs in BL and NPC would be very useful. 
This study aimed to develop a system to introduce EBER expression into EBER-negative cell 
lines that were relevant to BL and NPC. Such a system would enable the study of gene 
expression changes correlating with EBER expression in these cell lines and would provide 
suitable systems for the validation of the potential EBER target genes previously identified 
[110]. A lentiviral vector approach was used to introduce EBER expression into EBER-
negative adherent cell lines, LCLs and healthy nasopharyngeal cells. Lentiviral vectors 
efficiently transduce a variety of cell lines, including cell types naturally infected by EBV. 
Lentiviral vectors also facilitate the production of stable cell lines, and bypass the need for 
continuous drug selection in cell culture, which could have an impact on cellular gene 
expression profiles. 
 
4.2 Experimental design for development of a lentiviral vector 
system to introduce EBERs into EBER-negative cell lines 
Transfection efficiency in LCLs is typically poor, ranging from 20-40%. Also any 
potential EBER-induced gene expression changes might result from downstream processes 
which take time to be established. Therefore a viral vector-based approach was used. 
Lentiviral vectors were chosen over other viral vectors because they stably insert into the host 
genome and can transduce non-dividing cells [456-458]. A VSV-G pseudotyped second 
generation lentiviral vector system was used, i.e. the vesicular stomatitis virus (VSV) coat 
glycoprotein replaced the wild type coat to broaden the tropism of the vector (see sections 
1.4.4 and 1.4.6). Therefore the same vectors could be used to transduce several different cell 
lines. Cells used for transduction were HeLa, HEK 293T, LCLs and NP460 hTERT. HeLa 
and HEK 293T cells are easily transduced so were used for initial experiments. LCLs are 
similar to latently infected B cells in vivo and were the cells used in the previous microarray 
study [110]. NP460 hTERT cells are EBV-negative nasopharyngeal epithelial cells (derived 
from a healthy human nasopharynx) that have been immortalised for cell culture by 
expression of telomerase, and are a useful model to study the development of NPC [473]. 
The experimental approach was as follows: Firstly, lentiviral vectors were adapted to 
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express EBER1 or EBER2. These were tested for transduction and EBER expression was 
optimised, aiming for stable EBER-expressing cell lines. The vectors could also be used to 
transduce EBER1 knockout (ΔEBER1/ΔE1) or EBER2 knockout (ΔEBER2/ΔE2) LCLs, with 
the goal of complementing EBER expression in these cell lines. The ultimate long-term aim 
was the possible validation of the EBER target genes previously identified [110] and the 
identification of novel EBER targets by high throughput transcriptome analysis. 
Because of the highly structured nature of the EBER RNAs, which might inhibit 
genome packaging or expression, it was not clear whether it would be possible to generate 
EBER-expressing lentiviral vectors. However the potential advantages of the system made 
pursuit of this technique worthwhile. 
 
4.3 Results 
 
4.3.1 Lentiviral vectors were modified to produce EBER RNAs 
The lentiviral vector system used here is adapted from one developed by the Trono 
lab (EPFL, Lausanne). The system is a second generation lentiviral vector system (see section 
1.4.6) and consists of three plasmids: an expression vector containing the transgene cassette, 
a packaging vector and a VSV-G coat vector (see sections 1.4.4 and 1.4.5). Expression 
vectors (also referred to as lentiviral vectors, LV) containing the following transgene 
cassettes were created by modification of the pWPT vector (see section 2.6.6): H1 promoter + 
EBER1, H1 promoter + EBER2, and H1 promoter only control. The H1 promoter is a strong 
RNA polymerase III promoter [491] that is compatible with the EBER AGGA transcription 
start site, and is typically used for the expression of siRNAs from plasmid vectors [484]. The 
transgene cassettes replaced the eGFP coding region in the original pWPT vector. The 
resulting constructs were named pWPT-H1, pWPT-EBER1, and pWPT-EBER2, respectively, 
and confirmed by sequencing.  
 
          
Figure 4.1 Schematic of the HI RNA polymerase III promoter Sp1 = Sp1 promoter element, DSE = distal 
sequence element, PSE = proximal sequence element, TATA = TATA box. Transcription begins from an A 
nucleotide, marked in bold, and is terminated by a short run of T residues. Promoter sequence before -230 is not 
included in pSUPER-derived vectors. 
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Firstly, EBER expression from the three constructs was confirmed in a transient 
transfection assay. 0.8 µg of each construct was transfected into 2 x 10
5
 HEK 293T cells.  
0.8 µg of pSUPER-EBER1 and pSUPER-EBER2 were used as positive controls. Total cell 
RNA was harvested four days after transfection and analysed by Northern Blot (Figure 4.2). 
The data shows the lentiviral expression vectors were capable of EBER expression. The 
stronger signal from pSUPER-derived vectors may be accounted for by the fact they are 
around 2.5 times smaller than the pWPT-derived vectors (~3.8 kb compared to ~ 9.5 kb) and 
thus more copies were present per unit mass. 
 
Figure 4.2 EBER expression from EBER1 and EBER2 expression cassettes is retained upon cloning into 
lentiviral vector pWPT-GFP 0.8 µg of pWPT-EBER1, pWPT-EBER2, pWPT-H1, pSUPER-EBER1 and 
pSUPER-EBER2 was each transfected into 2 x 10
5
 HEK 293T cells. Total cell RNA was harvested after 4 days 
and analysed by Northern Blot. Each lane contains 0.5 µg of total cell RNA and the positive control is total cell 
RNA from wild type LCLs. LV denotes “lentiviral vector”.  
 
4.3.2 EBER sequence containing lentivirus particles are transduction competent 
Lentivirus stocks were generated by co-transfection of the three plasmid components 
of the system into HEK 293T cells as described in section 2.3.1. HEK 293T cells were used 
as they are a standard cell line with high transfection efficiency. Stocks were titrated to verify 
production of functional infectious particles. Titration was initially carried out using pWPT-
GFP containing lentivirus (denoted GFP-LV) as EBER-expressing lentiviruses lacked GFP. 
Lentivirus was titrated onto 8 x 10
3
 HeLa cells and GFP-positive cells were counted after 
four days. HeLa cells are a standard cell line for lentiviral titration as their regular shape 
facilitates counting of transduced cells, either by fluorescence microscopy or by FACS. 
Percentages of transduced cells are displayed in Table 4A. The lentivirus produced is 
transduction-competent and capable of transducing 100% of cells in a culture. The volume of 
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lentivirus required for 100% transduction was 1 ml and the viral titre was estimated to be 
TC50 = 160 µl. Assuming approximately 2.65 x 10
5
 cells per well at the time of counting 
(considering a doubling time of 19 hours for HeLa cells, there were 5.05 doublings in 4 days 
giving 2
5.05
 x 8 x 10
3
 cells), there were around 265 transducing units per µl. 
 
Table 4A Titration of eGFP-expressing lentivirus Lentivirus was titrated on 8.3 x 10
3
 HeLa cells and GFP-
positive cells were counted four days post infection. 100% transduction was achieved using 1 ml lentivirus. The 
estimated viral titre TC50 was 160 µl. 
 
4.3.3 EBER expression was detected after enhancement of transduction by centrifugal 
inoculation  
Following titration using GFP-LV, up to 1 ml of lentivirus made from each of pWPT-
H1, pWPT-EBER1, and pWPT-EBER2 (denoted as H1-LV, E1-LV and E2-LV, respectively) 
was titrated onto HeLa cells in an identical protocol. After four days total cell RNA was 
harvested and EBER expression was analysed by Northern Blot. No EBER expression was 
detected. This could have occurred due to poor transduction, either from a poor transduction 
efficiency or low titre, in consideration that EBER expression from the lentiviral vectors had 
been confirmed. To address this problem, an improved protocol was used in which cells were 
inoculated with lentivirus by centrifugation (a process known as centrifugal inoculation or 
“spinoculation”) as described in section 2.3.2. Studies have demonstrated that this procedure 
can enhance retroviral transduction of cell cultures [492-495]. Transduction using the above 
lentiviruses was performed using this protocol and EBER expression was tested after four 
days by Northern Blot (Figure 4.3). EBER expression was detected (demonstrating that 
lentiviruses were expression and transduction competent), albeit at low levels, suggesting that 
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these lentiviruses differed from GFP-LV in transduction efficiency, titre or gene expression 
levels. 
   
 
Figure 4.3 EBERs are expressed by E1-LV and E2-LV transduced HeLa cells E1-LV, E2-LV and H1-LV 
were each titrated on 5x10
4
 HeLa cells. Total cell RNA was harvested after 4 days and analysed by Northern 
Blot. Each lane contains 0.5 µg of total cell RNA. The positive control is total cell RNA from wild-type LCLs. 
Minus (-) indicates transduction without centrifugation. EBERs were detected in cells transduced with over 500 
µl lentivirus stock, but at low levels. 
 
 
4.3.4 EBER expression introduced by GFP and EBER co-expressing lentiviruses is 
variable 
The initial lentiviral vector system provided no direct way to titre the EBER-
expressing lentiviruses. Therefore a new cloning strategy was carried out, as outlined in 
section 2.6.7, to insert the EBER gene cassette downstream of the eGFP cassette. 
Consequently lentiviral vectors with the EBER cassette were now capable of GFP expression 
and could be titrated directly. The new expression vector constructs were denoted pWPT-
GFP-H1, pWPT-GFP-EBER1 and pWPT-GFP-EBER2, and were used to generate the 
lentiviruses H1-GFP-LV, E1-GFP-LV and E2-GFP-LV, respectively.  
These three lentiviruses were titrated on HeLa cells by centrifugal inoculation as 
described in section 2.3.2 and EBER expression after four days was analysed by Northern 
Blot (Figure 4.4). High transduction levels were confirmed by fluorescence microscopy 
(Figure 4.4). This time, the EBER expression was slightly improved, but varied between 
different transduction experiments. Figure 4.4 represents the highest EBER levels achieved.  
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Figure 4.4 EBERs are expressed upon transduction of HeLa cells with GFP and EBER co-expressing 
lentiviruses H1-GFP-LV, E1-GFP-LV and E2-GFP-LV were each titrated on 8 x 10
3
 HeLa cells. Total cell 
RNA was harvested after four days and analysed by Northern Blot. Each lane contains 0.5 µg of total cell RNA. 
The positive control is total cell RNA from wild-type LCLs. The table indicates the proportion of GFP-positive 
cells in each sample, as determined by fluorescence microscopy directly before harvesting. 
 
4.3.4 Transduction of LCLs with GFP-EBER lentiviruses 
Once EBER expression had been confirmed in HeLa cells, the lentiviruses were tested 
for transduction of EBER knockout LCLs in order to complement EBER expression. As the 
LCLs contained the EBV bacterial artificial chromosome (BAC), which is GFP-positive, it 
was necessary to titrate the lentiviruses on GFP-negative LCLs first. The GFP-negative LCLs 
used were those created by infection of human B cells with the wild type B95-8 EBV strain 
and are thus referred to as LCLs + B95-8 EBV. The volumes of lentivirus used to achieve 
100% transduction were used as a starting point for following experiments. 
The lentiviruses E1-GFP-LV and E2-GFP-LV were used to transduce EBER 
knockout LCLs in order to complement EBER expression. The GFP-expressing lentiviruses 
were used, despite GFP-positive target cell lines, in order to provide consistency between 
experiments. Lentiviruses were concentrated as described in section 2.3.1 in order to improve 
transduction efficiency. Lentiviruses were titrated onto 5 x 10
4
 LCLs. Total cell RNA was 
harvested after four days and EBER expression was analysed by RT-PCR and Northern Blot 
(Figures 4.5 and 4.6). Figure 4.5 shows RT-PCR analysis of EBER expression after 0-20 μl 
E1-GFP-LV and E2-GFP-LV each were titrated on EBER1 knockout (ΔE1) and EBER2 
knockout (ΔE2) LCLs, respectively. Figure 4.5 shows that transduction with E1-GFP-LV 
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introduced EBER1 expression into ΔE1 LCLs and transduction with E2-GFP-LV introduced 
EBER2 expression into ΔE2 LCLs, at levels comparable to those in wild type LCLs.  
 
 
                  
 
Figure 4.5 RT-PCR shows EBER expression can be introduced into EBER-negative LCLs by lentiviral 
vectors 5 x 10
4
 EBER1 knockout (ΔE1) and EBER2 knockout (ΔE2) LCLs were transduced with 200 μl E1-
GFP-LV and E2-GFP-LV, respectively. Total cell RNA was harvested after four days and analysed by RT-PCR 
for EBER expression. The housekeeping gene GAPDH was used as a loading control. Transduction with E1-
GFP-LV introduced EBER1 into ΔE1 LCLs and transduction with E2-GFP-LV introduced EBER2 into ΔE2 
LCLs, at levels comparable to wild type expression levels in LCLs. 
 
 
To improve EBER levels, increased amounts of lentivirus were added. 200 μl was the 
concentrated volume of one 10 cm dish of lentiviral supernatant, therefore this volume was 
used to transduce EBER deletion LCLs. 5 x 10
4
 ΔE1 and ΔE2 LCLs were transduced with 
200 μl E1-GFP-LV and E2-GFP-LV, respectively. Total cell RNA was harvested after four 
days and EBER expression was analysed by RT-PCR and Northern Blot (Figure 4.6).  
RT-PCR analysis showed that transduction with E1-GFP-LV introduced EBER1 into 
ΔE1 LCLs and transduction with E2-GFP-LV introduced EBER2 into ΔE2 LCLs. In RT-
PCR analysis, levels of transduced EBERs greatly exceeded wild type EBER levels in LCLs, 
concurrent with the use of ten times more lentiviral supernatant than in the previous 
experiment. However, in Northern Blot analysis of the same samples, LCL-derived EBERs 
were detected but lentivirus-derived EBERs were not detected. This shows that high levels of 
EBER1/EBER2 sequence-containing RNAs were introduced into LCLs, but not correctly-
sized mature EBERs.  
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Figure 4.6 Transduction of ΔE1 and ΔE2 LCLs with E1-GFP-LV and E2-GFP-LV introduces high levels 
of EBER-containing RNA species but does not introduce expression of mature EBERs  200 μl E1-GFP-LV 
and E2-GFP-LV were used to transduce 5 x 10
4
 ΔE1 and ΔE2 LCLs, respectively. Total cell RNA was 
harvested after four days and analysed by RT-PCR and Northern Blot. The housekeeping gene GAPDH was 
used as a loading control for RT-PCR. Each lane of the Northern Blot contains 0.5 µg of total cell RNA.  
 
 
4.3.4 Transduction of cell lines relevant to NPC with EBER-expressing lentiviruses 
As lentiviral transduction did not introduce correct EBER expression into LCLs, but 
was able to introduce EBER expression into HeLa cells, the GFP and EBER co-expressing 
lentiviruses were used to transduce other cell lines. H1-GFP-LV, E1-GFP-LV and E2-GFP-
LV were used to transduce HEK293T cells as well as the EBER-negative nasopharyngeal 
epithelial cell line NP460 hTERT (provided by Prof G Tsao, Hong Kong University) [473].  
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Figure 4.7  Low levels of EBERs are introduced into HEK 293T cells and human nasopharyngeal 
epithelial cells by lentiviral transduction  Lentiviruses H1-GFP-LV, E1-GFP-LV and E2-GFP-LV were used 
to transduce HEK 293T (293T) cells and human nasopharyngeal epithelial cell line NP460 hTERT (hTERT) 
[473]. Transduction was confirmed by fluorescence microscopy. Total cell RNA was harvested after four days 
and analysed by Northern Blot. Each lane contains 0.5 µg of total cell RNA. The positive control is total cell 
RNA from wild-type LCLs.  
 
5 x 10
4
 HEK 293T (referred to as “293T” cells) or NP460 hTERT (referred to as 
“hTERT” cells) were transduced with H1-GFP-LV, E1-GFP-LV or E2-GFP-LV. After four 
days, transduction was confirmed by fluorescence microscopy and total cell RNA was 
harvested. Total cell RNA was analysed by Northern Blot (Figure 4.7). Investigation of GFP 
expression by fluorescence microscopy indicated that transduction of cells was maximal. 
EBER2 was detected at low levels in both cell lines. Higher levels of EBER2 were detected 
in 293T cells compared to hTERT cells. Trace levels of EBER1 were detected in both cell 
lines as Northern Blot detection of EBER1 was impaired relative to detection of EBER2.  
 
4.3.5 Development of puromycin-resistant lentiviral vectors 
The experiments so far indicated that lentiviral-introduced EBER expression varied 
according to the cell lines used for transduction. Therefore lentiviral vectors were modified to 
rectify this. A means of selecting for a minimum amount of integrated lentivirus in a 
transduced cell line would be useful to select for cells expressing a minimum level of 
transgene. This would enable the growth of a cell line with only the highest transgene content 
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as well as the elimination of untransduced cells. A means of selection would only be applied 
in the initial outgrowth of cell lines and not during continuous culture. 
To achieve this, the GFP-EBER lentiviral expression vectors were adapted to co-
express a puromycin resistance cassette (puro
R
) along with eGFP and EBERs, as detailed in 
section 2.6.8. The new vectors were named pWPT-puro-H1, pWPT-puro-E1 and pWPT-puro-
E2. Application of puromycin selection to transduced cells in culture would ensure the 
survival of only the cells containing sufficient levels of transgene expression, hopefully 
correlating with higher levels of EBER expression. Firstly, puromycin was titrated onto 
different cell lines in order to determine the minimum concentration required to kill 
untransduced cells (Figure 4.8). Suitable concentrations of puromycin were determined for 
each cell type: 0.5 μg/ml for ΔE1ΔE2 LCLs and 1 μg/ml for both HeLa and hTERT cells. 
 
 
 
Figure 4.8 Titration of puromycin on hTERT cells, HeLa cells and LCLs Different concentrations of 
puromycin were added to cultures of hTERT cells, HeLa cells and EBER double-knockout (ΔE1ΔE2) LCLs in 
order to determine the minimal concentration of puromycin required to kill each cell type. Viable cells were 
counted four days after the introduction of puromycin selection. Suitable concentrations of puromycin for each 
cell type were 0.5 μg/ml for ΔE1ΔE2 LCLs and 1 μg/ml for both HeLa and hTERT cells. 
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Following titration, lentiviruses were generated from each of the new lentiviral 
expression vectors: H1-puro-LV, E1-puro-LV and E2-puro-LV were produced from pWPT-
puro-H1, pWPT-puro-E1 and pWPT-puro-E2, respectively. The lentiviruses were each used 
to transduce each of HeLa, hTERT and ΔE1ΔE2 (EBER double knockout) LCL cell lines (as 
described in sections 2.3.2 and 2.3.3). One week after initial transduction, puromycin 
selection was added to transduced cells: 0.5 μg/ml to ΔE1ΔE2 LCLs and 1 μg/ml to HeLa and 
hTERT cells. Cultures were monitored for the outgrowth of transduced cell lines. Outgrowth 
was unsuccessful, possibly due to poor expression of the puromycin resistance cassette, 
therefore this approach was not continued. 
 
4.3.6 Use of FACS-based selection of transduced cells 
 Another means of selecting for a minimum amount of integrated lentivirus in a 
transduced cell line is Fluorescence Activated Cell Sorting (FACS). Cells transduced with 
GFP-expressing lentivirus can be selected on the basis of higher GFP expression levels (due 
to increased copy number of integrated lentivirus) with the intention that higher GFP 
expression correlates with higher levels of EBER expression. HeLa cells were transduced 
with 200 µl concentrate of each of H1-GFP-LV, E1-GFP-LV and E2-GFP-LV, as described in 
sections 2.3.2 and 2.3.3, in order to create lentiviral transduced cell lines. These cell lines 
were grown out and subjected to FACS-based selection after two population doublings of the 
grown-out culture. FACS-based selection was carried out by Dr M Paulsen as described in 
section 2.4.2 and profiles of the selected cell populations are shown in Figure 4.9. The 
process selected for cells in the transduced population with the highest levels of GFP 
expression, which were then returned to continuous culture. After one week of continuous 
culture, total cell RNA was harvested from cell lines that had undergone selection. Total cell 
RNA was analysed for EBER expression by Northern Blot (Figure 4.10). Unfortunately, 
correctly processed EBERs were not detected in the transduced cell lines.  
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Figure 4.9 FACS-based selection of transduced cells with highest levels of GFP expression HeLa cells 
transduced with GFP and EBER co-expressing lentiviruses were subjected to FACS-based selection in order to 
select for cells with the highest levels of GFP expression. The dot plots along the top row indicate the forward 
and side scatter profiles of the cells analysed, with the gated population in each case marked by an oval. The dot 
plot on the second row indicates the GFP expression level versus the staining with a live/dead cell marker. The 
gated population P4, marked by a rectangle, represents those live cells which have the highest GFP expression 
levels. 
 
 
HeLa cells transduced with E1-GFP-LV 
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HeLa cells transduced with E2-GFP-LV 
 
 
HeLa cells transduced with H1-GFP-LV 
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Figure 4.10 Correct EBER expression is not detected in FACS-selected transduced HeLa cells 200 μl H1- 
GFP-LV, E1-GFP-LV and E2-GFP-LV were used to transduce 1 x 10
5
 HeLa cells. Cells were allowed to grow 
out for two weeks then were selected on the basis of high GFP expression by FACS. Selected cultures were 
allowed to grow out for two weeks then total cells RNA was harvested and analysed by RT-PCR (A) and 
Northern Blot (B). The housekeeping gene GAPDH was used as a loading control for RT-PCR. Each lane of the 
Northern Blot contains 0.5 µg of total cell RNA. The positive control is total cell RNA from wild-type LCLs. 
 
4.3.7 Generation of improved lentiviral vectors 
Following the inability to achieve EBER expression in transduced cell lines, a new 
approach was taken to improve the usability and EBER expression levels of the lentiviral 
expression vectors. Firstly, the lentiviral vector system was adapted to express mCherry 
instead of eGFP. The eGFP gene in the parent pWPT vector was replaced by the mCherry 
coding region as described in section 2.6.9, to generate new lentiviral expression vector 
pWPT-RFP/pCWPT. mCherry expression was confirmed by transient transfection of 0.8 μg 
of pCWPT  into HEK 293T cells and subsequent fluorescence microscopy. The presence of 
mCherry as opposed to eGFP in the lentiviral vectors enabled titration of the vectors for the 
first time in GFP-positive EBV BAC-containing EBER knockout LCLs. To demonstrate this, 
lentivirus was generated from pCWPT (denoted CWPT-LV) and 600 μl concentrated CWPT-
LV (equivalent to 3 x 10 cm dishes of lentiviral supernatant) were used to transduce 1 x 10
5
 
ΔE1ΔE2 LCLs as described in section 2.3.3. Cell lines were allowed to grow out and 
mCherry expression was studied after two weeks using fluorescence microscopy (Figure 
4.11). Transduction of GFP-positive LCLs demonstrated that it was possible to transduce 100% 
of the target LCL cell culture. 
A 
B 
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Figure 4.11 Transduction of LCLs with mCherry-expressing lentivirus indicates that the entire population 
of target LCLs can be transduced 1 x 10
5
 ΔE1ΔE2 LCLs were transduced using 600 μl concentrated CWPT-
LV mCherry-expressing lentiviral vector (equivalent to 3 x 10 cm dishes lentiviral supernatant). Cell lines were 
allowed to grow out and mCherry expression was studied after two weeks using fluorescence microscopy. The 
mCherry marker enables the visualisation of transduction levels in GFP-positive cell lines. In this case 100% 
transduction was achieved. 
 
Next, it was imperative to improve EBER expression levels from the lentiviral vectors. 
It was possible that wild type EBER levels were not achieved by transduction as the 
endogenous EBER cassettes were not used. Therefore endogenous EBER cassettes were 
cloned into the pCWPT lentiviral expression vector using a strategy outlined in Komano et al. 
(1999) [332], as described in section 2.6.10. This was a complex cloning procedure. 
Endogenous EBER gene expression cassettes were obtained from the B95-8 EBV BACs that 
were used to generate recombinant EBER-deletion EBV (made by Prof P Farrell, see section 
2.6.5). The EBV BACs used to generate new lentiviral vectors were wild type (wt), EBER1 
knockout (ΔE1), EBER2 knockout (ΔE2) and EBER double knockout (ΔE1ΔE2). The EBER 
coding region is contained within the EcoRI J fragment of B95-8 EBV [20]. Therefore this 
region was excised from the BACs by EcoRI restriction digest and cloned into pCWPT. To 
maximise EBER expression, five copies (concatemers) of the EBER-containing fragments 
were introduced into the lentiviral vector. In Komano et al. (1999)  [332], ten concatemerised 
copies of the EBER-containing Akata EBV K fragment were introduced into a plasmid vector. 
EBER levels in EBV-negative Akata cells transfected with plasmids containing one copy of 
the EBV K fragment were 10% of those in EBV-reinfected Akata cells. However transfection 
with plasmids containing ten concatemerised copies of the EBV K fragment achieved up to 
80% EBER expression relative to that of re-infected clones. As lentiviral titre decreases 
concomitantly with the size of the lentiviral genome [472], it was not feasible to consider 
including a larger copy number of EcoRI J fragments. The cloning strategy is illustrated in 
Figure 4.12. At the time of writing, vectors had been developed containing two copies of each 
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of the different recombinant EBER fragments. 
 
 
 
 
Figure 4.12 Cloning strategy for inserting recombinant, EBV BAC-derived EBER fragments into pCWPT 
and subsequent concatemerisation 
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4.4 Discussion 
A second generation lentiviral vector system was developed to determine whether it 
was possible to use a viral vector system to introduce EBER expression into EBER negative 
cell lines. This would enable the study of potential EBER targets directly and in a variety of 
cell lines. A viral vector approach was taken due to its superiority to transfection in 
introducing stable gene expression without an impact on cell viability and because of the low 
transfection efficiency of LCLs. The lentiviral vector system was modified to contain 
minimal EBER-expression cassettes. The highly structured nature of the EBERs made it 
uncertain as to whether it was possible to make EBER-expressing lentiviruses, however the 
lentiviral vectors were able to transduce 100% of a cell culture and were capable of EBER 
expression. An 100% transduction efficiency was also achieved in LCLs, demonstrating the 
benefits of this approach compared to transfection.  
 
4.4.1 Lentiviral vectors can introduce EBER expression into a variety of adherent cell 
lines 
Lentiviral vectors capable of expressing either EBER1 or EBER2 were generated by 
cloning EBER expression cassettes into the lentiviral expression vector pWPT and these 
expression vectors were then used to create VSV-G pseudotyped lentiviruses. Initial titration 
with a GFP-expressing, EBER-negative lentivirus in HeLa cells (Table 4A) demonstrated the 
ability of the lentiviral vector system to transduce 100% of a cell population. HeLa cells 
transduced with EBER-expressing lentiviruses were shown to express EBERs by Northern 
Blot (Figure 4.3), albeit only after enhancement of transduction by centrifugal inoculation. 
The improved EBER detection upon centrifugal inoculation was likely due to a lower titre or 
transduction efficiency of EBER1-LV/EBER2-LV compared to GFP-LV, although it was 
also possible that the EBERs were expressed at lower levels compared to GFP in transduced 
cells. 
The inability to directly titre the lentiviruses was a major caveat and therefore the 
vectors were modified to co-express the EBERs and GFP. This also alleviated the potential 
problem of promoter interference from the eIF1α promoter (for eGFP expression) which was 
situated upstream of the H1 promoter in the first set of lentiviral vectors. This time higher 
levels of EBER expression were achieved upon transduction of HeLa cells (Figure 4.4). 
However, EBER expression upon lentiviral transduction varied considerably between repeats 
and Figure 4.4 represents the maximum EBER expression levels achieved. These GFP and 
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EBER co-expressing lentiviruses were also used to transduce other cell lines, namely HEK 
293T and NP460 hTERT. NP460 hTERT is an EBV- nasopharyngeal epithelial cell line 
immortalised by the reactivation of telomerase [473] and is therefore relevant to the study of 
EBV-associated NPC. Whilst transduction of HEK 293T and NP460 hTERT cells was seen 
to be maximal according to GFP expression (visualised by fluorescence microscopy), EBER 
expression was low in these cell lines (Figure 4.7). EBER2 was detected at higher levels than 
EBER1 in these cells due to disparity in detection by the Northern Blot probes. In general, 
higher levels of EBERs were detected in HEK 293T cells compared to NP460 hTERT cells.  
Overall, the lentiviral vectors were able to introduce EBER expression into various 
adherent cell lines, but EBER expression was found to be variable and generally low. In an 
attempt to improve levels of EBER expression, a puromycin resistance selectable marker was 
introduced into the GFP and EBER co-expressing lentiviral vectors. The aim was that high 
levels of puromycin resistance gene expression would correlate with high levels of EBER 
expression, and therefore by increasing levels of puromycin only cells with the highest EBER 
expression would be selected. These modified lentiviral vectors were used to transduce LCLs, 
HeLa and hTERT cells. However, transduced LCL cell lines did not grow out and the other 
cell lines did not survive well in culture. This might be due to poor expression of the 
puromycin resistance gene from the CMV promoter, which is known to have decreased 
activity in B cells. There could have also been promoter interference between the CMV 
promoter driving puro
R
 expression and the eIF1α promoter upstream in the lentiviral 
expression vector. Therefore it is possible that transgene expression from these vectors was 
simply too low to enable survival of transduced cells at the puromycin concentrations that 
were required to eliminate untransduced cells. 
A second approach was taken to select for transduced cells with maximal transgene 
expression. Fluorescence activated cell sorting (FACS) of transduced cells was performed, 
selecting for cells with the highest levels of GFP expression, with the expectation that high 
levels of GFP expression would correlate with high levels of EBER expression. Whilst 
EBERs could be detected in the selected cells by RT-PCR, the EBERs could not be detected 
by Northern Blot (Figure 4.10). This again indicates that GFP expression from lentiviral 
vectors does not correlate with EBER expression. The EBER-containing RT-PCR products 
detected in transduced cells were unlikely to be the lentiviral RNA genome used to transduce 
the cells, as the sorted cells had been growing for some time and the lentiviral vectors were 
replication incompetent. The RT-PCR products instead might be incorrectly terminated 
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EBER-containing transcripts, suggesting that the lentiviral vectors might not be processing 
the EBERs correctly.  
To increase EBER expression levels, the endogenous EBER expression cassettes were 
cloned into the lentiviral vectors in order to account for any factors that might act in cis to 
enhance EBER expression. Five copies of each cassette were incorporated into each vector as 
a previous study had shown an increase in vector-derived EBER levels from 10% to 80% of 
endogenous levels by the use of a vector containing ten concatemerised copies of the EBER 
coding region, as opposed to only one copy [332]. As lentiviral titre decreases concomitantly 
with lentiviral genome size [472], it was not feasible to consider incorporating a greater 
number of EBER expression cassettes.   
 
4.4.2 Lentiviral vectors are unable to introduce EBER expression into LCLs 
As lentiviral vectors were successful in introducing EBER expression into HeLa cells, 
the same vectors were used to introduce EBER expression into lymphoblastoid cell lines 
(LCLs). LCLs were used as they are relevant to Burkitt’s lymphoma (BL) and were used in 
the previous microarray study by the lab [110]. Primary B cells however were not used as 
they are refractory to transduction by VSV-G pseudotyped lentiviral vectors [496]. The 
ultimate aim was to use lentiviral transduction to introduce EBER1 expression into ΔE1 
LCLs and EBER2 expression into ΔE2 LCLs.  
Upon transduction, EBER RNAs were detected in the target LCLs by RT-PCR but not 
by Northern Blot (Figures 4.5 and 4.6). The levels of EBER-containing RNA species 
correlated with the volume of lentivirus added. These RNA species were not correct, mature 
EBERs but rather some form of EBER sequence-containing RNA species, likely incorrectly 
processed transcripts from the lentiviral genome. Also, as total cell RNA was harvested after 
only four days, this species could still be the lentiviral RNA genome. There is a possibility 
that correct, mature EBER RNAs were produced but at levels below the detection threshold 
of the Northern Blot.  
The data show that the system must be improved to achieve EBER expression in 
transduced LCLs. The levels of correct, mature EBERs need to be increased and the 
production of aberrant transcripts needs to be rectified. This has started to be addressed by the 
generation of lentiviral vectors containing multiple copies of the endogenous EBER 
expression cassettes (section 4.3.7). However, the ability of the lentiviral vector system to 
transduce 100% of the target LCL population (as shown in Figure 4.11) demonstrates the 
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potential for this system to introduce expression of transgenes into the entirety of an LCL 
population.  
 
4.4.3 Perspectives and future directions 
Whilst the lentiviral-vector based system was able introduce EBER expression into 
some cell lines, its main drawback was the variability of EBER expression between cell lines. 
The data show a disparity between lentivirus-derived EBER expression levels and GFP levels, 
as microscopy of transduced cells indicated that GFP expression, and therefore transduction, 
was maximal. Inconsistent EBER expression could arise from transcription from the lentiviral 
vector producing aberrant or incorrectly terminated products. This possibility is supported by 
the observation that EBER-containing transcripts are always detected in transduced cells by 
RT-PCR. This is likely in transduced, long-term cell lines (Figure 4.10), where the RNA 
species cannot be the lentiviral RNA genome.  However in transduced cells at four days post 
infection, the lentiviral RNA genome might still be present. Taken together, the data indicate 
a distinct possibility that the EBER-containing RNA species detected in transduced cells 
represent incorrectly processed EBER transcripts. This would occur through incorrect 
termination and post-transcriptional modification of the EBER transcripts. The EBER 
expression vectors used here contain a minimal EBER expression element, and potentially 
exclude further downstream elements required for correct termination of EBER transcription. 
For example, the minimal termination sequence used in these vectors could represent a 
truncated version of the endogenous EBER termination sequence. Therefore vital parts of the 
termination sequence would be excluded, reducing the efficiency of termination and thus 
allowing the creation of a high proportion of incorrectly terminated EBER transcripts. 
Another possible explanation is that the EBER genes undergo some form of silencing in most 
of the transduced population.  
It is also worth considering that the EBER expression cassettes used for the bulk of 
this work were not those contained endogenously in EBV. Therefore there might be upstream 
or downstream enhancer elements acting in cis to increase EBER expression from the EBV 
genome. This was the reason for the final cloning strategy of introducing the B95-8 EBV J 
fragments into lentiviral vectors (section 4.3.7). However, it is possible that any cis-acting 
elements might be encoded outside of the EBV J fragment. It is also possible that EBV 
encodes trans-acting factors, such as viral proteins (e.g. EBNA1 [273]), viral functional 
RNAs or long-range enhancer elements, that act in EBV infected cells to increase EBER 
expression. Therefore an absence of these factors might account for low levels of EBER 
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expression observed on lentiviral transduction of EBV-negative cell lines. It might be that 
EBER expression is modulated by cellular factors [274], and cell type specificity of these 
factors is responsible for variable EBER expression between transduced cell lines. It is 
possible that EBER expression levels might be linked to the particular lentiviral expression 
vector used or the transgene cassette insertion site in the vector. The WPT lentiviral 
expression vector contains a WPRE (woodchuck hepatitis virus post-transcriptional 
regulatory element) transgene expression enhancing element, which might influence EBER 
expression. It could be that using another lentiviral expression vector might alter EBER 
expression levels.  
However, it is not certain whether the EBERs produced, although shown by Northern 
Blot to be correctly sized, are identical to the mature EBERs produced in EBV latently 
infected cells. The limited knowledge of the physiological roles of the EBERs means that 
there is no specific phenotypic change that can be used to confirm the functionality of EBERs 
expressed from the lentiviral vector. The EBERs might be post-transcriptionally modified and 
this might not occur correctly using a lentiviral vector system. It is possible that any 
immature EBERs produced have different kinetics, and might be degraded more quickly than 
wild-type EBERs. It is also possible that immature EBERs would behave differently in the 
cell in terms of their interactions. This conundrum can only be solved by further study into 
the roles of the EBERs. 
 The ultimate aim of the work started here is to achieve high levels or EBER 
expression upon lentiviral transduction of EBER-negative cell lines. In EBER-knockout 
LCLs, this would enable complementation of EBER expression, which would provide a 
useful tool for the validation of existing results. Once achieved, this would be followed up by 
“functional” confirmation of the EBERs expressed in transduced cells. Fluorescence 
microscopy of rpL22 localisation would be used to confirm that EBER1 was correctly folded 
and modified. EBER1 has been shown to relocalise rpL22 in EBV-infected cells [110] and 
this phenomenon is a useful test for EBER1 “functionality”. Unfortunately, due to the limited 
understanding of the roles of the EBERs, there is no such “functional assay” for EBER2. 
Once EBER1 has been confirmed in this way, single transduced cells can be grown out into 
cultures of individual clones in order to generate EBER-expressing stable cell lines. These 
cell lines could be subjected to a high-throughput transcriptome analysis, such as RNA-seq, 
to enable determination of any global gene expression changes correlating with expression of 
EBER1 or EBER2. Any expression changes identified could be compared to previous 
microarray analysis of potential EBER gene targets in LCLs [110].  
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This system could also be used to complement EBER expression in primary infection, 
with EBER knockout EBVs being used to infect human B cells. Lentiviral vectors could be 
used to reintroduce EBER expression into infected B cells. However, quiescent B cells are 
generally refractory to transduction by the current VSV-G pseudotyped system [496]. This 
has been shown to be because these cells lack the LDL receptor [497], which is the receptor 
for VSV [467]. Therefore the lentiviral vectors would require a different pseudotype in order 
to transduce these cells. This has been developed [471], where transduction of quiescent B 
cells can be achieved by the use of a measles virus coat glycoproteins. There is also a 
possibility that EBERs could be introduced into activated B cells by transduction, as activated 
B cells have higher transduction efficiencies than quiescent B cells [496]. However artificial 
activation of B cells may not be fully representative of the cellular environment in newly-
infected B cells.  
Future work might also consider the structure and sequence of the EBERs. As 
previously mentioned, the EBERs might undergo some form of post-transcriptional editing 
and this might modulate their interactions and roles. Therefore it would be interesting to 
perform sequencing studies on EBERs isolated from different EBV-infected cell lines to 
identify if any modifications are present on the EBERs and whether this might affect their 
roles in vivo. 
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5 Conclusion 
 
This study has focused on the development of systems to further understand the roles 
of the EBERs in EBV infection of different cell lines. The EBERs are abundantly expressed 
in all forms of latent infection and all EBV-associated malignancies [19], indicating potential 
cellular and physiological roles. In this study, two basic approaches were taken in order to 
investigate potential roles of the EBERs: firstly, the use of EBER knockout viruses, and 
secondly, the introduction of EBERs into EBER negative cell lines. The approaches were 
used in order to follow on from two previous investigations, the first of which identified 
EBER target genes in LCLs [110], and the second of which showed EBERs to induce an 
interferon response in newly-infected B cells, respectively [110, 281]. This study therefore 
aimed firstly to investigate cellular gene expression during primary infection, in order to 
identify whether the previously identified EBER target genes responded to EBER expression 
during primary infection, and also to determine whether the EBERs had any effect on the 
expression of interferon-related genes during early infection of B cells. The results indicated 
that expression changes in the target genes, and in interferon related genes, did not occur 
directly following infection. This suggested that the expression changes previously identified 
might be a downstream result of several complex processes. Secondly, this study aimed to 
ascertain whether a lentiviral vector-based approach could be used for the introduction of 
EBER expression into EBER-negative cell lines, which would be a valuable system for use in 
future studies into the roles of the EBERs. EBER expression was achieved from this system 
and this system will be suitable for use in future studies after EBER expression has been 
optimised.  
 
5.1 EBER-regulated genes during primary EBV infection 
 Gene expression changes in primary human B cells infected with EBER knockout 
strains of EBV were analysed by RT-PCR. It was the first time that these recombinant EBVs 
with single EBER deletions had been used in primary infection studies. In vitro primary 
infection is a good model for the early stages of B cell infection in vivo. The genes analysed 
were firstly those identified as EBER target genes in the microarray [110] and secondly 
individual interferon alpha genes. EBER target genes were initially analysed 72 hours after 
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infection, because this is when EBER expression first reaches steady state levels [63]. The 
first genes to be analysed were EBER1 target genes CHL1, IFNA4, IFNA5, CDC42BPA, 
IL12RB2 and ADARB1. These genes showed no difference in expression between infection 
with wild type or ∆EBER1 EBV. The next set of genes to be analysed included EBER2 target 
genes and those involved in the immune responses, and comprised CXCR3, TBX15, MMP7, 
GPR125, CXCL12, IL10, SEPP1, TMPRSS3, IGF1, FYB, HCK, IFNA, IFNA2 and IGSF4. 
Again these genes did not show reproducible expression changes in response to EBER 
expression. To account for the timepoints being taken too early in the process of latent 
infection, the timecourse was extended to 25 days. The genes studied, TBX15, MMP7, 
ADARB1, CXCR3, CDC42BPA and IL12RB2, again showed consistent expression between 
infections regardless of EBER presence. Next, the expression of each of the interferon alpha 
genes was analysed up to 24 hours post infection, with the highest expressed also analysed at 
72 hours post infection, which again showed no reproducible expression changes that 
correlated with EBER expression.  
Taken together, these results show no reproducible expression changes in the genes 
studied at the chosen timepoints. This evidence, although not conclusive, suggests that the 
EBERs might not cause gene expression changes during the early stages of latent infection. 
The expression changes identified in LCLs [110] might represent the downstream result of 
complex EBER-induced cellular processes. It is also worth considering the inherent 
variability of B cells isolated from different donors, also evident in the microarray study 
[110], which might hamper attempts to define reproducible EBER-associated gene expression 
changes. Another issue to consider is that although the MoI used was chosen in accordance 
with previous work [94, 281], an increase in the MoI might enable any differences in gene 
expression to be detected. It however is possible that EBERs are acting at the protein level 
rather than the transcription level, perhaps by interacting with mRNA or miRNA. Therefore 
protein level studies were also started: metabolic labelling of EBER knockout LCLs showed 
no large scale protein level changes in response to EBER expression, indicating that any 
effect of the EBERs is at the level of specific proteins.  
It is possible that the in vitro B cell system does not represent the physiological targets 
of EBER1 and EBER2. It has recently been suggested that the EBERs are released from 
EBV-infected cells in exosomes [426, 490], implying target cells other than B cells. It might 
be that EBERs act in the initiation of epithelial infection, in accordance with the dual tropism 
model [22, 23]. EBERs may act more at a physiological level, which is being explored by the 
lab in mouse studies performed in collaboration with Prof C. Münz (University of Zurich). It 
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could be that EBERs are important in stages of the EBV life cycle other than primary 
infection and Latency III, and that these stages might involve interactions with other cells. 
Therefore future work needs to consider the potential roles of the EBERs in diverse cell lines 
and physiological situations, which in part can be investigated with the aid of a lentiviral 
vector approach to introduce EBER expression. 
 
5.2 Using lentiviral vectors to introduce EBER expression into 
EBER negative cell lines 
 A lentiviral vector system was developed to determine whether it was possible to use 
a viral vector system to introduce EBER expression into EBER negative cell lines. Such a 
system would enable the study of potential EBER targets directly and in a variety of cell lines. 
A viral vector approach was taken due to its superiority to transfection in introducing stable 
gene expression without an impact on cell viability and because of the low transfection 
efficiency of LCLs. Lentiviral vectors containing the EBER genes were generated and 
demonstrated to be competent for both EBER expression and transduction. The lentiviral 
vectors were used to transduce HeLa cells, 293T cells, LCLs, and NP460 hTERT EBV-
negative immortalised nasopharyngeal cells [473]. Lentiviral vectors gave 100% transduction 
efficiency and EBER expression was detected in HeLa, 293T and NP460 hTERT cells, albeit 
at a variable level. EBER expression was not detected upon transduction of LCLs. Steps were 
taken to improve EBER expression levels in transduced cells: cells were selected for the 
highest lentiviral genome copy number, the endogenous EBER cassettes were cloned into the 
lentiviral vectors, and work was begun to increase the EBER gene copy number within the 
lentiviral expression vectors. Steps were also taken to improve titration of the lentivirus, 
namely the inclusion of each of the fluorescent markers eGFP and mCherry.  
 Initially it was not clear whether it would be possible to generate EBER expressing 
lentiviral vectors due to the possibility that the highly structured EBER RNAs could inhibit 
genome production and packaging or impede gene expression from lentiviral vectors. The 
work indicates that it is possible to generate transduction competent lentiviral vectors 
containing EBER genes and that EBERs can be expressed from lentiviral expression vectors. 
However, EBER expression upon transduction is variable and appears to vary with the cell 
line used. This could be a cell-type specific effect relating to differential expression from the 
lentiviral vectors following transduction. It is possible that gene expression from various 
parts of the lentiviral vectors could be silenced over time. It is also uncertain whether the 
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EBERs produced, although shown by Northern Blot to be correctly sized, are the same as 
mature EBERs produced in EBV latently infected cells. It is not clear whether EBERs are 
post-transcriptionally modified and perhaps this does not occur correctly in the systems used. 
It could be that incorrectly modified EBERs are degraded hence the lack of detectable 
expression. It is possible that EBER expression from the lentiviral vectors is not maximal, 
and that EBER expression in vivo is enhanced by EBV factors, such as EBNA1 [273], acting 
in trans. It also could also be that the cellular factors that might enhance EBER expression 
[274] are cell line-specific. Until a definite phenotype is found for the EBERs, it is hard to 
confirm the functionality of exogenously expressed EBERs. However EBER expression 
systems that can target a variety of EBV latently infected cell lines will clearly be useful for 
the continuing study of the roles of the EBERs. 
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6 Appendix 
 
6.1 Genes with expression changes correlating with EBER1 
expression [110] 
 
Gene Symbol Description Fold-Change p-value Fold-Change p-value 
  wt/delE1  E1R/delE1  
CDC42BPA CDC42 binding protein kinase alpha (DMPK-
like) 
29.4 4.1E-10 27.0 7.7E-11 
CSRP2 cysteine and glycine-rich protein 2 12.6 2.9E-13 11.1 8.5E-14 
SEPP1 selenoprotein P, plasma, 1 11.7 1.2E-10 16.4 9.1E-13 
CD96 CD96, T-cell surface protein tactile 11.0 1.2E-12 4.7 6.6E-10 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 9.7 7.5E-15 11.6 1.3E-16 
DDAH1 dimethylarginine dimethylaminohydrolase 1 8.7 1.9E-15 12.3 6.6E-18 
CHL1 cell adhesion molecule with homology to 
L1CAM 
8.4 6.2E-11 8.2 8.3E-12 
RHOU ras homolog gene family, member U 7.9 4.9E-12 11.9 1.0E-14 
ADCY6 adenylate cyclase 6 6.7 2.1E-10 8.8 1.4E-12 
GAS2 growth arrest-specific 2 5.9 2.3E-07 7.7 3.2E-09 
ASS argininosuccinate synthetase 5.7 5.3E-11 3.5 3.1E-09 
HLXB9 homeobox HB9 5.2 1.0E-04 6.5 4.0E-06 
GLIS3 GLIS family zinc finger 3 5.1 6.8E-10 8.5 3.6E-13 
HOXB6 homeobox B6 5.1 2.0E-06 8.7 2.6E-09 
RNF43 ring finger protein 43 4.8 4.8E-06 6.9 3.3E-08 
GPR171 G protein-coupled receptor 171 4.6 2.2E-11 3.4 1.6E-10 
CRIM1 cysteine rich transmembrane BMP regulator 1 
(chordin-like) 
4.5 1.4E-10 3.9 1.1E-10 
KCNV1 potassium channel, subfamily V, member 1 4.3 1.1E-10 5.8 2.6E-13 
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NCKAP5 Nck-associated protein 5 4.2 1.9E-12 2.9 9.7E-11 
PTGS1 prostaglandin-endoperoxide synthase 1 4.0 5.9E-07 2.9 6.6E-06 
TNFRSF21 tumor necrosis factor receptor superfamily, 
member 21 
3.9 7.1E-11 3.1 2.8E-10 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 3.9 2.2E-06 5.9 4.4E-09 
IFNA6 interferon, alpha 6 3.7 1.4E-09 2.7 4.2E-08 
AMOTL1 angiomotin like 1 3.6 6.7E-11 3.2 5.8E-11 
KL klotho 3.6 8.1E-10 3.2 6.8E-10 
ZDHHC14 zinc finger, DHHC-type containing 14 3.5 1.2E-06 2.9 1.9E-06 
TCF2 transcription factor 2, variant hepatic nuclear 
factor 
3.5 1.3E-09 4.6 2.7E-12 
IFNA5 interferon, alpha 5 3.3 5.2E-07 2.5 5.6E-06 
TGM2 transglutaminase 2 3.2 1.4E-07 2.6 5.2E-07 
IFNA4 interferon, alpha 4 3.2 4.5E-07 2.4 6.2E-06 
FUT4 fucosyltransferase 4 3.1 2.0E-09 2.7 2.7E-09 
SLC7A11 solute carrier family 7, member 11 3.0 6.5E-08 2.6 9.0E-08 
EFNA1 ephrin-A1 2.6 4.0E-05 3.2 5.6E-07 
ASPH aspartate beta-hydroxylase 2.6 4.3E-05 2.4 3.8E-05 
PHGDH phosphoglycerate dehydrogenase 2.6 1.7E-06 2.1 1.6E-05 
TGFB1I1 transforming growth factor beta 1 induced 
transcript 1 
2.6 3.8E-08 2.3 9.5E-08 
SASH1 SAM and SH3 domain containing 1 2.6 1.4E-05 2.2 2.1E-05 
PLD1 phospholipase D1, phosphatidylcholine-
specific 
2.5 7.5E-07 3.7 2.4E-10 
IQCD IQ motif containing D 2.4 5.3E-08 2.2 4.2E-08 
EDN1 endothelin 1 2.3 1.6E-04 2.6 8.3E-06 
WWTR1 WW domain containing transcription regulator 
1 
2.2 2.0E-10 2.4 2.6E-12 
CHST6 carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 6 
-2.1 6.7E-05 -2.3 3.4E-06 
PIK3R5 phosphoinositide-3-kinase, regulatory subunit -2.7 3.3E-07 -2.0 1.2E-05 
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5, p101 
SETBP1 SET binding protein 1 -3.5 3.4E-06 -3.5 6.3E-07 
PRUNE2 protein prune homolog 2 -3.7 3.3E-06 -3.7 5.5E-07 
LRRC32 leucine rich repeat containing 32 -3.8 3.8E-05 -2.6 4.4E-04 
NRIP1 nuclear receptor interacting protein 1 -4.3 1.8E-14 -2.7 3.6E-12 
HHEX homeobox, hematopoietically expressed -4.8 1.6E-08 -3.2 4.6E-07 
LEPREL1 leprecan-like 1 -5.1 1.8E-09 -5.5 9.0E-11 
TCEAL2 transcription elongation factor A (SII)-like 2 -5.1 3.0E-09 -2.7 2.1E-06 
ADARB1 adenosine deaminase, RNA-specific, B1 -5.4 7.0E-08 -6.3 2.3E-09 
CCDC74B coiled-coil domain containing 74B -7.8 2.9E-08 -6.0 4.0E-08 
IL12RB2 interleukin 12 receptor, beta 2 -17.0 4.8E-11 -6.8 9.1E-09 
FAM189A1 transmembrane protein FAM189A1 -19.9 8.9E-11 -13.0 2.0E-10 
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6.2 Genes with expression changes correlating with EBER2 
expression [110] 
 
Gene Symbol Description Fold-Change p-value Fold-Change p-value 
  wt/delE2  E2R/delE2  
TBX15 T-box 15 65.4 8.1E-09 17.2 7.9E-07 
MMP7 matrix metallopeptidase 7 52.4 1.1E-06 29.3 2.2E-06 
GPR125 G protein-coupled receptor 125 50.2 4.4E-14 14.3 1.3E-11 
SASH1 SAM and SH3 domain containing 1 43.7 2.5E-10 13.0 3.7E-08 
DACT1 dapper, antagonist of beta-catenin, 
homolog 1 (Xenopus laevis) 
31.5 2.2E-10 8.8 1.3E-07 
LINCR E3 ubiquitin-protein ligase neuralised-like 
protein 3 (NEURL3) 
24.1 5.5E-09 10.8 1.2E-07 
CNKSR3 CNKSR family member 3 18.9 2.1E-09 12.0 6.0E-09 
CD9 CD9 antigen 15.1 8.1E-11 8.5 9.0E-10 
PAG1 phosphoprotein associated with 
glycosphingolipid microdomains 1 
13.3 4.7E-07 7.8 2.8E-06 
LRRK2 leucine-rich repeat kinase 2 13.2 1.2E-11 6.0 1.7E-09 
FXYD2 FXYD domain containing ion transport 
regulator 2 
13.1 7.3E-07 5.4 5.2E-05 
LMO3 LIM domain only 3 (rhombotin-like 2) 12.0 6.5E-11 5.4 1.3E-08 
ZNF462 zinc finger protein 462 10.0 2.3E-07 5.2 7.1E-06 
GOLPH2 golgi phosphoprotein 2 9.7 1.6E-08 5.1 6.2E-07 
KCNK1 potassium channel, subfamily K, member 1 9.4 3.9E-11 4.6 6.9E-09 
ACTN1 actinin, alpha 1 9.0 4.3E-09 8.7 7.0E-10 
PPIC peptidylprolyl isomerase C (cyclophilin C) 8.7 6.4E-07 4.4 3.0E-05 
IGSF4 immunoglobulin superfamily, member 4 8.1 3.8E-04 9.5 4.8E-05 
MYO6 myosin VI 8.0 7.7E-09 4.0 1.1E-06 
EGLN3 egl nine homolog 3 (C. elegans) 7.9 1.2E-06 4.3 3.4E-05 
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RICH2 Rho GTPase-activating protein RICH2 7.3 8.7E-05 5.8 1.0E-04 
PLA1A phospholipase A1 member A 6.9 1.4E-09 3.5 3.4E-07 
MEX3A RNA-binding protein MEX3A 6.8 7.5E-09 4.4 9.4E-08 
ASS argininosuccinate synthetase 6.8 7.3E-12 3.5 3.7E-09 
S100A4 S100 calcium binding protein A4 6.0 3.8E-07 5.4 1.7E-07 
TMEM16K transmembrane protein 16K 5.9 8.0E-09 3.3 1.0E-06 
CYP2J2 cytochrome P450, family 2, subfamily J, 
polypeptide 2 
5.6 3.0E-08 4.3 7.1E-08 
ACSM3 acyl-CoA synthetase medium-chain family 
member 3 
5.3 1.2E-10 3.0 3.5E-08 
QPCT glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) 
5.3 1.4E-10 3.7 1.7E-09 
MYBPC2 myosin binding protein C, fast type 5.1 7.0E-06 4.8 2.7E-06 
CEP70 centrosomal protein 70kDa 5.0 9.0E-09 3.5 1.2E-07 
ZNF649 zinc finger protein 649 4.4 7.8E-11 2.8 6.9E-09 
FGL2 fibrinogen-like 2 4.3 1.9E-06 2.8 5.0E-05 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 4.2 9.1E-07 3.0 1.1E-05 
SERPINB9 serpin peptidase inhibitor, clade B 
(ovalbumin), member 9 
4.2 1.4E-07 3.0 1.6E-06 
GDF15 growth differentiation factor 15 4.1 4.7E-05 3.3 1.1E-04 
MTAC2D1 membrane targeting C2 domain containing 1 4.1 4.3E-06 5.1 9.1E-08 
GPR56 G protein-coupled receptor 56 4.0 1.0E-04 6.2 5.6E-07 
CLCF1 cardiotrophin-like cytokine factor 1 3.9 1.8E-08 2.5 1.4E-06 
KALRN kalirin, Huntingtin-associated protein-
interacting protein 
3.6 4.8E-06 2.5 9.4E-05 
IGF1 insulin-like growth factor 1 (somatomedin C) 3.6 1.0E-06 2.5 2.4E-05 
MBOAT2 membrane bound O-acyltransferase domain 
containing 2 
7.7 2.7E-07 6.6 1.6E-07 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
7.4 4.9E-06 3.9 1.6E-04 
HOOK1 hook homolog 1 (Drosophila) 7.4 3.2E-12 4.4 1.4E-10 
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AKAP7 A kinase (PRKA) anchor protein 7 3.5 8.0E-08 2.8 3.8E-07 
TMTC2 transmembrane and tetratricopeptide repeat 
containing 2 
3.5 1.5E-11 2.5 6.8E-10 
EPB41L2 erythrocyte membrane protein band 4.1-like 
2 
3.5 1.1E-07 2.8 3.6E-07 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin 
domain containing 8 
3.2 3.1E-06 2.8 4.1E-06 
HES5 hairy and enhancer of split 5 (Drosophila) 3.2 1.2E-05 2.7 2.4E-05 
TGM2 transglutaminase 2  3.2 1.9E-07 2.1 1.8E-05 
PITPNC1 phosphatidylinositol transfer protein, 
cytoplasmic 1 
3.1 6.7E-06 3.5 3.3E-07 
ZNF439 zinc finger protein 439 3.1 6.2E-10 3.1 8.7E-11 
NDRG1 N-myc downstream regulated gene 1 3.1 2.1E-05 4.6 4.5E-08 
RNF43 ring finger protein 43 3.1 3.0E-04 3.2 6.4E-05 
HPCAL1 hippocalcin-like 1 3.0 2.2E-07 2.2 9.6E-06 
CD55 CD55 molecule, decay accelerating factor 
for complement 
3.0 1.6E-08 2.1 1.4E-06 
TRBV5-4 T cell receptor beta variable 5-4 3.0 1.9E-06 2.0 1.1E-04 
ZNF93 zinc finger protein 93 2.9 9.0E-08 3.1 3.8E-09 
AGRIN agrin 2.8 2.7E-09 2.4 4.9E-09 
FAM90A1 family with sequence similarity 90, 
member A1 
2.8 3.0E-05 2.6 2.0E-05 
ZNF682 zinc finger protein 682 2.8 2.7E-05 2.8 5.7E-06 
CLEC2D C-type lectin domain family 2, member D 2.8 3.6E-07 2.2 3.4E-06 
FBXL16 F-box and leucine-rich repeat protein 16 2.7 9.9E-08 2.2 8.8E-07 
CYP2U1 cytochrome P450, family 2, subfamily U, 
polypeptide 1 
2.7 9.6E-08 2.1 1.6E-06 
TMEM23 transmembrane protein 23 2.6 7.6E-05 2.9 4.6E-06 
TNFSF10 tumor necrosis factor (ligand) superfamily, 
member 10 
2.5 4.1E-05 2.5 1.6E-05 
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 2.5 8.9E-06 2.2 9.6E-06 
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SLC7A11 solute carrier family 7, member 11 2.3 3.2E-06 2.4 5.0E-07 
FBN1 fibrillin 1 2.3 1.6E-08 2.4 9.5E-10 
TNFRSF10C tumor necrosis factor receptor superfamily, 
member 10c 
2.1 4.8E-05 2.0 3.3E-05 
T T, brachyury homolog (mouse) -2.0 1.1E-06 -2.3 7.8E-09 
TNFRSF1B tumor necrosis factor receptor superfamily, 
member 1B 
-2.0 2.9E-06 -2.1 3.9E-07 
FOXO1A forkhead box O1A -2.0 4.7E-04 -2.9 6.6E-07 
NMT2 N-myristoyltransferase 2 -2.1 1.8E-04 -2.2 3.2E-05 
FHOD3 formin homology 2 domain containing 3 -2.2 4.6E-10 -3.7 1.8E-15 
NALP1 NACHT, leucine rich repeat and PYD 
containing 1 
-2.2 3.2E-07 -2.1 2.6E-07 
VANGL1 vang-like 1 (van gogh, Drosophila) -2.5 1.2E-06 -2.1 5.5E-06 
DNAH14 dynein heavy chain 14, axonemal -2.5 1.0E-04 -2.2 1.1E-04 
MICAL3 protein MICAL-3 -2.6 2.3E-09 -2.2 1.4E-08 
ATF5 activating transcription factor 5 -2.9 1.3E-06 -2.0 7.5E-05 
TNFRSF19 tumor necrosis factor receptor superfamily, 
member 19 
-3.1 4.6E-06 -2.3 4.3E-05 
NOTCH2 Notch homolog 2 (Drosophila) -3.1 4.4E-05 -3.0 1.4E-05 
CHST6 carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 6 
-3.2 8.7E-08 -2.3 2.9E-06 
CD1A T-cell surface glycoprotein CD1a -3.5 1.5E-04 -2.9 2.7E-04 
ARHGAP24 Rho GTPase activating protein 24 -3.8 1.3E-05 -3.7 3.4E-06 
AUTS2 autism susceptibility candidate 2 -3.9 1.5E-07 -2.6 5.6E-06 
NETO1 neuropilin (NRP) and tolloid (TLL)-like 1 -4.1 4.0E-04 -5.1 1.7E-05 
EHD3 EH-domain containing 3 -4.1 9.5E-06 -4.8 3.9E-07 
GHR growth hormone receptor -4.3 4.9E-06 -2.7 1.8E-04 
GPRC5D G protein-coupled receptor, family C, 
group 5, member D 
-4.4 2.4E-07 -3.9 1.5E-07 
PPM1H protein phosphatase 1H -4.6 1.7E-06 -6.4 1.1E-08 
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CCDC74B coiled-coil domain containing 74B -7.0 7.0E-08 -3.8 4.5E-06 
HCK hemopoietic cell kinase -7.4 1.2E-07 -4.0 6.0E-06 
PRSS21 serine protease 21 (testisin) -7.6 6.2E-06 -6.0 7.0E-06 
FCRL3 Fc receptor-like 3 -8.2 2.9E-07 -5.6 1.2E-06 
SLAMF8 SLAM family member 8 -8.5 1.1E-13 -6.6 1.6E-13 
HECW2 HECT, C2 and WW domain containing E3 
ubiquitin protein ligase 2 
-8.8 1.1E-07 -4.4 7.1E-06 
TLX2 T-cell leukemia homeobox 2 -9.0 1.1E-07 -12.1 1.7E-09 
MSRB3 methionine sulfoxide reductase B3 -9.2 4.4E-07 -5.3 5.5E-06 
CXCL12 chemokine (C-X-C motif) ligand 12 -9.9 1.9E-09 -4.9 1.6E-07 
GIMAP5 GTPase, IMAP family member 5 -10.0 6.2E-07 -5.1 1.9E-05 
CXCR3 chemokine (C-X-C motif) receptor 3 -10.4 6.4E-09 -7.5 1.3E-08 
ALPK2 heart alpha-kinase -10.7 1.1E-09 -6.9 6.4E-09 
TIMD4 T-cell immunoglobulin and mucin domain 
containing 4 
-12.9 6.3E-08 -5.7 4.5E-06 
TMPRSS3 transmembrane protease, serine 3 -15.7 2.2E-06 -6.1 1.3E-04 
GABRA4 gamma-aminobutyric acid (GABA) A 
receptor, alpha 4 
-17.1 3.3E-07 -15.2 1.1E-07 
IL12RB2 interleukin 12 receptor, beta 2 -30.5 1.1E-12 -10.2 2.8E-10 
TXNDC3 thioredoxin domain containing 3 -31.6 2.1E-08 -9.6 3.2E-06 
      
 
ADARB1 adenosine deaminase, RNA-specific, B1 -5.2 1.1E-07 -3.3 2.8E-06 
CLEC4C C-type lectin domain family 4, member C  -5.7 7.4E-08 -4.8 6.1E-08 
SGK serum/glucocorticoid regulated kinase -6.1 5.3E-12 -5.1 4.6E-12 
PGDS prostaglandin D2 synthase, hematopoietic -6.2 1.2E-06 -5.7 4.4E-07 
DNAH17 dynein, axonemal, heavy polypeptide 17 -6.2 9.8E-07 -3.5 4.0E-05 
HHEX homeobox, hematopoietically expressed -6.5 6.2E-10 -3.4 1.7E-07 
FYB FYN binding protein (FYB-120/130) -6.7 1.5E-06 -5.1 2.7E-06 
